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ABSTRACT 
 
Monoclonal immunoglobulin free light chains (FLCs) cause a range of disorders in the 
kidney. In multiple myeloma, FLCs can activate the proximal tubule to release MCP-1, 
an important cytokine in renal fibrosis. Distal tubular cast formation can also occur 
when FLCs co-precipitate with uromodulin.  However a pathogenic role for the elevated 
polyclonal FLC concentrations seen in chronic kidney disease has not been assessed to 
date. This thesis explores the biology of monoclonal FLCs as well as polyclonal FLCs. 
Detailed histological analyses demonstrated that in multiple myeloma, interstitial 
fibrosis can progress rapidly in situ and indicated that intratubular cast numbers might 
be linked to potential for renal recovery. The functional basis of this fibrosis was 
explored by in vitro studies, which showed that upon endocytosis of FLCs, oxidative 
stress activated redox signalling, resulting in MCP-1 production. Further in situ 
analyses showed that in chronic kidney disease, polyclonal FLCs co-localised with 
uromodulin in distal tubular casts. Relationships between these casts and markers of 
progression of chronic kidney disease were demonstrated. In vitro analyses then showed 
that polyclonal FLCs bind to uromodulin and promote aggregation. These findings: 
(i) further delineate the pathways for proximal tubular injury in myeloma and (ii) 
indicate a potential pathogenic role for polyclonal FLCs in the distal nephron. 
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1. BACKGROUND AND LITERATURE REVIEW 
1.1 Introduction  
Plasma cell dyscrasias (PCD) are relatively common disorders, the prevalence of 
monoclonal gammopathy of undetermined significance (MGUS) in the over-50’s is 
around 3.2%, and multiple myeloma accounting for 10% of all haematological 
malignancies.(Kyle and Rajkumar 2004; Kyle et al. 2006) Plasma cell dyscrasias are 
characterised by the proliferation of a clone of B-cell lineage. There is associated 
production of clonal immunoglobulin (Ig) which frequently includes a variable quantity 
of clonal immunoglobulin free light chain (FLC). Each clone of FLC has distinct 
physico-chemical properties which may lead to differential injury at tissue sites. As 
FLCs are primarily cleared from the circulation by the kidneys,(Abraham and 
Waterhouse 1974; Wochner et al. 1967; Maack et al. 1979) this organ is often damaged 
in the setting of PCD (Table 1.1). The clinical features of this are wide, ranging from 
slowly progressive chronic kidney disease (CKD) often associated with heavy 
proteinuria, to life-threatening acute kidney injury (AKI). In multiple myeloma alone, 
up to 50% of patients can have renal impairment at diagnosis, 20% may have AKI and 
up to 10% require dialysis.(Kyle et al. 2003; Knudsen et al. 2000; Gertz 2005; Blade et 
al. 1998)  
 
Monoclonal FLCs can damage both the glomerular and tubulo-interstitial compartments 
in disease-dependent patterns.(Sanders et al. 1991) For example: primary (AL) 
amyloidosis can affect all compartments of the kidney, but predominantly involves the 
glomeruli; in myeloma kidney (cast nephropathy), there is proximal tubular  
  
 2 
 
Table 1.1 Renal manifestations of plasma cell dyscrasias.  
Plasma Cell Dyscrasia Renal Manifestation 
MGUS None 
Multiple myeloma 
Smouldering myeloma  
Plasmacytoma  
Plasma cell leukaemia 
Amyloidosis  
LCDD  
HCDD 
LHCDD 
Cast nephropathy (myeloma kidney) 
Cryoglobulinaemic fibrillary glomerulopathy  
AL-amyloidosis Amyloidosis 
Waldenstrom’s 
macroglobulinaemia 
Hyperviscosity 
Glomerular endocapillary IgM deposits 
Casts in distal tubules 
Amyloidosis  
B-cell lymphoproliferative 
disorders 
GOMMID 
Other Proliferative glomerulonephritis with 
monoclonal Ig deposits 
MGUS, monoclonal gammopathy of uncertain significance; LCDD, light chain 
deposition disease; HCDD, heavy chain deposition disease; LHCDD, light and heavy 
chain deposition disease; GOMMID, glomerulonephritis with organised microtubular 
monoclonal immunoglobulin deposits. 
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inflammation, and in the distal tubules, precipitation of light chain casts, with secondary 
interstitial involvement; light chain deposition disease (LCDD) can affect the 
mesangium, the glomerular and tubular basement membranes and blood vessels. The 
clinical and histological features of the different disease states are summarised in Table 
1.2. 
 
Whilst the clinical phenotypes of monoclonal diseases are well recognised and a large 
body of evidence exists defining the pathogenic effects of monoclonal FLCs, little is 
known about the pathogenic potential of polyclonal FLCs. The advent of highly 
sensitive immunoassays has enabled the measurement of the concentrations of these 
proteins down to even small quantities.(Bradwell et al. 2001) These assays have 
enabled accurate assessments of the concentrations of these proteins in patients with 
CKD.(Hutchison et al. 2008c) These studies have shown that as glomerular filtration 
rate (GFR) declines, there is a corresponding increase in serum polyclonal FLC 
concentration, an observation which has led to increasing interest in the potential 
contribution of these low molecular weight proteins (LMWPs) towards the development 
of kidney injury, in particular, inflammation and fibrosis.  
 
In this introductory chapter, I explore the current understanding of mechanisms of renal 
injury due to monoclonal FLCs. I describe how the structure of FLCs facilitates 
pathological effects that are dependent on both the extracellular deposition of proteins 
and the activation of intra-cellular signalling pathways, to produce distinct patterns of 
injury. This will form a basis for understanding the relevance of the experimental work 
that I performed and is presented in this thesis. In addition I summarise the current 
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knowledge of the role of polyclonal light chains in inflammation and injury. A 
significant part of the work that is presented in this thesis describes experiments that 
were performed to start to ascertain if polyclonal FLCs contribute to the development of 
CKD. 
 
1.2 Light Chain Structure, Production and Distribution  
A basic immunoglobulin molecule consists of four subunits; two identical heavy chains 
and two identical light chains, linked by disulphide bonds to give a Y-shaped 
configuration (figure 1.1).(Edelman et al. 1968; Porter 1973) There are five known 
heavy chain isotypes. Two light chain isotypes exist (κ and λ); each containing a 
variable and a constant region. The variable region of each light chain and each heavy 
chain pair combine to produce antigen binding sites (Fab) at the two prongs of the “Y”.  
 
Each light chain is made up of around 220 amino acids (AAs) and has a molecular 
weight (MW) of 25 kDa.(Day 1990) The genes coding for κ and λ light chains are 
situated on chromosomes 2 and 22 respectively.(McBride et al. 1982; Malcolm et al. 
1982; Solomon 1986) There is very little variation within the constant (CL) region of κ 
light chain and λ light chain; κ CL is coded for by a single gene and λ CL by one of 
several gene segments.(Solomon 1986; Kawasaki et al. 1995) In contrast, the variable 
(VL) region of a light chain comprises four framework regions which form a 
hydrophobic core, (Bruccoleri et al. 1988; Chothia and Lesk 1987; Chothia et al. 1989; 
Glockshuber et al. 1990; Rocca et al. 1993) and within which are scattered three 
segments of hypervariable AA sequences called complementary determining regions 
(CDR1, CDR2 and CDR3).(Bruccoleri et al. 1988; Chothia and Lesk 1987; Chothia et 
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al. 1989) The diversity of CDRs is attributable to the large number of VL and joining (J) 
gene segments which encode them. κ light chain is constructed from 40 Vκ and five Jκ 
segments and λ light chain from 30 Vλ segments and eight Jλ segments respectively, 
giving rise to a vast number of possible combinations.(Solomon 1986) Amino Acid 
substitutions in the VL region can result in alterations of primary and tertiary 
structure.(Nyquist et al. 1993; Preud'homme et al. 1994; Stevens et al. 1995; Wetzel 
1997) Structural variations due to disparities and mutations in gene segment 
combinations are important in determining the toxicity of an individual FLC. 
 
The frequent presence of the amphipathic AAs tyrosine and tryptophan in light chain 
CDRs may enable intact Ig to cross-react with structurally similar ligands.(Mian et al. 
1991) These AAs: (i) are not affected by the change from a hydrophilic to a 
hydrophobic environment that occurs on antigen binding; (ii) take part in a wide variety 
of electrostatic interactions and; (iii) have flexible side chains which can generate a 
structurally plastic region. Although these factors may improve antigen binding and 
broaden the repertoire of an antibody, they may also predispose to undesirable effects 
such as the interaction of FLCs with uromodulin.  
 
Intact Ig production begins in developing B cells. Normally, there is a 40% 
overproduction of light chain compared to heavy chain.(Bradwell 2010) Around 500 
mg/day of polyclonal FLCs are released into the circulation from bone marrow and 
lymph nodes.(Solomon 1985; Waldmann et al. 1972) The biology of polyclonal FLCs 
are discussed in section 1.12 and in experimental Chapters Six and Seven. If there is 
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Figure 1.1. Structure of immunoglobulin and light chain. 
(Legend on following page) 
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Figure 1.1 Above: An immunoglobulin molecule (e.g. IgG), indicating its modular construction from light chains and heavy chains, 
held together by disulphide bonds. Antigen binding sites are formed from the variable regions of light and heavy chains, whereas the Fc 
portion is formed from the constant region of heavy chains. FLCs can exist as monomers, dimers or higher oligomeric and polymeric 
forms. Below: Light chain domains, showing variable and constant regions. Interspersed between framework regions (FR) within the 
variable region are the three complimentary determining regions (CDR). CDRs form part of the antigen binding site. It is the variable 
region which is implicated in the renal manifestations of FLC mediated conditions seen in plasma cell dyscrasias. The reaction site for 
generation of hydrogen peroxide is located within the VL region. Domains and their corresponding gene segments are also indicated. The 
variable region is constructed from a combination of two gene segments, V (variable) and J (joining), while the constant region is 
constructed from a single C (constant) gene. The J segment comprises the terminal residues of CDR3 and all residues in FR4. 
 
  
 8 
proliferation of an aberrant clone of B cell lineage, it may then secrete clonal FLC, 
which is detectable in the serum and urine. 
 
Kappa FLC is monomeric and λ FLC dimeric, although higher oligomeric and 
polymeric forms of both FLCs also occur.(Bradwell 2010; Berggard and Peterson 1969; 
Myatt et al. 1994) Free light chains rapidly disperse such that they are present in 
roughly equal concentrations throughout extracellular compartments. For an individual 
with 2.5 L of intravascular fluid and 12 L of extravascular fluid almost 80% of FLC is 
extravascular.(Hutchison et al. 2007) Around two-thirds of light chain production is κ 
and this is reflected in a serum ratio of κ isotype to λ isotype of 1.8:1.(Katzmann et al. 
2002)  
 
1.3 Renal Handling of FLCs 
The kidney is the major site of FLC removal, primarily by catabolism in proximal 
tubular epithelial cells (PTEC).(Wochner et al. 1967; Miettinen and Kekki 1967; 
Solomon et al. 1964) The precise glomerular clearance is not known but from the size 
and cationic charge of FLCs,(Maack et al. 1979; Camargo et al. 1984) and from studies 
in humans and mice, κ FLCs are cleared at up to 40% per hour and λ FLCs at up to 20% 
per hour with a serum half-life of 2-4 hours.(Wochner et al. 1967; Solomon et al. 1964) 
Consequently the relative serum ratio of FLC isotypes in people with normal renal 
function is not a true representation of production but a function of differential 
clearance, with a κ:λ FLC ratio of 0.26-1.65 across all age groups.(Katzmann et al. 
2002) In established renal failure the reticuloendothelial system becomes the main route 
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of removal and the serum half-life of FLCs increase to 32 hours or more,(Miettinen and 
Kekki 1967) and the FLC ratio increases such that it moves closer to that of intact Ig. 
 
There is avid uptake and catabolism of FLCs and other proteins from glomerular 
ultrafiltrate by PTEC.(Pesce et al. 1980; Sanders et al. 1987) Up to 30 g/day of low 
MW protein can be processed by this pathway. Consequently, only 1-10 mg/day of FLC 
appears in the urine of individuals with normal kidney function.(Wochner et al. 1967; 
Maack et al. 1979; Clyne and Pollak 1981) If the FLC load presented to the proximal 
tubule exceeds reabsorptive capacity, then FLCs will pass into the distal nephron and 
can ultimately be detected in the urine, where, in PCD, it is also referred to as Bence 
Jones protein. 
 
The internalisation of FLCs by PTEC is a constant process and not influenced by the 
isoelectric point (pI) of an individual light chain.(Smolens and Miller 1987) Uptake 
occurs through rapid and saturable megalin-cubilin receptor-mediated endocytosis that 
utilises the clathrin-coated pit pathway, and results in vesicular trafficking, where the 
receptors are returned to the cell surface, and the endocytic vesicles containing their 
cargo enter the endosomal-lysosomal pathway and are acidified.(Batuman et al. 1990; 
Batuman and Guan 1997; Batuman et al. 1998; Klassen et al. 2005) This pathway is 
also dependent on receptor associated protein (RAP), which has a chaperone-like 
function to megalin.(Verroust et al. 2002) Megalin and cubilin also bind a wide range of 
other ligands, including albumin and provide a highly efficient physiological 
mechanism for conserving AAs and essential protein-bound molecules.(Christensen and 
Birn 2001; Kozyraki et al. 2001; Birn et al. 2005)  
  
 10 
1.4 Why do Some Clonal FLCs Cause Kidney Injury? 
FLCs isolated from patients with PCD and kidney injury have a higher ability to self-
associate and form higher MW aggregates under physiological conditions than FLCs 
purified from patients with PCD but without kidney injury. This is irrespective of the 
underlying type of renal injury.(Myatt et al. 1994) Furthermore, mice injected with 
FLCs from patients with a range of renal lesions developed similar lesions in the animal 
indicating that specific clones of FLCs cause a distinct pattern of injury.(Solomon et al. 
1991) This supports the principle that the primary structure of the molecule is an 
important determinant of the pattern of injury seen. 
 
1.5 Resident Renal Cells are Differentially Predisposed to Injury by FLC  
FLCs filtered from glomerular capillary blood are transported into the mesangium or 
pass into tubular ultrafiltrate. The responses of mesangial and tubular epithelial cells to 
the individual clone of FLC determine the specific patterns of injury that are seen at 
both sites. 
 
Mesangial Cells (MCs) support and maintain the glomerulus by secreting both 
extracellular matrix (ECM) and mediators and enzymes such as matrix 
metalloproteinases (MMPs), which regulate the composition and structure of ECM and 
the biological activity of MCs and other glomerular cells.(Schlondorff 1996; Vu and 
Werb 2000; Parks 1999; Mott and Werb 2004; Massova et al. 1998; Van Wart and 
Birkedal-Hansen 1990; Steffensen et al. 2001; Visse and Nagase 2003) Clonal FLC 
may disrupt these processes and cause glomerular injury by: (i) upon uptake promoting 
phenotypic changes in MCs, (ii) secretion into the ECM by MCs as amyloidosis fibrils 
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or LCDD deposits; (iii) direct deposition into the mesangium without cell processing. 
Interactions of mesangial cells with FLCs that cause glomerular injury are summarised 
in Figure 1.2. 
 
1.6 Disease Specific Considerations for Mesangial Cells and Glomerular 
Pathology 
1.6.1 AL Amyloidosis  
FLCs are the commonest cause of amyloidosis of at least 25 structurally unrelated 
proteins.(Westermark 2005) They are the most structurally diverse group of proteins 
implicated in this disease. The disease is recognised on histology by Congo red staining 
and apple-green birefringence under polarised light.(Divry and Florkin 1927) AL-
amyloidosis is associated primarily with PCD but can be associated with clonal 
proliferation of any cell of B-cell lineage.(Simmonds et al. 1997; Morel-Maroger et al. 
1970) Approximately 10% of patients with multiple myeloma also have detectable 
tissue deposits of AL-amyloid.(Kapadia 1980)  
 
AL-amyloidosis is defined in situ by immunostaining and electron microscopy. The 
presence of hypervariable regions may account for variable detection by specific 
antisera in conventional immunohistochemistry. Gold immunoelectron microscopy is a 
more sensitive and reliable method for identifying AL amyloidois in situ,(Toyoda et al. 
1991) however this is not always available in routine clinical practice.(Veeramachaneni 
et al. 2004) Biochemical typing of amyloid from formalin-fixed, paraffin-embedded  
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Figure 1.2.Interactions of FLCs with mesangial cells. 
(Legend on following page) 
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Figure 1.2 AL-amyloidosis (left) and LCDD (right). Both AL-amyloid and LCDD FLCs share a common route of entry into 
mesangial cells via a putative receptor. However, they are channelled into different intracellular trafficking pathways and exhibit 
different effects on the cell. AL-amyloid FLCs are catabolised within lysosomes, whereas LCDD FLCs are processed in endosomes. 
Processed FLCs are deposited in the mesangium as fibrils in the case of AL-amyloidosis, or as granular deposits with increased ECM in 
the case of LCDD. Both types of FLC initiate intracellular signalling, with migration of c-fos and NF-κB to the nucleus resulting in 
transcription of MCP-1 and PDGF-β. The release of PDGF-β is more pronounced with LCDD FLCs compared to AL-amyloid FLCs. 
MCP-1 recruits inflammatory cells. PDGF-β i) causes cell surface ruffling, resulting in increased cell surface area, and ii) promotes early 
mesangial cell proliferation, which is more pronounced in LCDD than AL-amyloidosis. TGF-β production is increased in LCDD, which 
i) causes cell deletion later in the disease and, ii) increases production of ECM proteins. Expression of MMP-7, which degrades tenascin, 
is reduced in LCDD. The result is increased ECM. In AL-amyloidosis, production of TGF-β is not increased and there is increased 
expression of MMPs, resulting in destruction of ECM, which is then replaced by amyloid fibrils. In vitro, mesangial cells undergo 
phenotypic changes in response to these FLCs: AL-amyloid FLCs induce a macrophage-like phenotype, in keeping with a more catabolic 
role. LCDD FLCs induce a myofibroblast-like phenotype, in keeping with a more synthetic role.    
LC, light chain;  SMA, smooth muscle actin; EEA, early endosomal antigen; MMP, matrix metalloproteinases; ECM, extracellular 
matrix. 
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specimens, as well as proteomic techniques have been reported, but these are not widely 
available.(Goni and Gallo 2005; Murphy et al. 2001)  
 
In AL amyloidosis FLCs aggregate into fibrillary, non-branching, beta-pleated sheet 
structures between 7 and 12 nm thick. As the disease develops there is a progressive 
replacement of normal matrix by amyloid fibrils, leading to destruction of glomerular 
architecture.(von Gise et al. 1981; Herrera et al. 1999; Herrera 2000) It has been shown 
that B cells from patients with AL-amyloidosis produced both intact FLCs and 
fragments of FLC, and these can then be extracted from amyloid deposits within the 
patient’s kidneys, suggesting that abnormal synthesis and/or ineffective proteolysis are 
important for the development of the disease.(Picken et al. 1986) The role of abnormal 
synthesis is emphasised by the ability of human amyloidogenic FLCs to cause 
amyloidosis in a murine model.(Solomon et al. 1992) A crucial co-factor in the 
development of the disease is the presence of serum amyloid protein (SAP) which binds 
to and protects fibrils from proteolytic degradation.(Gallo et al. 1988; Tennent et al. 
1995) SAP is a member of the pentraxin family of proteins, which are manufactured in 
the liver and also include C-reactive protein.   
 
1.6.2 Light Chain Variants and Amyloidosis 
AL-amyloidosis is more frequently associated with λ FLCs than κ FLCs.(Abraham et 
al. 2003; Bellotti et al. 2000; Dember 2006) FLCs containing the V λ VI subgroup have 
been demonstrated to be differentially deposited in the glomerulus compared to other 
sites.(Solomon et al. 1982; Comenzo et al. 2001) 
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It is the structural heterogeneity of the VL region that determines the organ specificity of 
the individual FLC.(Nyquist et al. 1993; Preud'homme et al. 1994; Abraham et al. 
2003; Bellotti et al. 2000) In one study, two recombinant VL domains derived from 
amyloidogenic FLCs  were compared to a VL domain derived from FLC which was not 
amyloidogenic.(Raffen et al. 1999) In vitro, amyloidogenic VL was significantly less 
stable in thermodynamic studies and tended to form fibrils. Site-directed mutagenesis 
showed that only destabilising AA substitutions induced fibril formation.  Denaturing 
the non-amyloidogenic VL with guanidine hydrochloride conferred fibril forming 
ability, further indicating that the stability of FLCs may determine amyloidogenic 
properties. Indeed, sequencing of AL-amyloid fibrils have demonstrated that the 
constituent FLCs can have different primary structures due to AA substitutions.(Dwulet 
et al. 1986; Karimi et al. 2003)  
 
Changes in AA sequences lead not only to changes in primary and secondary structure, 
but also to different post translational modifications, such as glycosylation,(Nyquist et 
al. 1993; Preud'homme et al. 1994; Stevens et al. 1995; Wetzel 1997) which are 
strongly correlated with formation of amyloid.(Nyquist et al. 1993; Omtvedt et al. 
2000) Amyloidogenic FLCs may have abnormal glycosylation in the hypervariable 
CDR or framework regions.(Omtvedt et al. 2000) Introduction of glycosylation receptor 
sites by AA substitutions may also increase the risk of fibril formation.(Stevens 2000) 
 
1.6.3 Differential Tissue Distribution in Amyloid  
In some groups of patients, despite the amyloidogenic FLCs being derived from the 
same gene with subsequent similarities in FLC structure, there can be pronounced 
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variability in deposition patterns.(Enqvist et al.) These observations imply that although 
the gene has some influence on tissue distribution of amyloid, other factors such as 
somatic mutations and post-translational modifications are also important determinants 
of distribution. Additionally, local tissue characteristics at sites of deposition are likely 
to play a role. This is supported by a recent report of a series of eight patients with 
cardiac Ig deposition disease, in four of whom there was amyloid deposition at 
extracardiac sites, while none had cardiac amyloid.(Toor et al. 2006) In the kidney, the 
glomerular basement membrane contains glycosaminoglycans, which are thought to 
interact with amyloidogenic proteins and promote fibril deposition by: i) inducing 
conformational changes; ii) stabilizing these proteins and iii) providing protection from 
proteolysis.(Scholefield et al.; Yamaguchi et al.; Zhu et al.; Ancsin and Kisilevsky; 
Stevens and Kisilevsky)   
 
1.6.4 Light Chain Deposition Disease  
Light chain deposition disease (LCDD) predominantly involves the glomerulus but can 
also be seen on tubular basement membrane. Kappa FLCs, particularly those containing 
the VκIV subgroup are over-represented in this disease.(Denoroy et al. 1994; Ganeval 
et al. 1984) In patients with PCD, LCDD is present in 5%,(Kyle 1975) and around two-
thirds have multiple myeloma.(Pozzi et al. 2003) The classical finding by light 
microscopy is of nodular glomerulosclerosis, similar in appearance to the Kimmelstiel-
Wilson nodules of diabetic nephropathy.(Bruneval et al. 1985) In early involvement the 
findings may resemble mesangial or membranoproliferative 
glomerulonephritis.(Sanders et al. 1991; Turbat-Herrera et al. 1997) The nodules 
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consist of extracellular matrix (ECM) proteins and clonal FLC. Free light chains can 
also be deposited in glomerular capillary walls. 
 
There are unusual hydrophobic AA substitutions in the CDR regions of LCDD 
associated FLCs.(Deret et al. 1997) These may facilitate a one-step precipitation out of 
solution in tissues, explaining the amorphous nature of LCDD deposits, as opposed to 
the organised, fibrillary deposition seen in amyloid, where electrostatic interactions may 
be more important.  
 
1.7 Cell Specific Processing and Activation Leads to the Differential Patterns 
that are seen in FLC Disease 
A direct toxic effect of FLCs on resident renal cells including MCs is supported by the 
observation that cytoreduction therapy aimed at the FLC-producing B-cell clone can 
result in the rapid improvement of clinical features such as proteinuria.(Dember et al. 
2001; Leung et al. 2005) These improvements occur too early to be explained purely by 
regression of disease in situ.(Zeier et al. 2003; Kyle et al. 1982; Merlini and Bellotti 
2003)  
 
Light chains affect MC function with expansion of ECM,(Sanders et al. 1991; Herrera 
et al. 1999; Turbat-Herrera et al. 1997; Johnson 1994; Keeling and Herrera 2005c; 
Schnaper et al. 1996) transformation of MC phenotype,(Johnson 1994; Ronco et al. 
2001; Darby et al. 1990; Watanabe et al. 2001; Herrera et al. 2001; Striker et al. 1989; 
Keeling et al. 2004) and the deposition of FLC derived protein in the 
mesangium.(Herrera et al. 1999; Turbat-Herrera et al. 1997) However there are 
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fundamental differences between different disease states in the handling and therefore 
the potential clinical manifestations associated with FLC clonality. For example, a 
central feature of amyloidogenic FLCs in vitro is the transformation of MCs to a 
macrophage phenotype.(Herrera et al. 2001; Keeling et al. 2004) The cells develop 
lysosomes within which degradation and remodeling of FLCs into amyloid 
occurs.(Shirahama and Cohen 1973; Shirahama and Cohen 1975; Bohne et al. 2004) 
Conversely, MC treated with LCDD FLCs are more likely to evolve a myofibroblast 
phenotype. 
 
Receptor mediated uptake of FLCs by MCs has been proposed.(Russell et al. 2001; 
Teng et al. 2004) Although this may be a common receptor, different types of FLCs 
activate different signalling pathways.(Teng et al. 2004; Russell et al. 2001) 
Amyloidogenic FLCs are internalized and transported to mature lysosomes, indicating 
involvement of the clathrin-coated pit pathway. In contrast, LCDD FLCs are 
predominantly phagocytosed into the endosomal compartment. Preferential uptake of 
certain species of FLC by MCs may partly explain favoured deposition in the kidney of 
light chains derived from specific germ lines such as VVI.(Comenzo et al.; Keeling et 
al.; Teng et al.) Further, studies have shown that tubulopathic FLCs are not taken up 
into MCs, indicating that they do not bind to receptors and in vivo would have passed 
unhindered to the proximal tubule. (Russell et al.)  
 
Although MCs are necessary for the formation of amyloid, there is both in vitro and in 
vivo evidence to support the hypothesis that amyloid fibrils themselves, once deposited, 
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can act as niduses for propagation, thus enhancing amyloid deposition.(Tagouri et al.; 
Merlini and Westermark; Lundmark et al.)   
 
The signalling pathways that are activated when glomerulopathic FLCs interact with 
MCs are being defined.(Russell et al. 2001; Rovin et al. 1995) Free light chains from 
patients with LCDD and AL-amyloidosis rapidly promote the migration of c-fos and 
NF-κB to the nucleus.(Russell et al. 2001) c-fos promotes cell surface ruffling, which 
increases cell surface area and interactions with FLC and also promotes secretion of 
PDGF-, with cell proliferation.(Russell et al. 2001) LCDD FLCs promote more 
PDGF- release than Amyloid FLCs; this may account for the early proliferative lesions 
seen in LCDD, before matrix expansion reaches a stage where cell deletion occurs. NF-
κB leads to gene activation and release of CSF-1, RANTES and MCP-1.(Russell et al. 
2001; Rovin et al. 1995; Duque et al. 1997) These cytokines promote the recruitment of 
inflammatory cells to the glomerulus. 
 
1.8 The Differential Role of TGF Beta in Amyloid and LCDD 
TGF- modulates progression of LCDD and AL-amyloid.(Sugiyama et al. 1996; Zhu et 
al. 1995; Teng et al. 2003) In MC culture, FLCs from patients with LCDD have been 
shown to alter calcium homeostasis, reduce cell proliferation, and increase extracellular 
matrix (ECM) secretion, including tenascin, an important protein component of ECM, 
and these effects are mediated by TGF-.(Truong et al.; Zhu et al. 1995; Zhu et al. 
1997) Blocking vesicular transport between endoplasmic reticulum and the Golgi 
apparatus in cells exposed to TGF-  normalised production of fibronectin and 
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tenascin.(Teng et al. 2003) PDGF- and TGF- act independently. PDGF- can induce 
cell proliferation, but does not influence tenascin and fibronectin production, however; 
these are regulated by TGF-. TGF- production has been shown to be increased by 
LCDD FLCs, but not by AL-amyloidosis FLCs.(Keeling and Herrera 2009) This may 
explain why in LCDD, there is greatly increased matrix, while in amyloid the matrix is 
replaced by fibrils. Finally, cell deletion by apoptosis in glomerulosclerosis is in part 
triggered by TGF-β. In vitro, FLCs from LCDD enhance TGF- mediated apoptosis of 
MCs.(Sugiyama et al. 1996; Negulescu et al. 2002; Herrera et al. 1994; Tagouri et al. 
1995)   
 
1.9 Matrix Metalloproteinases 
A number of studies have indicated that glomerular pathology may reflect expression 
patterns of MMPs.(Keeling and Herrera 2005b; Keeling and Herrera 2005c; Keeling 
and Herrera 2005a; Keeling and Herrera 2009) In one study, the expression of certain 
MMPs was six times higher in kidney biopsies from patients with AL-amyloidosis 
compared to LCDD or negative controls.(Keeling and Herrera 2005b) Furthermore, 
MMP-2 activity is increased in AL-amyloidosis compared to LCDD. These data 
indicate that activation of MMPs following delivery of amyloidogenic FLCs to the 
mesangium leads to matrix destruction and replacement with amyloid fibrils.  
 
Conversely, tenascin is present in excess in LCDD, because of decreased levels of 
MMP-7, which degrades tenascin.(Herrera 2000; Turbat-Herrera et al. 1997) There is 
inhibition of release of MMP-7 from MC by LCDD FLCs (Imai et al. 1994); this effect 
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is not present with AL-amyloidosis FLCs and cast nephropathy FLCs.(Keeling and 
Herrera 2009)  
 
Finally, MC function may be modulated by extracellular matrix proteins.(Saito et al. 
1993; Martin et al. 2001) So abnormal mesangium produced by MCs activated by 
FLCs, may itself alter MC function, and further potentiate glomerulosclerosis.  
 
1.10 Tubulointerstitial Disease Associated with Light Chains: The Proximal 
Tubule  
1.10.1 Adult Acquired Fanconi Syndrome 
Adult acquired Fanconi syndrome (AAFS) is a unique entity defined by selective 
reabsorptive dysfunction of the proximal tubule, with glycosuria, aminoaciduria, 
phosphaturia and hyperuricosuria, as well as bicarbonate loss causing a proximal (type 
II) renal tubular acidosis.(Lacy and Gertz 1999) The commonest underlying cause is a 
PCD, which is often low grade.(Maldonado et al. 1975) Classically, the histological 
finding is of crystalline deposits of FLCs within PTEC and which are resistant to 
proteolysis. However this appearance is not always present. The FLCs responsible are 
most frequently of the VI subgroup,(Rocca et al. 1995; Messiaen et al. 2000) although 
cases of λ FLCs associated with AAFS have also been reported.(Thorner et al. 1983; 
Bate et al. 1998)  
 
In a sequence study of five κ FLCs from patients with AAFS, all three FLCs from 
patients with crystalline deposits were derived from the same LCO2/O12 gene and had 
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non-polar AA residues exposed in the CDR1 region and a lack of accessible side chains 
in CDR3.(Deret et al. 1999) Hydrophobic or non-polar AA residues have also been 
reported elsewhere.(Messiaen et al. 2000) Crystallisation may result from these two 
factors. There has also been a report of a case of a patient with abnormal proximal 
tubular reabsorption and crystalline inclusions within PTECs.(Decourt et al. 2003) 
Sequencing of this patient’s monoclonal protein revealed a FLC of VκI subgroup, with 
non-polar residue substitutions in CDR1.  
 
In most patients with multiple myeloma, the presence of defects of tubular reabsorption 
and urine acidification is a consequence of the direct toxicity of FLCs on PTECs in the 
absence of crystalline deposits.(DeFronzo et al. 1978) It has been demonstrated that 
FLCs from patients with myeloma interfere with uptake of alanine, phosphate and 
glucose.(Batuman et al. 1986; Batuman et al. 1994) Finally, there has been one report 
of case a case of PCD, AAFS (diagnosed without renal biopsy) and nephrogenic 
diabetes insipidus, suggesting one potential outcome of tubular dysfunction is ADH 
resistance.(Smithline et al. 1976) Interestingly, this patient had distal (type I), not 
proximal, renal tubular acidosis.  
 
1.10.2 Cast Nephropathy (Myeloma Kidney) 
Cast nephropathy, or myeloma kidney, is the commonest renal manifestation in 
PCDs.(Herrera et al. 2004; Ivanyi 1989) This condition is characterised by 
tubulointerstitial inflammation and fibrosis, associated with hard, often fractured distal 
tubular protein precipitates (casts), consisting of uromodulin and FLCs (figure 
1.3).(Pasquali et al. 1987; Pirani et al. 1987) There is usually a reaction around the casts 
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of multinucleated monocyte/macrophage-derived giant cells.(Start et al. 1988; Alpers et 
al. 1989) Distal tubular cast formation may also be seen in up to a third of cases of 
LCDD and AL-amyloid.(Pozzi et al. 2003) 
 
1.10.3 Proximal Tubular Toxicity 
Proximal tubular epithelial cells (PTEC) are the most abundant cell type in the kidney. 
They are highly efficient at recovering filtered proteins from the tubular lumen. Excess  
filtered protein, including FLCs, can overload this process with subsequent tubular 
injury, inflammation and progressive fibrosis.(Remuzzi and Bertani 1998; Abbate et al. 
1998; Remuzzi 1999; Zoja et al. 1999) In the setting of PCDs, exposure to clonal FLCs 
can have dramatic pathological effects. Much recent work has elucidated the 
mechanisms underlying FLC mediated damage to PTECs. Interactions of PTECs with 
FLCs that cause tubulointerstitial injury are summarised in Figure 1.4. 
 
Studies on the effects of human FLCs on rodent proximal tubule have observed 
abnormal flux of water, glucose and chloride.(Sanders et al. 1987) Histological  
examination showed desquamation of cells and cytoplasmic vacuolation. Similar 
findings were reported in renal tissue from human subjects with multiple myeloma but 
with no tubular cast formation.(Sanders et al. 1988b) 
 
A number of studies have contributed significantly to our understanding of the cell 
signaling events which take place after FLCs are bound by megalin and cubilin and 
internalised by PTECs. These changes range from functional, such as suppression of 
Na-K-ATPase gene expression and a decrease in cell metabolism,(Guan et al. 1999) to  
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Figure 1.3. Cast nephropathy and accelerated in situ progression of interstitial 
fibrosis in a patient with multiple myeloma. 
A: Renal biopsy at presentation showing typical features of cast nephropathy. There 
is evidence of proximal tubular damage, with vacuolation of cells and cell debris 
within the lumina. There is an interstitial cellular infiltrate. Distal tubules contain 
casts. Note that in this biopsy there is little evidence of fibrosis. B: Renal biopsy 
from the same patient after 6 weeks. There is extensive interstitial fibrosis, with 
severe tubular atrophy. Note that some tubules still contain casts. (Both images, 
periodic acid methanamine silver, x200 magnification) C: High-power view of a 
light chain cast in a patient with multiple myeloma.The appearance is hard and 
waxy, with fractures. There is a peritubular inflammatory infiltrate, with invasion of 
the lumen and adhesion of cells to the cast. A giant cell reaction around the cast is 
seen. These casts are composed of light chain and uromodulin. (H&E, x400 
magnification) 
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Figure 1.4. Interactions of FLCs with proximal tubule epithelial cells. 
(Legend on following page) 
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Figure 1.4 Interactions of FLCs with proximal tubule epithelial cells (PTECs). Trafficking events are shown on the left, and 
signalling events on the right. Filtered FLCs are delivered to the proximal tubule where they engage megalin and cubilin on the brush 
border. Receptor-ligand complexes are concentrated in clathrin coated pits (CCP) and endocytosed to coated vesicles (CV), which 
mature into endosomal vesicles (EV), where receptors and ligands are disengaged, following which, receptors are recycled to the 
luminal cell surface via dense apical tubules (DAT). FLCs undergo proteolysis into their constituent peptides and amino acids within 
mature lysosomes (Lys), and these products are returned to the circulation. Following endocytosis, an early event is the production of 
H2O2. H2O2 oxidises the tyrosine kinase c-Src to its active state. Downstream signalling leads to activation of NF-κB. Proteasome 
(Prot) mediated degradation of the Iκ-B permits nuclear translocation of NF-κB subunits, leading to transcription of inflammatory 
cytokines. Recruitment of inflammatory cells to the interstitium ensues, promoting fibrosis. Activation of MAPKs also occurs. These 
exert additional activating effects on NF-κB, as well as influencing transcription via other pathways. EMT is seen in vitro when 
PTECs are exposed to certain LCs, a phenomenon which may contribute to fibrosis in vivo.  
FSP-1, fibroblast-specific protein 1; ECM, extracellular matrix. 
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more dramatic ultrastructural changes. In a study of the differential effects of FLC 
clones on PTEC, cells underwent changes that included abnormalities in the actin 
cytoskeleton to DNA degradation, apoptosis and necrosis.(Pote et al. 2000) 
Cytotoxicity of FLCs in this study was also demonstrated by increased levels of lactate 
dehydrogenase (LDH) in cell culture supernatants, indicating increased cell death.  
 
On endocytosis of clonal FLC there is a dramatic increase in production of the 
inflammatory cytokines IL-6, IL-8 and MCP-1, events which are dependent on nuclear 
translocation of NF-κB subunits.(Sengul et al. 2002) The release of these cytokines 
would explain much of the inflammatory cell infiltration and fibrosis seen in myeloma 
kidney. A subsequent study demonstrated that mitogen activated protein kinases 
(MAPKs) ERK 1/2, JNK 1/2, and p38 play a role in signaling leading to the production 
of these cytokines.(Sengul et al. 2003) Pituitary adenylate cyclase activating 
polypeptide with 38 residues (PACAP38) modulates MAPK signaling and activation of 
NF-κB. It acts via the G-protein-coupled receptors PAC1, VPAC1 and VPAC2, which 
are known to initiate several signal transduction pathways.(Harmar et al. 1998) In 
PTECs, PACAP38 acting via PAC1 and VPAC1, abrogated translocation of NF-κB and 
cytokine production when exposed to FLCs.(Arimura et al. 2006) Cytokine production 
in rat kidneys after injection of the animal with FLCs was also suppressed by injection 
of PACAP38. Interestingly, PACAP38 also suppressed growth and proliferation of κ 
and λ secreting myeloma cells in culture, thereby making PACAP38 a potential 
therapeutic candidate for treating patients with myeloma kidney through targeting two 
pathogenic processes.(Li et al. 2006) There is a published case report of a patient where 
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PACAP38 was used and urinary FLC concentrations decreased significantly, however 
the patient was concomitantly receiving Dexamethasone. (Li et al. 2007)  
 
Activation of NF-B and subsequent nuclear translocation of its subunits is required for 
transcription of inflammatory mediators in response to FLC. Nuclear translocation and 
DNA binding is regulated by inhibitors (IB).(Perkins; Hayden and Ghosh; Sanz et al.) 
Activating stimuli result in engagement of the IB inhibitor, IB kinase (IKK). IKK 
phosphorylates IB, targeting it for ubiquitination and subsequent degradation by 
proteasomes, which then permits nuclear translocation of NF-B.(Sanz et al.) 
Bortezomib, which is used in the treatment of multiple myeloma, specifically inhibits 
the 26S proteasome.(Richardson et al.; Stanford and Zondor; Bonvini et al.) 
 
In some forms of renal fibrosis fibroblasts may be derived from epithelial cells, a 
process referred to as epithelial-to-mesenchymal transition (EMT).(Rastaldi et al. 2002; 
Liu 2004) On exposure of PTECs to FLCs, there is increased expression of cytokines 
and alpha-SMA and reduced E-cadherin expression, indicating transformation from an 
epithelial to a myofibroblast phenotype.(Li et al. 2008b) There is also increased 
expression of TGF-ß dependent ECM components. Silencing p38 MAPK suppressed 
cytokine release and EMT was attenuated by bone morphogenic protein-7 (BMP-7) and 
PACAP38. Blocking endocytosis of FLCs by silencing megalin and cubilin expression, 
has been shown to markedly suppress cytokine production and to prevent EMT after 
exposure of cells to FLCs.(Li et al. 2008a) 
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Antibodies can oxidize water to produce hydrogen peroxide (H2O2), a feature that may 
improve their effectiveness against their targets.(Wentworth et al. 2001) The reaction 
site for this has been localised to a highly conserved segment of the light chain VL 
region consisting of β-pleated sheets forming a hydrophobic core. It has now been 
shown that FLCs in solution can also oxidise water and that H2O2 levels are increased in 
the supernatant of PTEC treated with monoclonal FLCs.(Wang and Sanders 2007) This 
effect was not seen with non-immunoglobulin-derived proteins. Hydrogen peroxide can 
act as an intracellular second messenger during signal transduction in response to many 
stimuli, including protein overload of PTECs.(Rhee 2006; Morigi et al. 2002; Nathan 
2003) Furthermore, MCP-1 production was markedly reduced when either H2O2 or NF-
κB activity was blocked. H2O2 can diffuse across the cell membrane lipid bilayer and 
also pass through aquaporin channels, so the specific assessment of the relative 
contributions of intracellular and extracellular production is difficult;(Bienert et al. 
2007) however, the addition of catalase to the medium had no effect on MCP-1 
production, indicating that sufficient quantities of H2O2 were produced intracellularly 
for signaling. Direct activation of the redox-sensitive tyrosine kinase c-Src by this H2O2 
has now been established as a key step in the signal transduction cascade.(Basnayake et 
al.) Again, blocking receptor-mediated endocytosis by silencing megalin and cubilin 
expression was shown to abrogate the MCP-1 response. c-Src has a central role in signal 
transduction in response to many external stimuli, and may be a potential therapeutic 
target.(Parsons and Parsons; Kim et al.)   
 
In many of these studies, it was repeatedly observed that FLCs have far more powerful 
proinflammatory effects on PTECs than other filtered proteins commonly implicated in 
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proximal tubule inflammation, such as albumin.(Sanders et al. 1987; Sengul et al. 2002; 
Li et al. 2008b; Wang and Sanders 2007) Although this effect may be multifactorial is 
likely that a significant component is associated with H2O2 production.  
 
1.11 Distal Tubular Cast Formation  
1.11.1 Tubular Toxicity and Cast Formation 
The primary structure of a protein influences the pI; when the pI is close to the ambient 
pH a protein carries no net charge and tends to precipitate out of solution.(Arakawa and 
Timasheff 1985) There is no correlation between the pI of a FLC clone and cytotoxicity 
to PTEC,(Sanders et al. 1988a; Norden et al. 1989; Smolens et al. 1983) despite a wide 
variation in pI between FLC clones.(Johns et al. 1986) This reflects pI independent 
receptor-mediated uptake of FLCs into PTECs. However, the pI does influence the 
potential of FLCs to  precipitate in the distal nephron.(Sanders et al. 1988a) Low MW 
proteins with pIs of 5.6-7.3 precipitated in the ascending limb of the Loop of Henle and 
distal tubule, while a protein with a pI of 5.1 precipitated more distally. As tubular fluid 
travels down the distal nephron acidification occurs through physiological mechanisms, 
this may then facilitate precipitation of proteins of progressively lower pI. This is 
supported by the observation that alkalinisation of urine ameliorated the negative effects 
of FLCs on inulin clearance in rats.(Holland et al. 1985) Other factors such as tubular 
fluid concentration, reduced flow rates, and the presence of uromodulin may also 
contribute. 
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Uromodulin is secreted by cells of the thick ascending limb of the Loop of Henle. It is 
heavily glycosylated, with the carbohydrate moiety accounting for 30% of a molecular 
weight of 80 kDa. It has a pI of 3.5.(Fletcher et al. 1970b; Fletcher et al. 1970a; Clyne 
et al. 1979) Uromodulin is tethered to the luminal cell surface membrane by a 
glycosylphosphatidylinositol (GPI) anchor. This is eventually cleaved, allowing 
uromodulin to be carried by tubular fluid down the distal nephron and to appear in the 
urine.(Rindler et al. 1990; Weichhart et al. 2005) It is the main urinary protein in 
healthy individuals, excreted at 30-50mg/day.(Hoyer and Seiler 1979; Kumar and 
Muchmore 1990; Serafini-Cessi et al. 2003) Uromodulin can self-aggregate into a gel-
like material, a process which is affected by increasing electrolyte concentrations in 
ambient solution.(Porter and Tamm 1955; Patel et al. 1964; Stevenson et al. 1971) It 
has the ability to bind to and co-precipitate with many low molecular weight 
proteins.(Sanders et al. 1988a; Koss et al. 1976; Bock 1997; Sanders et al. 1990) FLC 
interactions with uromodulin to promote cast formation in the distal nephron are 
summarised in figure 1.5. 
 
The specific physiological functions of uromodulin have yet to be elucidated. However 
there is evidence to support roles in protecting against ascending urinary tract infection 
and modulating immune responses.(Kumar and Muchmore 1990; Bates et al. 2004; Pak 
et al. 2001) Uromodulin has been shown to bind directly to certain fimbriated 
Escherichia coli strains.(Pak et al. 2001) It may have a pro-inflammatory role by the 
induction of inflammatory cytokines such as TNF-α and IL-8 from 
monocyte/macrophages and neutrophils.(Su et al. 1997; Kreft et al. 2002; Prajczer et al. 
2010) Uromodulin has also been shown to encourage neutrophil transmigration across  
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Figure 1.5. Light chain interactions in the distal nephron. 
(Legend on following page) 
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Figure 1.5 Uromodulin is secreted from the thick ascending limb of the loop of Henle. Upon cleavage of  its 
glycosylphosphatidylinositol (GPI) anchor, free uromodulin is released into the tubular lumen. FLCs entering this section of the 
nephron can bind directly to uromodulin. Uromodulin has the ability to form a gel, influenced by increasing electrolyte content and 
osmolality. Cast formation is also enhanced by these factors, which in the clinical setting can be caused by dehydration, 
hypercalcaemia, diuretics, non-steroidal anti-inflammatory agents and radiocontrast media. Cast formation results in increased 
intratubular pressure. Physiological mechanisms can increase tubular fluid osmolality and acidity, and the latter may affect FLC 
solubility by virtue of isoelectric point. Cast nephropathy is associated with interstitial inflammatory cell infiltration and invasion of the 
tubule, with macrophage-derived giant cell reaction around the casts. Uromodulin has been shown to activate dendritic cells and 
macrophage by direct engagement of toll-like receptor-4, facilitate transmigration of neutrophils across epithelial monolayers in vitro, 
and effect the release of inflammatory mediators from these cells. Inflammation may be exacerbated by damage to tubular basement 
membrane (BM) with leakage of uromodulin into the interstitium.  
Abbreviations: TAL, thick ascending limb; LC, light chain; BM, basement membrane. 
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renal epithelial monolayers in vitro.(Schmid et al. 2010) Macrophages and dendritic 
cells are activated by uromodulin through direct engagement of toll-like receptor 4 
(TLR4) and subsequent mobilisation of NF-κB, a phenomenon which may help innate 
immune cells identify invading pathogens with uromodulin bound to their 
surfaces.(Saemann et al. 2005; Anders et al. 2004) Although speculative, it is possible 
that, through these mechanisms, uromodulin attracts inflammatory cells to sites of cast 
formation, one consequence of which is the frequently seen giant cell reaction around 
casts.  
 
Animal studies have elucidated our understanding of myeloma cast formation to a 
considerable extent. Using an in vivo rodent nephron microperfusion model, it has been 
shown that certain low MW proteins (including FLCs), caused morphological damage 
to PTECs and interfered with fluid, chloride and glucose transport, while others 
precipitated in the distal tubule as casts.(Sanders et al. 1988a) These data support the 
concept that some FLC clones are toxic to the proximal tubule, while others FLC clones 
are cast-forming.  
 
 A subsequent microperfusion study demonstrated that cast forming proteins (FLCs and 
myoglobin) reduced chloride absorption in the proximal tubule. With FLCs, this was 
observed in a dose-dependent manner. In vitro, low MW proteins including all FLCs 
tested aggregated with uromodulin. Aggregation was dependent on the pI of the protein, 
as evidenced by albumin (pI 4.8) not binding uromodulin but cationic albumin (pI 9.2) 
binding very strongly. Aggregation was enhanced by increasing sodium chloride and 
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calcium ion concentrations in the solution. This may be a result of sodium and calcium 
ions increasing the viscosity of solutions containing uromodulin.(Stevenson et al. 1971) 
 
The rate of cast precipitation in nephrons infused with FLCs is related to the 
concentration of FLCs in solution, but can occur down to very low 
concentrations.(Sanders and Booker 1992) Obstruction of individual nephrons can 
result in tubular atrophy.(Tanner and Knopp 1986; Tanner and Evan 1989) Cast 
formation is accompanied by a rise in intratubular pressure, confirming the physical 
obstruction of tubules by casts.(Sanders and Booker 1992) Impairment of tubular fluid 
flow in other conditions has been associated with backflow and the presence of 
uromodulin upstream of its site of production, as far as the glomerulus.(McGiven et al. 
1978) It may be possible that uromodulin also contributes to inflammation at these sites.  
 
Reducing extracellular fluid volume by reducing fluid delivery to the animal, or 
concentrating tubular fluid by administering furosemide promoted aggregation of FLCs 
with uromodulin. Colchicine, by reducing uromodulin secretion by the nephron and 
reducing the carbohydrate composition of uromodulin, prevented cast 
formation.(Sanders and Booker 1992) An in vitro study to investigate the nature of FLC 
binding to uromodulin was then performed.(Huang et al. 1993) Different clones of 
FLCs bound to uromodulin with varying affinities. A specific region of uromodulin was 
identified as the binding site of all the FLCs tested. As FLCs bound to glycosylated as 
well as deglycosylated uromodulin, this region was inferred to be a peptide sequence. 
This was supported by blockade of FLC binding by a monoclonal antibody against a 
specific peptide segment of uromodulin. Subsequently a 9 AA sequence on uromodulin 
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was identified as the FLC binding domain,(Huang and Sanders 1997) with the CDR3 
region of FLCs as the site of interaction with uromodulin.(Ying and Sanders 2001)  
 
The presentation of patients with acute cast nephropathy has been associated with 
dehydration, hypercalcaemia, administration of diuretics and radiological contrast 
media.(Goranov 1996) The role of some of these co-factors have also been investigated 
in the binding of FLCs to uromodulin.(Huang and Sanders 1995) Acidic pH, calcium 
and furosemide increased FLC aggregation with uromodulin obtained from the urine of 
healthy donors. Treatment of the donors with colchicine resulted in them excreting 
uromodulin with reduced self-aggregation, but with no difference in the binding 
potential to FLC clones.  
 
The process of cast formation is likely to reflect multiple factors. The binding of FLCs 
to uromodulin is not multivalent. However, uromodulin can aggregate to form a gel 
depending on ambient conditions and it may be that upon FLC engagement, uromodulin 
undergoes an unknown conformational change, which further promotes aggregation or 
precipitation out of solution. Influenced by pH and other factors, FLCs in high 
concentrations entering the distal tubule may also precipitate without interaction with 
uromodulin, and be trapped within the uromodulin-gel, forming part of a larger 
cast.(Wangsiripaisan et al. 2001)  
 
1.12 Polyclonal Elevations in Light Chain Levels 
Polyclonal elevations in FLCs may result from either reduced clearance or increased 
production. Hutchison et al have shown that serum and urine polyclonal FLC 
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concentrations are raised in patients with CKD.(Hutchison et al. 2008c) In this study, 
the authors demonstrated a stepwise increase in serum polyclonal FLCs with an 
incremental decline in kidney function, an observation which reflects the fact that 
clearance of FLCs is GFR dependent. The results of this study raises the hypothesis that 
as CKD progresses and the number of functioning nephrons declines, the remaining 
nephrons are exposed to higher concentrations of polyclonal FLCs, leading to 
potentiation of pro-inflammatory signalling and thus fibrosis. Although the 
concentrations of polyclonal FLCs in CKD are lower than those of monoclonal FLCs 
often seen in multiple myeloma, the exposure occurs over a prolonged period.  
 
Polyclonal FLC levels are also elevated (independent of renal function) with generalised 
B-cell stimulation, in conditions such as systemic lupus erythematosus, rheumatoid 
arthritis, primary Sjogren’s disease and chronic infections.(Hoffman et al. 2003; 
Gottenberg et al. 2007; Solling et al. 1981) It is worth noting that although renal 
impairment is not infrequently seen in such conditions, the underlying causes of kidney 
injury are related to the individual disease or treatment and not related to 
FLCs.(O'Callaghan 2004)  
 
Investigations into the biological effects of polyclonal FLCs in the literature are few. 
The paucity of in vitro studies is likely to be a reflection of the complexity of purifying 
these proteins. They are normally present in serum and urine in only small 
concentrations and form only a small proportion of the total soluble protein. These 
factors can affect the efficiency of protein extraction processes.  
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A role for polyclonal FLCs as uraemic toxins which affect neutrophil function has been 
investigated by Cohen and co-workers.(Cohen et al. 1995; Cohen et al. 2003) These in 
vitro studies demonstrated that polyclonal FLCs isolated from dialysis effluent were 
capable of inhibiting essential functions of neutrophils. Neutrophils exposed to these 
FLCs exhibited a reduced state of activation, as assessed by hexose uptake, as well as 
reduced chemotaxis towards N-formyl-methionyl-leucyl-phenylalanine methyl-ester 
(fMLP-M). One consequence of this phenomenon in vivo might be an increased 
susceptibility to bacterial infections. These polyclonal FLCs were also able to prevent 
neutrophil apoptosis in a concentration-dependent manner in vitro. Phagocytic function 
was unaffected. In vivo, neutrophils perform a vital role in attacking and killing 
invading microorganisms. Timely removal of spent neutrophils, which are senescent 
and apoptotic, by macrophages is a crucial factor in controlling the balance between 
inflammation and repair at sites of infection and injury, by preventing excessive 
collateral damage and prolonged inflammation that may be caused by toxic neutrophil 
contents spilling into the interstitium.(Savill et al. 1989; Heinzelmann et al. 1999)  
 
Whilst polyclonal FLCs may have a dysregulatory effect on neutrophil function, there 
have been no published basic science studies to date on a direct renal effect and there is 
no demonstrable causative link between polyclonal FLCs and the progression of renal 
disease.  
 
As CKD progresses and serum polyclonal FLC concentrations rise, the remaining 
nephrons are exposed to increased levels filtered of FLCs. This would then result in 
increased uptake of FLCs into PTECs by receptor-mediated endocytosis. It may be 
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possible that in this setting, polyclonal FLCs exert pro-inflammatory effects on PTECs 
similar to monoclonal FLCs. If this were to be true, then it would be expected that in 
vitro, H2O2 generation might be observed in response to polyclonal FLCs. Such an 
observation would be highly significant, because this appears to be the initiating event 
in signal transduction, following endocytosis, resulting in the release of MCP-1 from 
PTECs, when they are exposed to monoclonal FLCs.(Wang and Sanders 2007)  
 
Another observation that would be expected if polyclonal FLCs contributed to renal 
disease, is increased release of MCP-1 from PTECs after exposure. Although a number 
of cytokines have been reported to be released from PTECs in response to monoclonal 
FLCs, including IL-6 and IL-8, MCP-1 is of particular interest in the development and 
progression of renal interstitial fibrosis for a number of reasons. First, localised, intra-
renal production of MCP-1 plays a major role in inflammation by directing macrophage 
recruitment to sites of injury in the interstitium.(Grandaliano et al. 1996; Tesch et al. 
1999) Second, urinary, but not serum, MCP-1 levels are elevated in patients with CKD, 
supporting the importance of intra-renal production.(Wada et al. 2000) Third, there are 
close relationships between urinary MCP-1 and both albumin/creatinine ratio (ACR) 
and infiltrating macrophage numbers.(Eardley et al. 2006) Fourth, PTECs are likely to 
be the major source of MCP-1 in CKD in the absence of acute proliferative 
glomerulonephritis.(Grandaliano et al. 1996) Fifth, MCP-1 can also stimulate PTECs to 
secrete additional inflammatory mediators.(Viedt et al. 2002) All of these observations 
point to a central role for MCP-1 in progression of renal fibrosis.  
 
  
 40 
Some monoclonal FLCs have also been shown to have cytotoxic effects on 
PTECs.(Pote et al. 2000) If polyclonal FLCs also had such cytotoxic potential, PTECs 
exposed to these FLCs would be expected to undergo lysis, releasing LDH into the cell 
culture supernatants.  
 
One of the most commonly performed tests in the investigation of kidney disease is the 
microscopic examination of urinary sediment. A common finding in patients with CKD 
are urinary casts, composed of proteins (hyaline casts) or a mixture of cell types 
(granular, waxy or broad casts) bound together with uromodulin.(Simerville et al.) 
Since it is known that uromodulin also binds to FLCs with high affinity, and there is an 
increased filtered load of FLCs in CKD, it may be possible that polyclonal FLCs exert a 
biological effect in the kidney in CKD. If this hypothesis were true, then it could be 
expected that polyclonal FLCs could be detected in kidney tissue from patients with 
CKD by immunohistochemical methods. Quantification of casts in situ might also 
provide useful information on progression of disease.   
 
1.13 Scope of this Thesis and Hypothesis 
From reviewing the literature it is clear that monoclonal FLCs cause a broad spectrum 
of renal diseases. All compartments of the kidney can be affected, and diseases can be 
broadly classified into those affecting the glomerulus or the tubulo-interstitium. 
Knowledge of how injury is mediated is growing. Free light chains can: promote 
functional changes; be processed and deposited; mediate inflammation, apoptosis and 
fibrosis; and physically obstruct nephrons. Each clone of FLC is unique and the precise 
type of pathology caused is determined by the primary structure and post-translational 
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modification of that clone. Treatment of clonal FLC disease is evolving and knowledge 
of the pathways that promote renal injury should lead to the further development of new 
treatments that specifically target this component of plasma cell dyscrasias. 
 
In CKD, the clearance of FLCs is dependent on GFR. As CKD progresses and the 
number of functioning nephrons dwindles, the quantity of polyclonal FLCs delivered to 
the remaining hyperfiltering nephrons increases. Although there have been a small 
number of studies on neutrophils, there are no published studies to date on the effects of 
polyclonal FLCs in the kidney and on progression of renal fibrosis.  
 
The primary hypothesis of this thesis is that in the setting of CKD, polyclonal FLCs 
exert pro-inflammatory effects, which are similar to those exerted by monoclonal FLCs 
in myeloma kidney. These effects are achieved by activation of PTECs and cast 
formation in distal tubules leading to progressive fibrosis and progression of CKD.  
 
The aims of the studies presented in this thesis are: (i) to further assess the pathogenicity 
of monoclonal immunoglobulin light chains in myeloma kidney; (ii) to explore the 
hypothesis that increased serum polyclonal FLC levels in the setting of CKD and the 
resulting increased delivery of polyclonal FLCs to remaining nephrons leads to injury, 
which then contributes to progression CKD.  
 
To address these aims, firstly I have performed detailed in situ morphometric analyses 
on kidney biopsy specimens obtained from patients with acute kidney injury due to 
myeloma cast nephropathy, as detailed in Chapter 3. Here, in addition to detailed 
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examination of the features of myeloma cast nephropathy, a comparison of histological 
features before and after a period of treatment aimed at reducing FLC concentrations 
and a comparison of histological features associated with renal outcomes is made. The 
findings indicated that whilst fibrosis may progress rapidly, a reduction in cast numbers 
in response to treatment might indicate potential for late renal recovery.  
 
In Chapter 4, I present results from an in vitro study of specific signalling events that 
occur with monoclonal FLCs. Here, it is shown that the link between H2O2 generation 
following FLC endocytosis and pro-inflammatory intracellular signalling, which results 
in transcription of MCP-1, is oxidation and activation of the redox-sensitive tyrosine 
kinase c-Src.   
 
Chapter 5 details the development of methodology for the purification of polyclonal  
and  FLCs from pooled blood donor sera, by applying advanced protein chemistry 
techniques.  
 
In Chapter 6, I present results from detailed in situ studies performed on kidney biopsies 
from patients with CKD. First, patterns of deposition and co-localisation of polyclonal 
FLCs were demonstrated. Polyclonal FLCs were seen within PTECs, as well as in distal 
tubular casts. An assessment of casts in these biopsies is then presented, demonstrating 
their relationship with established, robust markers of CKD progression.  
 
In Chapter 7, the in situ findings of Chapter 6 are complemented by in vitro studies, 
using the polyclonal FLCs purified as described in Chapter 5. Here, an assessment of 
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the pathogenicity of polyclonal FLCs in the proximal tubule is presented, followed by 
an assessment of the cast-forming ability of polyclonal FLCs in the distal nephron. The 
results indicated that whilst there is no detectable pro-inflammatory effect on PTECs, 
polyclonal FLCs, like monoclonal FLCs, can co-precipitate with uromodulin in distal 
tubules, to form casts.   
 
Chapter 2 contains details of materials and methods used. Chapter 8 is the discussion 
and conclusion.  
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Table 1.2. Renal manifestations of plasma cell dyscrasias, site and composition of deposits and summary of clinical and histological 
features.  
Renal Manifestation Associated 
Monoclonal 
Gammopathies 
Sites of 
Deposits 
Composition 
of Deposits 
Clinical Features Histological Features 
Cast nephropathy 
(myeloma kidney) 
Multiple myeloma, 
plasma cell leukaemia, 
Waldenström’s  
macroglobulinaemia 
PTEC, 
interstitium, 
distal tubules 
LC + 
Uromodulin 
Renal impairment: 20-
40% of patients at 
diagnosis, >50% 
during illness. ESRF: 
up to 10% 
PTEC damage, interstitial 
inflammation and fibrosis. 
Distal tubular casts with 
giant cell reaction 
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Renal Manifestation Associated 
Monoclonal 
Gammopathies 
Sites of 
Deposits 
Composition 
of Deposits 
Clinical Features Histological Features 
Amyloidosis AL-amyloidosis, AH- 
amyloidosis, multiple 
myeloma, plasma cell 
leukaemia, 
Waldenstrom’s 
macroglobulinaemia 
All 
compartments 
of kidney may 
be affected, but 
glomeruli 
predominate.  
LC: κ/λ 1:3  
HC 
Renal impairment: 
20% of patients at 
diagnosis, ESRF in 
20% by 1 year 
Proteinuria common 
Deposits stain with Congo 
red giving apple green 
birefringence under 
polarised light. EM: fibrils 
7-12nm wide and 30-
1000nm long 
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Renal Manifestation Associated 
Monoclonal 
Gammopathies 
Sites of 
Deposits 
Composition 
of Deposits 
Clinical Features Histological Features 
Monoclonal Ig 
deposition diseases 
i)LCDD 
ii) HCDD 
iii)LHCDD 
Multiple myeloma, 
plasma cell leukaemia 
Mesangium, 
peritubular 
areas, vascular 
and GBM 
i) LC: mainly 
VκI and VIV  
ii) HC 
iii)LC + HC 
(~10% of 
LCDD cases)  
Renal impairment: 
96% of patients over 
course of illness. 
ESRF in 60% at 1year. 
Proteinuria >1g/day: 
84%. Nephrotic range 
proteinuria: 40% 
 
Prominent mesangial 
nodules, thickening of 
peripheral basement 
membrane 
IF: LC (also HC in HCDD 
and LHCDD) in mesangial 
nodules, peritubular 
regions, vessels, 
interstitium and GBM.  
EM: Fine granular deposits 
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Renal Manifestation Associated 
Monoclonal 
Gammopathies 
Sites of 
Deposits 
Composition 
of Deposits 
Clinical Features Histological Features 
Crystal storing 
histiocytosis 
Multiple myeloma, 
Waldenström’s  
macroglobulinaemia 
Lysosomes in 
PTEC 
:λ 9:1 Acquired Fanconi 
syndrome, type II 
RTA, chronic renal 
impairment.   
 
Tubular atrophy and 
interstitial fibrosis, crystals 
concentrated in PTEC 
lysosomes  
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Renal Manifestation Associated 
Monoclonal 
Gammopathies 
Sites of 
Deposits 
Composition 
of Deposits 
Clinical Features Histological Features 
Cryoglobulinaemic 
GN 
Multiple myeloma, 
plasma cell leukaemia 
Glomeruli IgG κ or λ 
IgMκ and 
polyclonal 
IgG 
Renal disease: 20% of 
patients at diagnosis 
and >50% during 
course of illness. 
Proteinuria and 
microscopic 
haematuria (30%), 
nephrotic syndrome 
(20%), CRF (20%), 
ARF (10%), ESRF in 
15%.  
 
Thickened GBM, capillary 
thrombi containing 
precipitated cryoglobulins. 
IF: Diffuse glomerular 
intracapillary IgM deposits 
EM: Subendothelial 
fibrilar deposits 
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Renal Manifestation Associated 
Monoclonal 
Gammopathies 
Sites of 
Deposits 
Composition 
of Deposits 
Clinical Features Histological Features 
Waldenström’s  
macroglobulinaemia 
glomerulonephritis 
Waldenström’s  
macroglobulinaemia 
Glomeruli  IgM κ or λ, 
LC 
Renal involvement 
rare. Nephrotic 
syndrome and ARF 
can occur (the latter 
due to hyaline 
thrombi) 
Nodular 
glomerulosclerosis may be 
seen. most patients have 
interstitial infiltrates. IF: 
IgM deposits within 
capillary lumina 
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Renal Manifestation Associated 
Monoclonal 
Gammopathies 
Sites of 
Deposits 
Composition 
of Deposits 
Clinical Features Histological Features 
GOMMID Multiple myeloma Small vessels 
and capillaries 
IgG κ or λ Renal impairment, 
systemic vasculopathy, 
erosive 
polyarthropathy  
Neutrophil and 
macrophage infiltration, 
endocapillary hyperplasia 
and protein thrombi 
EM: Subendothelial mixed 
granular and organised 
deposits with microtubular 
organisation. 
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Renal Manifestation Associated 
Monoclonal 
Gammopathies 
Sites of 
Deposits 
Composition 
of Deposits 
Clinical Features Histological Features 
Proliferative GN with 
monoclonal Ig 
deposits 
Serum monoclonal IgG 
detected in 50% 
Glomeruli  Monoclonal 
IgG κ or λ 
Proteinuria present in 
all, nephrotic 
syndrome in 44%. 
Renal failure seen in 
80% 
Endocapillary proliferative 
or membranoproliferative 
GN. IF: Monoclonal IgG. 
EM: Mesangial and 
subendothelial granular 
deposits. 
PTEC, proximal tubule epithelial cell; LC, light chain; ESRF, end stage renal failure; HC, heavy chain; EM, electron microscopy; LCDD, 
light chain deposition disease; HCDD, heavy chain deposition disease; LHCDD, light and heavy chain deposition disease; IF, 
immunofluorescence; GBM, glomerular basement membrane; RTA, renal tubular acidosis; GN, glomerulonephritis; CRF, chronic renal 
failure; ARF, acute renal failure; GOMMID, glomerulonephritis with organised microtubular monoclonal immunoglobulin deposits.  
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2. MATERIALS AND METHODS 
2.1 Introduction   
This chapter presents the methods that were used for the experiments that I performed, 
the results of which are presented in this thesis. A wide variety of methods were 
employed. These included: quantitative image analysis techniques for morphometric 
analyses on kidney biopsy tissue (chapters three and six); in vitro cell culture based 
assays for the assessment of the effects of monoclonal and polyclonal FLCs on human 
PTECs (chapters four and seven);  extensive protein chemistry techniques to produce 
purified polyclonal FLCs (chapter five). Additionally, immunofluorescence and 
immunohistochemistry techniques were used to assess the presence of polyclonal FLCs 
in kidney biopsies (chapter six). Finally, in chapter seven, protein chemistry techniques 
were used to investigate interactions between proteins that may be relevant to cast 
formation in chronic kidney disease.  
 
2.2 Immunohistochemistry and Immunofluorescence  
2.2.1 Background  
Immunohistochemistry (IHC) is a widely used technique in the detection of specific 
antigens at tissue sites. The pivotal reagent common to all IHC techniques is the antigen-
specific antibody (also referred to as the primary antibody). These antibodies are 
prepared by immunising animals with the target antigen (the immunogen). The result of 
immunisation is the production of IgG against the immunogen by the host’s B-
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cells.(Hayat 2002; Onley 2007)  The primary antibody is applied to the tissue in 
conditions determined experimentally to be optimal.  
2.2.2 Polyclonal Antibodies 
Following immunisation, many B-cells will be stimulated to produce antibodies against 
more than one epitope on the immunogen; each one will be immunochemically distinct 
from the others. These are termed polyclonal antibodies. They are most frequently raised 
in the rabbit, but also in the goat, sheep and donkey, amongst others. Polyclonal 
antibodies have the advantages of being relatively cost-effective and straightforward to 
produce. The potential limitations of polyclonal antibodies include cross-reactivity and 
batch-to-batch variation. Polyclonal antibodies are vended in varying grades, 
representing different degrees of purity, ranging from total IgG fraction to affinity 
purified.(Onley 2007)  
 
2.2.3 Monoclonal Antibodies 
Following immunisation of a mouse, B-cells may be harvested from spleen or lymph 
node and then fused with non-secreting murine myeloma cells, to create hybridomas. 
These are long-lived in culture and secrete immunochemically identical antibodies. 
These are termed monoclonal antibodies. Hybridomas may be grown in live mice (in 
ascitic fluid), or by cell culture in vitro. The main advantages of monoclonal antibodies 
over polyclonal antibodies are that they react to a single epitope only, and thus possess 
better specificity, homogeneity and consistency. However these properties can limit their 
range of applications and the experimental conditions under which they may be used. If 
the target epitope is unstable and easily lost upon tissue fixation or antigen retrieval, 
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monoclonal antibodies are at a disadvantage when compared to polyclonal 
antibodies.(Onley 2007) 
 
2.2.4 Recombinant Antibody Technology 
Recombinant antibodies can be produced in vitro. These frequently have applications as 
therapeutic antibodies, and their usage as laboratory reagents is increasing. The basic 
unit of a recombinant antibody is usually composed of a VL and VH segments, similar to 
a Fab fragment, joined by a linker. These can be dimerised to improve avidity for 
antigen, and thereby improve utility.(Onley 2007)  
 
2.2.5 Detection Systems 
Antibody bound to an antigen of interest must be visualised in some way. This is 
achieved by a colour change, which may be seen on ordinary light microscopy, or by the 
use of fluorescent markers, which emit light, and can be detected by specialised 
fluorescence microscopes or confocal laser scanning microscope (CLSM). 
 
2.2.6 Chromogenic Detection 
Chromogenic detection utilises an enzymatic reaction on a substrate, which results in a 
colour change at the site where antibody has bound antigen. The enzyme can be 
conjugated directly to the primary antibody (direct detection), or to secondary antibodies 
or avidin-biotin complexes (indirect detection). The latter two are incubated with tissue 
after application of primary antibody. Substrate is applied, which undergoes enzymatic 
conversion to a stable precipitate of a specific colour, which is then visible on ordinary 
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light microscopy. The most commonly used label and substrate are horseradish 
peroxidase (HrP) and 3,3’diaminobenzidine tetrahydrochloride (DAB), which gives a 
brown-black colour.(Mardle 2007) Secondary antibodies and enzyme can also be 
attached to a polymer backbone. In this type of system, a single length of polymer may 
have numerous secondary antibodies and enzyme molecules, thus giving significant 
signal amplification.(Kumar and Rudbeck 2009)  
 
2.2.7 Fluorescence Detection 
Fluorescence detection, or immunofluorescence (IF) utilises fluorochromes conjugated 
to the primary antibody (direct detection), or to secondary antibodies or avidin-biotin 
complexes (indirect detection). The latter two are incubated with tissue after application 
of primary antibody. Fluorochromes absorb energy from light of a specific wavelength 
(the excitation wavelength) and then emit light at a lower wavelength (the emission 
wavelength). Different fluorochromes absorb and emit at different wavelengths, which 
enables detection of multiple antigen targets on the same tissue section.(Mardle 2007)  
 
2.2.8 Labelling of Antibodies with Fluorochromes  
An initial immunohistochemical study was planned for the investigation of in situ 
deposition patterns FLC in the kidney. The experiments were designed to detect the 
presence of  and  FLC, and to differentiate between proximal and distal tubules. This 
required applying antibodies against at least 3 antigens on the same section. Traditional 
enzyme-based chromogenic detection systems would have been hard to interpret, 
especially where targets co-localise. Therefore fluorescence detection was chosen. 
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Antibodies against  and  FLC and uromodulin (The Binding Site) were raised in 
sheep. This made indirect detection difficult, as anti-sheep secondary antibody would 
have reacted with all three antibodies, so direct detection was chosen, where the primary 
antibodies were labelled with fluorochrome.  
 
Anti- antibody was conjugated to fluorescein isothiocyanate (FITC) by the 
manufacturer. Anti- and anti-uromodulin antibodies were conjugated to DyLight 649 
and DyLight 549 fluorochromes, respectively, in the laboratory using a kit (Thermo 
Scientific Pierce) where the fluorochromes were activated with N-hydroxysuccinimide 
(NHS) esters, which reacts with primary amines on the antibody. These fluorochromes 
were chosen because (i) of their intense fluorescence output, (ii) their excitation spectra 
were compatible with instruments in our laboratory, and (iii) their emission spectra were 
sufficiently separated to minimise fluorescence overlap, thus improving their ability to 
identify colocalising targets.  
 
Both anti- and anti-uromodulin antibodies were shipped in glycine buffered saline, 
which was incompatible with the selected method of protein labeling, as well as 
bicinchoninic acid (BCA) assay. Dialysis into phosphate buffered saline (PBS) was 
carried out by five repeated cycles of diluting 1 ml of antibody 1:10 in PBS followed by 
centrifugation back down to 1 ml in a spin column with a molecular weight cut-off o 10 
kDa (Vivaproducts, Littleton, MA, USA). In the final cycle, centrifugation was 
continued until the retentate, (containing antibody) volume was approximately 0.5 ml. 
TSP in the retentate was then measured by BCA assay; if necessary, PBS was added to 
adjust TSP to between 1-2 mg/ml. The retentate was transferred to a microfuge tube. 
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The filtrate was tested by A280 to ensure it did not contain significant quantities of 
protein, and then discarded.  
 
Forty µl of the labeling buffer (0.67 M sodium borate pH 8.5) was added to 0.5 ml of 
antibody. This solution was pipetted into the vial containing the DyLight reagent, gently 
vortexed and briefly centrifuged to collect sample at the bottom of the tube. The reaction 
vial was then incubated in the dark, at room temperature, for 2 hours. The supplied 
purification resin was centrifuged in a spin column to remove its storage solution. 240-
270 µl of the reaction mixture was then added to the resin, and gently mixed by pipetting 
up and down. The columns were centrifuged for 45 seconds at x1000g to collect the 
labeled antibody in the filtrate. Bovine serum albumin (BSA) was added to a final 
concentration of 1% as a stabilising agent, and antibodies were stored in the dark at 4 ˚C.  
 
2.2.9 Tissue Fixation and Embedding 
As soon as tissue is removed for histology, it begins to undergo deterioration as a result 
of hypoxia, autolysis, lysosomal degradation, and putrefaction due to environmental 
organisms. Fixation and embedding is therefore an essential step in preserving tissue. 
Formaldehyde is the most commonly used fixative, and acts by reacting with basic 
amino acids, resulting in protein cross-linking by methylene bridges. Formaldehyde 
fixing can react with the target antigen however, rendering it non-immune reactive to 
antibody detection. Antigen retrieval is then required to restore epitopes to an immune-
reactive state prior to detection by antibody.(Renshaw 2007)  
 
  
 58 
Paraffin wax is used most commonly as the embedding medium for tissue that has been 
fixed in formaldehyde, and functions to support the tissue during transport, storage and 
microtomy. Fixatives are aqueous, whereas paraffin is hydrophobic; thus there is a need 
for a transition phase, which in practice usually involves passing the tissue through 
graded alcohols of increasing concentration, then into a solvent that is miscible with 
paraffin, such as xylene, and then allowing the paraffin to replace the xylene.(Renshaw 
2007) Prior to IHC staining, paraffin must be removed, by the reversal of the process 
described above.   
 
2.2.10 Tissue Sectioning 
Sections of tissue for IHC were prepared by John Gregory, Department of Cellular 
Pathology, University Hospital Birmingham. Formaldehyde-fixed, paraffin-embedded 
tissue blocks were sectioned to a consistent thickness of 2 µm using a microtome (Leica 
Microsystems, Milton Keynes, UK), and placed on glass slides (Superfrost Plus, 
Surgipath Europe, Peterborough, UK) before being oven-dried at 60 C overnight. These 
slides were cooled and stored until required.  
 
2.2.11 Dewaxing  
The embedding paraffin wax was softened by warming the slides in an oven for 30 
minutes, at 60 ˚C. Dewaxing was then carried out by sequentially transferring the slides 
through baths of xylene and ethanol (Fisher Scientific, Loughborough, UK), for 3 
minutes each, as follows: xylene, xylene, ethanol 100%, ethanol 100%, ethanol 95%, 
ethanol 95%. Transfer from oven to xylene and from one solvent bath to another was 
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done quickly to prevent the wax setting again or the tissue drying out in air. After the 
final ethanol bath, sections were rinsed gently with distilled water and then transferred to 
wash buffer, normally either PBS or tris-buffered saline (TBS). A ring was drawn 
around each section with a PAP pen to easily identify the location of the tissue, and to 
retain solutions placed over the tissue.(Kumar and Rudbeck 2009)  
 
2.2.12 Antigen Retrieval 
Antigen retrieval is required in formaldehyde-fixed specimens in order to break cross-
linking methylene bridges, thus unmasking epitopes and restoring their immune 
reactivity.  
 
2.2.13 Proteolytic Digestion 
Proteolytic enzymes such as trypsin, pronase, and proteinase K can be used to carry out 
antigen retrieval. Enzymatic antigen retrieval can be problematic due to the temperature-
sensitivity of enzymes, as well as the risk of over-digestion of tissues. However, this 
method has been described as useful in IF studies performed on formaldehyde-fixed, 
paraffin-embedded tissue, and therefore was of interest to me.(Viegas et al. 2007)    
 
2.2.14 Proteinase K 
Lyophilised proteinase K (Sigma-Aldrich, Gillingham, UK) was reconstituted in 
distilled deionised water to make a stock solution of 1 mg/ml. For the working solution, 
this was diluted 1:50 in PBS, pH 8.0, to make 20 µg/ml. 100 µl of working solution was 
applied by pipette to each tissue section and incubated in a humidity chamber for 10 
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minutes at room temperature. Sections were then rinsed gently with PBS with 0.05% 
Tween-20 (PBS-T) from a wash bottle, and then washed three times in a bath of PBS-T 
for 5 minutes each.  
 
2.2.15 Heat Induced Epitope Retrieval (HIER) 
This may be performed in a variety of appliances, such as a microwave oven, pressure 
cooker, vegetable steamer or autoclave. A microwave oven set at 800 W was used. 
Slides with dewaxed sections were placed in a plastic rack and completely immersed in 
a bath of 0.01 M sodium citrate (Sigma-Aldrich) at room temperature. This was placed 
in the microwave oven set to 800 W and heated to 95 ˚C for 25 minutes, then allowed to 
cool for 30 minutes.(Renshaw 2007) Slides were then transferred to wash buffer.    
 
2.2.16 Quenching and Blocking Steps – Prevention of Background Staining 
Endogenous biotin can react with detection systems which utilise avidin/biotin. 
Endogenous enzymes such as peroxidase can react with chromogen. The kidney is rich 
in both. The presence of Fc receptors in tissue can also cause non-specific binding of 
antibody. All three factors can give rise to undesirable background staining. Blocking 
steps are therefore required to prevent these from occurring.  
 
2.2.17 Endogenous Peroxidase Quenching with Hydrogen Peroxide 
This step was performed in all IHC experiments using a HrP enzymatic detection 
system. 0.3% v/v hydrogen peroxide (H2O2; Sigma-Aldrich) in methanol (Fisher 
Scientific) was applied to each slide after antigen retrieval, and incubated in a humidity 
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chamber for 30 minutes. Sections were then gently rinsed with TBS-T using a wash 
bottle, and then washed 3 times in a bath of TBS-T for 5 minutes each.  
 
2.2.18 Endogenous Biotin Block with Avidin and Biotin 
This step was performed in all IHC experiments using an avidin/biotin complex 
detection system. 0.1% avidin solution (Dako, Ely, UK) was applied for 10 minutes, and 
incubated in a humidity chamber. Sections were then washed in TBS-T as above. 0.01 % 
biotin solution (Dako) was then applied for 10 minutes, followed by TBS-T washes as 
above.  
 
2.2.19 Fc Receptor Block with Serum 
This step was performed in all IHC and IF experiments. Serum from the same species as 
the secondary antibody (or primary antibody in the case of primary-labelled antibodies) 
was diluted in wash buffer to 10% v/v. Diluted serum was applied to each tissue section 
for 20 minutes in a humidity chamber, and the excess serum was then gently tapped off.  
 
2.2.20 Primary Antibody  
The primary antibody was applied to the tissue in conditions determined experimentally 
to be optimal. These variables included antibody dilution and duration of incubation. 
The dilutions for each antibody are shown in the Appendix. Following application of the 
primary antibody, slides were rinsed gently with wash buffer from a wash bottle, and 
then further washed three times in baths of wash buffer, for five minutes each.  
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2.2.21 Isotype Control 
For each immunohistochemical experiment performed, a tissue section should be 
processed in parallel, in an identical fashion, except with the primary antibody 
substituted with an isotype control antibody. This isotype control antibody, which is not 
antigen-specific but in all other respects similar to the primary antibody, ensures that any 
positive staining observed is due to binding of antibody to the specific antigen of 
interest, and not just a result of non-specific antibody binding leading to artefact. This is 
implied if positive staining is seen in the same regions on the isotype control section as 
the test section.  
 
2.2.22 Autofluorescence  
Autofluorescence results from the natural ability of biological tissues to fluoresce. This 
occurs independently of fluorochromes used in staining, and can be problematic, leading 
to false-positives, and masking true staining. Autofluorescence is commonly attributable 
to three causes: (i) elastin and collagen, (ii) lipofuscin, and (iii) aldehyde fixative-
induced. Elastin and collagen are present in abundance in the kidney, in blood vessels, 
and in areas of established chronic damage. Lipofuscin is a product of peroxidation of 
lipids. It accumulates with age within lysosomes of many cells, including those in the 
kidney. The use of aldehyde fixatives results in the formation of fluorescent compounds. 
This phenomenon is most pronounced with the use of glutaraldehyde, but still significant 
with formaldehyde. It tends to have a more diffuse and more generalised appearance 
than specific staining. The best approaches to removing autofluorescence are: avoiding it 
(which is not always possible), filtering it out during image acquisition (which is not 
always practical as molecules responsible for autofluorescence have broad combined 
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emission spectra), and chemically removing it (which can result in reduced “real” 
signal).(Jackson 2007) However, there are numerous studies, which report the successful 
use of formaldehyde-fixed, paraffin-embedded tissue in immunofluorescence 
studies.(Mason et al. 2000; Baschong et al. 2001; Nasr et al. 2006; Viegas et al. 2007)  
 
Pontamine blue dye has been described as an effective means of quenching elastin and 
collagen derived autofluorescence, but because the dye works by shifting the fluorescent 
emission of elastin and collagen from green to red, it is only of use in reducing 
autofluorescent interference with FITC staining.(Cowen et al. 1985) It has been reported 
that lipofuscin autofluorescence can be effectively quenched using Sudan black, 
including in studies using CLSM techniques, and that improved results were obtained 
when short-burst UV-irradiation was also carried out (253-400 nm, at 30 W for 2 
hours).(Baschong et al. 2001; Viegas et al. 2007) Sodium borohydrate treatment is used 
to quench aldehyde-induced autofluorescence. However sodium borohydrate is a highly 
dangerous explosive.(Jackson 2007)   
 
2.2.23 Protocol for Quenching of Autofluorescence  
A combination of photobleaching and Sudan black, reported as effective in minimising 
autofluorescence was tested in early experiments.(Viegas et al. 2007) Slides with 
sections of tissue were first photobleached prior to dewaxing under a high-intensity (30 
W) UV lamp with a discreet emission spectrum of 253-400 nm (Philips, Guilford, UK) 
for 2 hours at room temperature. Dewaxing and antigen retrieval was carried out in the 
usual way. Immediately prior to the serum block, sections were incubated with 0.1% 
Sudan black in 70% ethanol for 20 minutes at room temperature, and then washed with 
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PBS-T 5 times. A final jet of PBS-T was applied to remove any excess completely. 
Serum block was then applied and the staining procedure proceeded according to the 
standard method. This method resulted in satisfactory quenching of autofluorescence, 
but also caused excessive interference with staining, to the point where very little 
staining was visible. This method was therefore abandoned.  
 
2.2.24 Protocol for Multiple Immunofluorescent Staining of FLC in Kidneys 
Slides with sections of formaldehyde-fixed, paraffin-embedded tissue were dewaxed in 
xylene and graded ethanol and transferred to PBS. A ring was drawn around each 
section with a PAP pen. HIER was performed in a microwave oven, and slides were 
allowed to cool for 30 minutes, and then transferred to PBS-T wash buffer. A serum 
block was performed using 10% sheep serum for 20 minutes. Antibodies were prepared 
by mixing together as a cocktail in PBS-T: anti-, 1:100; anti-, 1:50; anti-uromodulin, 
1:100. After gently tapping off excess serum, antibody cocktail was pipetted over the 
sections. From this point onwards slides were protected from light. Slides were then 
placed in a humidity chamber and incubated overnight at 4˚C. Slides were then washed 
in PBS-T three times. Nuclear counterstaining was performed with 300 nM 4',6-
diamidino-2-phenylindole, dilactate (DAPI) for 10 minutes, followed by washing three 
times in PBS-T. Slides were incubated with equilibration buffer provided with the anti-
fade mounting medium (ProLong Gold; Invitrogen, Paisley, UK) for 10 minutes. After 
tapping off equilibration buffer, one drop of anti-fade mounting medium was placed 
over each section and a glass coverslip was lowered into place. The mountant cures, thus 
negating the need to seal edges with nail polish. Slides were stored at -20 ˚C.  
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2.2.25 Protocol for multiple IF staining - controls  
Polyclonal IgG from non-immunised sheep () was used as isotype control. One possible 
source of false-positive staining was the reactivity of anti-FLC antibodies with intact 
immunoglobulin, which may have been present in the kidneys. Although these 
antibodies are specifically raised against light chain epitopes normally hidden in intact 
immunoglobulin, fixation or antigen retrieval may have resulted in these epitopes being 
exposed. To assess this, additional controls were performed in parallel to each 
experiment using a cocktail of FITC-labelled anti-IgG, anti-IgA and anti-IgM antibodies 
(). Each antibody was present at a final dilution of 1:100. Positive staining in these 
sections was interpreted as indicating potential false-positive staining in the test sections 
stained with anti-FLC antibodies. A third control section was also included in each 
experiment, to give an indication of the degree of background autofluorescence. This 
section was processed in an identical fashion to the others, except that primary antibody 
was substituted with PBS-T.  
 
In initial experiments calbindin D28K was chosen as a marker for distal tubules, using a 
mouse monoclonal antibody (Sigma-Aldrich), which was detected by an anti-mouse 
antibody labelled with DyLight 549.(Kumar et al. 1994; Loffing et al. 2004) However, 
staining with this antibody was suboptimal, and this method was abandoned, in favour of 
the anti-uromodulin antibody, as described above.  
 
2.2.26 Visualisation of Immunofluorescent Staining and Image Acquisition 
Initial attempts to visualise antibody binding using a standard fluorescence microscope 
were unsuccessful due to high levels of autofluorescence. Attempts to quench 
  
 66 
autofluorescence resulted in significant interference with staining. Therefore a confocal 
laser scanning microscope (Axiovert 100M; Carl Zeiss, ) was employed. This method 
had the advantage of being able to adjust the settings of the microscope digitally to 
minimise autofluorescence. A control section was processed with each experiment, 
which was processed in an identical fashion, except that antibody was substituted with 
wash buffer. This section was examined first under the CLSM and gain settings adjusted 
to cut out autofluorescence. These settings were used for the parallel test slide in the 
experiment.  
 
Images were visualised with the microscope and lasers set up with four collection 
windows as follows: 351, 364 nm laser (14.9%), window 385-470 nm; 488 nm laser 
(5%), window 505-550 nm; 543 nm laser (100%), window 560-615 nm; 633 nm laser 
(20%), window 650 nm. Images were routinely acquired using the x10, x20 and x40 
water immersion objective lenses, with microscope in sequential mode, with a line 
average of 4 and a resolution of 1024 x 1024 pixels. Images were viewed using 
proprietary software (LSM Image Browser; Carl Zeiss)  
 
2.2.27 Protocol for Immunohistochemical Staining of Macrophages and 
Interstitial Capillaries  
Initial experiments using a polymer-backboned system to detect primary antibodies 
(EnVision; Dako) resulted in extensive background staining, and was therefore 
abandoned in favour of an established avidin-biotin detection method.(Eardley et al. 
2006; Eardley et al. 2008) Formalin-fixed, paraffin-embedded sections were dewaxed 
and rehydrated, then HIER was carried out in 0.01M citrate buffer. Slides were then 
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transferred to TBS-T. Endogenous peroxidase was blocked with 0.3% H2O2 in 70% 
methanol for 30 minutes, Endogenous biotin was blocked by sequential application of 
first 0.1% avidin, then 0.01% biotin. Sections were then blocked with 10% rabbit serum 
for 20 minutes, and excess gently tapped off. This serum block was not washed off prior 
to application of primary antibody. Three-stage indirect immunohistochemical staining 
was then performed. Primary antibody (either anti-C68 or anti-CD34) were applied as 
follows: anti- CD68, pan-macrophage antigen (clone KP1; Dako) at 1:200 dilution; anti-
CD34, endothelial marker (Clone QBEnd 10; Dako) at 1:25 dilution for 30 minutes at 
room temperature. Biotinylated anti-mouse secondary antibody (Dako) at 1:100 dilution 
was applied or 30 minutes, followed by a HrP-conjugated streptavidin-biotin complex 
(StreptABComplex; Dako) for 30 minutes. Antibody binding was visualised by the 
addition of DAB for 1-10 minutes. Sections were counterstained with Mayer’s 
haematoxylin (Sigma-Aldrich), except those sections for quantitative analysis, which 
were left uncounterstained. Slides were washed thrice for 10 minutes each time in TBS-
T between each of the above steps unless otherwise stated. They were then dehydrated 
with graded alcohol as follows: ethanol 100%, 10 minutes; xylene, 10 minutes. One drop 
of synthetic resin mountant (DPX; Sigma-Aldrich) was placed on a coverslip, and the 
coverslip was then lowered onto the tissue section, and allowed to dry in a fume 
cupboard. Mouse monoclonal IgG1 (Dako) was used as an isotype control for both anti-
CD68 and anti-CD34 antibodies, at 1:200 and 1:25 dilutions respectively. Tissue 
sections were grouped into batches of 20 to help maintain consistency in the technique 
used between samples.  
 
  
 68 
2.3 Image Analysis of Kidney Biopsies 
2.3.1 Patients 
Approval was sought from and granted by the local ethics committee to use kidney 
tissue taken from patients undergoing renal biopsy at University Hospital Birmingham 
(South Staffordshire Research Ethics Committee, project reference 07/Q2602/42). The 
scope of the ethics application was to investigate the deposition patterns of free light chains 
(FLC) in kidneys of patients with chronic kidney disease (CKD) and other factors related to 
inflammation and fibrosis. The tissue used for experiments represented archived tissue that 
was surplus to diagnosis. The study population included any patient who had undergone a 
renal biopsy at this institution, who fulfilled the criteria for this study.  
 
2.3.2 Quantification of Interstitial Macrophage Infiltration and Interstitial 
Capillary Density  
Coded sections stained for CD68 and CD34 were observed under a microscope (Eclipse 
E400; Nikon Instruments, Amstelveen, The Netherlands) at x200 magnification, and 
images acquired using proprietary software. The entire length of each biopsy section was 
imaged in this way.  
 
The Aequitas interactive image analysis system was used for blinded assessment of 
interstitial macrophage numbers. This technique has previously been found to be a 
reliable method in the analysis of human and animal renal sections.(Furness et al. 1997; 
Thomas et al. 2002) For analysis, each image was converted to a two-colour scale 
image. By altering the threshold the image was processed so that positive staining was 
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represented by yellow pixels measured as a percentage of the area of total image 
analysed. Sections where background staining made it impossible to digitally 
differentiate specific staining were excluded from analysis. For each patient a mean 
measurement of 5 randomly selected non-confluent microscopic fields was determined. 
Glomerular staining was excluded from the analysis by the computer software. 
 
2.3.3 Quantification of Interstitial Fibrosis/Chronic Damage  
Chronic damage, representative of areas of fibrosis within kidney biopsies, was 
measured using a previously validated image analysis technique. This index of chronic 
damage has previously been demonstrated to be a rigorous predictor of renal 
outcome.(Howie et al. 2001) Briefly, one routinely prepared, periodic acid-methenamine 
silver (PAMS) stained section from each patient was examined under a microscope 
(Nikon) at x100 magnification and images were captured. Using image analysis software 
(Aequitas IA; Dynamic Data Links, Cambridge, UK), the cortical area was outlined, 
selected and the area quantified. The cortex was defined as that part of the biopsy core 
beneath the capsule extending to the medullary aspect of the deepest glomeruli, or the 
cortical aspect of arcuate vessels. Areas of established chronic damage were defined as 
glomeruli which were globally (but not partially) sclerosed; areas of interstitial fibrosis, 
which appeared more solid and deeply stained than normal; or areas of interstitial 
oedema, atrophic tubules, defined as those smaller than normal, with thinned epithelium, 
including those which were cystic, and any arteries that were completely occluded. 
Within this, areas of chronic damage were outlined. After outlining areas of chronic 
damage, the image was then exported as a screen-grab, using computer software (Grab, , 
Cupertino CA, USA) for the purposes of cast counting (see below). The index of chronic 
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damage was then quantified as the percentage of total cortical area occupied by areas of 
chronic damage. 
 
2.3.4 Cast Counting   
Screen-grab images taken from the Aequitas IA program (see above) were opened in a 
second image analysis program (ImageJ, National Institutes of Health, USA). The 
number of proteinaceous precipitates (casts) in distal tubules were counted using ImageJ 
as follows. A grid was applied to the image using ImageJ. Using the cell counting 
function in ImageJ and the computer mouse as a button counter, all tubules were 
counted, and subdivided firstly into those located inside or outside areas of chronic 
damage and secondly into those containing or not containing casts. The cast burden 
could then be calculated as the percentage of the total tubules counted which contained 
casts, rounded to the nearest integer.  
 
2.4 Cell Culture: HK-2 Cells 
2.4.1 Culture and Propagation of HK-2 Cells 
HK-2 Cells (American Type Culture Collection, Manassas, VA, USA) are a proximal 
tubule epithelial cell (PTEC) line derived from transfection with HPV 16 E6/E7 genes. 
(Ryan et al. 1994) Grown as a monolayer, they exhibit brush-border enzymes, cell 
surface receptors and biochemical and morphological characteristics similar to other 
widely used PTECs in stable culture. HK-2 cells have been used in numerous studies on 
the effects of monoclonal FLC on kidney cells, and have exhibit similar responses to 
monoclonal FLCs exposure as other proximal tubule cell lines, and therefore are a good 
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model in this setting.(Basnayake et al. 2010) See Appendix for an image of normal HK-
2 cells.  
 
2.4.2 Containers 
Culture flasks, plates and dishes (Nunc, Rochester, NY, USA) were coated with 5 
µg/cm
2
 rat tail collagen type 1 (Invitrogen, Carlsbad, CA, USA) for 1 hour at room 
temperature. Thin-coating with type 1 collagen was used to facilitate anchorage and 
proliferation of HK-2 cells to containers. This type of collagen has been used in the past 
in studies investigating the effects of myeloma FLCs on PTECs, at independent 
laboratories.(Pote et al. 2000; Wang and Sanders 2007). Type 4 collagen is found in 
basement membranes in the kidney and therefore may be a more physiological 
anchorage agent with fewer pro-inflammatory effects than type 1 collagen. However, as 
previous studies using the same myeloma FLCs successfully utilised type 1 collagen 
coated containers, this type of collagen was selected for my own studies for consistency. 
In addition, as control proteins did not elicit significant responses from PTECs in 
culture, it was felt that any pro-inflammatory effects of type 1 collagen were negligible. 
Immediately prior to use, the collagen was aspirated, and the containers rinsed twice 
with PBS (Invitrogen).  
 
2.4.3 Growth Medium   
Complete growth medium (hereafter referred to as K-SFM) was prepared as follows: 
keratinocyte serum-free medium, supplemented with 5 ng/ml recombinant human 
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epidermal growth factor and 0.05 mg/ml bovine pituitary extract, 100 µg/ml penicillin, 
100 µg/ml streptomycin and 250 ng/ml amphotericin B (Invitrogen).  
 
2.4.4 Initiation of Culture 
Cells were shipped frozen on dry ice, and stored in liquid nitrogen vapour phase. After 
rapid thawing to 37 ˚C (1 minute) in a bead bath, each vial of cells was diluted in 5-7 
ml of K-SFM and transferred to a T-25 flask. The cells were routinely cultured at 37°C 
in a humidified atmosphere of 95% air-5% CO2. Medium was exchanged at 48-hour 
intervals. Cells were never allowed to become overcrowded, and were passaged when 
they reached 80% confluence.  
 
2.4.5 Passaging of Cells 
Medium was aspirated and cells were washed briefly in PBS. Cells were detached by 
incubating with typsin 0.05% and ethylenediaminetetraacetic acid (EDTA) 0.2 g/L 
(Invitrogen) for 1-5 minutes at 37 ˚C, diluted in K-SFM and centrifuged at x 125 g for 
10 minutes to collect a soft pellet. Supernatant medium was poured off and the pellet 
gently resuspended in fresh K-SFM. Cell counting was done at this stage, if required for 
estimating seeding density into plates or dishes for experiments (see below). For the 
purposes of propagation, each flask was split 1:2 or 1:3, transferred to the incubator. 
Cells were not passaged beyond 25 to 30 times. 
 
  
 73 
2.4.6 Enumeration of Cells using a Haemocytometer   
Cells were counted using a Neubauer haemocytometer. This instrument facilitates the 
quantification of cells in a determined volume of fluid, thus enabling the quantification 
of the total number of cells in a suspension. A standard haemocytometer is made of 
glass, scored to form a grid of nine large squares, which are further subdivided by 
scoring. A coverslip is placed over the grid. When a suspension of cells is infused, 
capillary action draws the fluid under the coverslip. Each square represents a volume of 
10
-4
 cm
3
. See Appendix for a figure of a haemocytometer. 
 
To be able to count cells accurately, it is important that they are not so concentrated that 
they overlap on the grid; serial dilutions may be required. Prior to transferring to the 
haemocytometer, the cell suspension is mixed 1:2 with trypan blue. This dye is taken up 
into dead cells, thus helping differentiate viable ones from those that are dead or dying.  
 
10 µl of prepared cell suspension is pipetted into each groove-shaped sample 
introduction point. Using a button-counter, the total number of cells in several squares is 
counted. For cells at the boundaries of the squares, those touching the left and top 
boundaries are counted, while those touching the right and bottom boundaries are 
disregarded. The number of cells per ml can then be calculated as follows:  
 
     Total no cells in n squares 
 Cells/ml = -------------------------------- x 10
4
 x dilution factor 
      n 
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Where n is the number of large squares in which cells were counted.  
 
2.4.7 Cryopreservation  
Cells were detached from the flask with trypsin as above, diluted in K-SFM and 
centrifuged at x 125 g for 10 minutes to form a soft pellet. The supernatant was 
discarded and cells were gently resuspended in freezing medium (K-SFM supplemented 
with 7.5% v/v dimethyl sulfoxide; Sigma-Aldrich). Roughly, 8 x 10
6
 cells 
(approximately equivalent to one T-75 flask or half of one T-160 flask) were suspended 
in 1.5 ml freezing medium, and stored in a single cryogenic vial, in liquid nitrogen 
vapour phase.  
 
2.4.8 Preparation of Polyclonal FLC Stock Solution for In Vitro use   
Lyophilised polyclonal  and  FLCs were made into stock solutions, which were 
diluted as required for experiments. FLCs were weighed and dissolved in the relevant 
medium for the cell type used at 10 mg/ml. This solution was filter sterilised by passing 
through a 0.22 µm filter (Millipore, Billerica, MA, USA). Stock solution was aliquoted 
and stored at -20 ˚C until required.  
 
2.4.9 Protocol for Incubation of HK-2 Cells with FLC 
HK-2 cells were grown on collagen coated 6-well plates until they reached 80% 
confluence, the medium was removed, and cells washed briefly in PBS. Each well was 
then overlaid with 1 ml of medium containing protein at the desired concentration and 
the plates returned to the incubator. After incubating for the designated amount of time, 
  
 75 
medium was collected, placed on ice, centrifuged at 4 ˚C to pellet any debris, and 
assayed. Where cell lysates were required, lysis was carried out (see below)  
 
2.4.10  Protocol for Cell Lysis  
Plates were placed on ice. After removal of medium, cells were washed briefly in cold 
PBS. Cells were lysed in radioimmunoprecipitation (RIPA) buffer, supplemented with 
protease inhibitor cocktail (cOmplete; Roche Applied Science, Indianapolis, IN, USA) 
was applied (roughly 200 µl per well in a 6-well plate), and placed on a rocking platform 
at 4 ˚C for 15 minutes. Wells were then scraped and the lysate was transferred to 
microfuge tubes, centrifuged at x 15,000 g for 15 minutes, at 4 ˚C to pellet cellular 
debris. The supernatants were transferred to fresh microfuge tubes on ice, and then 
promptly either assayed or placed in a freezer at -70 ˚C.  
 
2.4.11  Hydrogen Peroxide Assay 
A critical event following endocytosis of tubulo-toxic monoclonal FLCs by PTECs is 
the generation of H2O2.(Wang and Sanders 2007) This phenomenon was investigated 
with polyclonal FLCs. Cells were incubated with FLCs as above, overnight. 
Supernatants were collected, centrifuged and promptly assayed. H2O2 concentration was 
measured using one-step assay a kit (Amplex Red Hydrogen Peroxide/Peroxidase Assay 
Kit; Invitrogen) and was carried out according to manufacturer’s instructions. The assay 
utilises the reaction of Amplex Red (10-acetyl-3,7-dihydroxyphenoxazine) in the 
presence of peroxidase, to form a red-fluorescent oxidation product, resorufin. 50 µl per 
well of samples and H2O2 standards were pipetted in duplicate into a black, 96-well 
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fluorescence plate (Nunc). 50 µl of Amplex Red working solution was then added to 
each well, and the plate was incubated at room temperature for 30 minutes, shielded 
from light. Fluorescence emission was measured using a plate reader, at an excitation 
frequency of 535 nm and emission at 560 nm.  
 
2.4.12  MCP-1 Assay  
Human MCP-1 in cell culture supernatants was measured by an enzyme-linked 
immunosorbent assay (ELISA). A capture assay was performed according to 
manufacturer’s instructions (Human CCL2/MCP-1 Immunoassay; R&D Systems, 
Minneapolis, MN, USA). All reagents were brought to room temperature. Cell culture 
supernatants were centrifuged at 4 ˚C at x 10,000 g for 5 minutes to pellet any debris, 
and were subsequently kept on ice. Standards, wash buffer, calibrator diluent and 
substrate solution were prepared according to instructions. 200 µl of each standard and 
sample were added in duplicate to wells in the provided microplate, and incubated for 2 
hours. The wells are provided pre-coated with an anti-MCP-1 capture antibody. Wells 
were then aspirated and washed 3 times using a plate washer. After the third wash, the 
plate was inverted and blotted against paper towels to ensure all liquid was removed 
from the wells. 200 µl of HrP-conjugated detection antibody was then added to each 
well, and incubated for 1 hour, followed by washing as above, before 200 µl per well of 
substrate solution was added, and the plate incubated, protected from light, for 20 
minutes, after which 50 µl of stop solution was added to each well. Absorbance was 
measured using a plate reader at 450 nm. Sample readings were measured against the 
standard curve generated by a four-parameter logistic curve-fit using plate reader 
software. Where necessary, results were expressed by multiplying concentration (in 
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pg/ml) by the volume of medium per well (in ml) and expressed as pg/day.  
 
2.4.13  Lactate Dehyrogenase Assay  
Monoclonal FLCs have cytotoxic effects on proximal tubular cells, resulting in 
increased lactate dehydrogenase (LDH) release due to cell death.(Pote et al. 2000) The 
cytotoxic effects of polyclonal FLC on HK-2 cells were studied using a colorimetric 
assay kit, which quantitatively measures LDH by the conversion of tetrazolium salt into 
a red formazan product (CytoTox 96; Promega, Madison, WI, USA). After incubation of 
cells with K-SFM containing protein or controls as above, medium was harvested, and 
centrifuged to pellet debris. A control plate, to measure the maximum LDH release from 
the cells, was incubated with K-SFM alone, and lysed by 3 freeze-thaw cycles in liquid 
nitrogen. 50 µl of supernatant from each well was transferred in duplicate to a 96-well 
plate. K-SFM alone was also loaded onto the plate as a control for background 
absorbance, which could be subtracted from the sample readings. The substrate mix was 
prepared and 50 µl added to each well, the plate covered and incubated for 30 minutes at 
room temperature, shielded from light. Stop solution was added, and absorbance 
measured at 490 nm using a plate reader.  
 
When it was required, cytotoxicity could then be expressed as the experimental release 
of LDH as a percentage of the maximum LDH release:  
 
    Experimental LDH release 
 % Cytotocity =  -------------------------------- x 100 
    Maximum LDH release 
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2.4.14  Silencing of Gene Expression with siRNA   
Small interfering RNA (siRNA) are short (20-25 nucleotide) double-stranded RNAs, 
which prevent gene expression at a post-transcriptional level, by preventing translation 
of mRNA into polypeptide.(Elbashir et al. 2001) They are highly specific. In practice, a 
lipid-based transfection reagent is used to deliver double-stranded siRNA cytoplasm, 
where it engages RNA-induced silencing complex (RISC). RISC has an RNAse 
component, which then destroys one siRNA strand. The remaining strand acts as a 
guide, by binding to its complementary target sequence in the cell’s mRNA, results in 
the mRNA being cleaved by RISC. siRNA mode of action is summarised in the 
Appendix. All reagents for silencing of gene expression were obtained from Santa Cruz 
Biotechnology, Santa Cruz, CA, USA, unless otherwise stated, and protocols carried out 
according to manufacturer’s instructions. siRNAs specifically targeting mRNA for 
human c-Src, megalin, and cubilin and a non-targeting scramble-sequence siRNA as a 
negative control were used. c-Src expression was silenced by transfecting HK-2 cells 
with a pool of four target-specific 20- to 25-nucleotide siRNAs (50 pmol). Targeted 
knockdown of megalin and cubilin was achieved using pools of three target-specific 20- 
to 25-nucleotide siRNAs (50 pmol). HK-2 cells in log phase were enumerated and 
seeded onto 6-well plates at a density of 4 x 10
5
 per well in antibiotic-free growth 
medium. At 60-80% confluence, cells were washed with transfection medium, then 
overlaid with siRNA-transfection reagent complexes, and returned to the incubator. 
After 6 hours, fresh medium was added to minimize toxicity. Cells were incubated for a 
further 48 hours, before protein expression was assessed by Western blotting.  
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2.4.15 Immunoblotting of Cell Culture Lysates  
2.4.15.1 Western Blotting - c-Src Phosphorylation  
In the inactive state, c-Src is phosphorylated at Y527. Upon oxidation at C245 and 
C487, it becomes dephosphorylated at Y527, phosphorylated at Y416, undergoes 
conformational change, and becomes active. This was detected by Western blot analysis 
of cell lysates using a primary antibody that specifically detects phosphorylation at 
Y416.  
 
SDS-PAGE gels were cast in the laboratory according to instructions (see Appendix). 
Cell lysates (20-60 µg) were boiled for 3 minutes in Laemmli buffer and separated by 
12% SDS-PAGE (BioRad), before undergoing electrophoretic wet-tank transfer onto 
polyvinylidene difluoride (PVDF) membranes at 4 ˚C. These were blocked in 5% skim 
milk for and then incubated at 4°C overnight with one of the following primary 
antibodies: rabbit-anti-human phospho-c-Src Y416 (1:1000 dilution) or rabbit-anti-
human total c-Src (1:1000; Cell Signaling Technology, Danvers, MA). Blots were 
incubated for 1 hour at room temperature with horseradish peroxidase (HrP)-conjugated 
goat-anti-rabbit secondary antibody (1:2000 dilution; Thermo Scientific Pierce). 
Visualization was by enhanced chemiluminescence (ECL, SuperSignal West Dura, 
Thermo Scientific Pierce) on film (BioMax MR; Carestream Health, Rochester, NY).  
 
GAPDH served as a loading normalisation control and was determined by stripping the 
blots (Restore; Thermo Scientific Pierce) and reprobing with mouse-anti-human 
GAPDH (1:10,000; Abcam, Cambridge, MA), detected with a HrP-conjugated goat-anti-
mouse (1:2000 dilution) secondary antibody.  
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For experiments investigating the effect of DMTU on c-Src phosphorylation, total c-Src 
was used as a normalisation control.  
 
2.4.15.2 Western Blotting - Megalin and Cubilin   
Cell lysates (20- 60 µg) were boiled for 3 minutes in Laemmli buffer and separated by 7-
12% gradient SDS-PAGE (purchased pre-cast gels from BioRad), transferred onto 
PVDF membranes, and blocked in skim milk as above. Blots were then incubated at 4°C 
overnight with one of the following primary anti-bodies: goat-anti-human megalin (C19) 
or cubilin (Y20) (1:250 dilution; Santa Cruz). GAPDH served as a loading normalization 
control as above. Blots were incubated for 1 hour at room temperature with horseradish 
peroxidase (HrP)-conjugated donkey-anti-goat (1:10,000 dilution; BioRad) secondary 
antibodies. GAPDH was used as a normalisation control. Visualisation and densitometry 
was performed as above.  
 
2.4.15.3 Densitometry    
Films were scanned (Microtek Int., Taiwan) and band densitometry was performed using 
Quantity One software (BioRad).  
 
2.4.15.4 Detection of c-Src Oxidation by Carboxymethylation   
To determine whether oxidation of c-Src occurs in response to exposure to FLC in HK-2 
cells, N-(biotinoyl)-N’-(iodoacetyl)ethylenediamide (BIAM, Invitrogen), a thiol-reactive 
biotinylating reagent for proteins, was used. BIAM specifically identifies the thiolate 
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form of cysteine residues when they are in the reduced state, making it a very useful tool 
to detect redox-regulation of proteins, including c-Src.(Dominici et al. 1999; Kim et al. 
2000; Giannoni et al. 2005) Using this method, I measured reduced c-Src levels in HK-2 
cells after exposure to FLC.  
 
Cells were grown on 100 mm dishes and allowed to reach 80-90% confluence. Medium 
was then removed, the cells were rinsed briefly with PBS, and then medium containing 
FLC (1 mg/ml) was added. At 2, 6, 12, and 24 hours, medium was removed and cells 
were snap-frozen in liquid nitrogen. RIPA buffer containing 100 µM BIAM  was 
rendered free of oxygen by bubbling with nitrogen gas at a low flow rate for 20 minutes. 
Frozen cells were then exposed to 0.5 ml of this RIPA buffer, followed by sonication for 
three periods of 1 minute each separated by 30-second intervals, and then incubated for 
15 minutes at room temperature. Lysates were then clarified by centrifugation and 
immunoprecipitated with anti-human total c-Src antibody (Cell Signaling Technology, 
Danvers, MA, USA) using Protein G PLUS-Agarose immunoprecipitation reagent 
(Santa Cruz Biotechnology). Total soluble protein concentration was determined by 
BCA assay, before separation by SDS-PAGE and transferred to polyvinylidene 
difluoride membranes as above. Each sample was divided into two equal parts: one half 
was used for detection of c-Src labeled with BIAM by HrP-conjugated streptavidin and 
the other half was probed for total c-Src for normalisation, as above. Visualisation was 
by ECL onto film as above.  
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2.4.16  Inhibition of c-Src Activity   
4-Amino-5-(4-chlorophenyl)-7-(tert-butyl)pyrazolo[3,4-d]pyramidine (PP2; EMD 
Biosciences, Gibbstown, NJ) is a potent selective chemical inhibitor of c-Src 
activity.(Hanke et al. 1996) To suppress c-Src activity in HK-2 cells during experiments, 
PP2 was added to the medium to a final concentration of 10 µM at the same time FLC 
was added.  
 
2.4.17  Removal of Extracellular and Intracellular H2O2   
To investigate whether H2O2 involved in signaling was produced intracellularly or 
extracellularly, catalase was added to the medium. As a powerful extracellular scavenger 
of H2O2, exogenously applied catalase would quickly destroy any H2O2 in the 
supernatant. For experiments where the effect of extracellular H2O2 was to be abolished, 
catalase from bovine liver (Sigma-Aldrich) was added to the medium to a final 
concentration of 500 U/ml before addition to wells containing HK-2 cells.  
 
The effect of inhibition of intracellular reactive oxygen species (ROS) on FLC–induced 
MCP-1 production was examined by overnight co-incubation of HK-2 cells exposed to 
FLC with DMTU, 30 mM, a cell-permeable chemical trap for H2O2.(Parker et al. 1985)  
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2.5 Purification of Polyclonal FLCs and Protein Chemistry  
2.5.1 Total Soluble Protein (TSP) Quantification 
2.5.1.1 Ultraviolet Absorbance at 280 nm (A280) 
Proteins absorb UV light due to the presence of tyrosine and tryptophan residues. The 
quantities of these amino acids vary considerably between proteins, and so the molar 
extinction coefficient (a measure of how strongly a chemical absorbs light at a given 
wavelength, per unit mass) varies from protein to protein (Appendix). For crude 
solutions and extracts, nucleic acids and nucleotides can interfere with absorbance and 
requires correction. However, as protein purification progresses and such interfering 
compounds are removed this effect becomes negligible. (Scopes 1994)  
 
A280 was measured using a spectrophotometer (Ultrospec II; Pharmacia-LKB, Uppsala, 
Sweden). After setting the absorbance wavelength to 280 nm. 1,000 µl of buffer was 
placed in a clean glass cuvette, placed in the chamber, and the reading was set to 0. This 
was then exchanged for a cuvette containing 1,000 µl of sample, and the reading taken. 
If the readout was above 1.0, the solution would be diluted 1:2 in buffer and retested. 
TSP was calculated using the following equation:  
 
 OD x Path Length* of Cuvette (mm) x Dilution Factor 
TSP (mg/ml or g/L) =  ---------------------------------------------------------------- 
      Extinction Coefficient 
 
*Path length of most cuvettes is 10 mm.  
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2.5.1.2 Bicinchoninic Acid (BCA) Assay 
This method utilises the biuret reaction (reduction of Cu
+2
 to Cu
+1
 by amino acid 
residues in an alkaline environment), and the highly sensitive and selective colorimetric 
detection of Cu
+1
 using bicinchoninic acid. (Smith et al. 1985) The assay is robust, 
easily reproducible, detergent-compatible and the intensity of colour change is nearly 
linear across a broad concentration range of protein (20 – 2,000 µg/ml). A BCA assay 
kit was obtained (Thermo Scientific Pierce, Rockford, IL, USA) and assays carried out 
according to the manufacturer’s protocol. BSA standards were prepared to dilutions 
between 0 – 2,000 µg/ml. Serial dilutions of sample were made in buffer. In a 96-well 
plate, 25 µl per well of standards and samples were loaded using a pipette.  The BCA 
working reagent was prepared by mixing BCA Reagent A from the kit with BCA 
reagent B in a 50:1 ratio. Using a multi-channel pipette, 200 µl per well of the working 
reagent was loaded and the plate was covered and mixed on a plate shaker for 30 
seconds. The microplate was then incubated at 37 ˚C for 30 minutes. Absorbance was 
read at 562 nm on a plate reader (Spectramax M2e; Molecular Devices, Sunnyvale, CA, 
USA). Results were viewed with plate reader software, which compared standard curve 
to results from samples (SoftMax Pro; Molecular Devices).  
 
2.5.2 Free Light Chain Quantification  
The FLC concentration in samples during the protein purification process was measured 
at  Ltd, using a particle-enhanced nephelometric assay (Freelite; , Birmingham, 
UK).(Bradwell et al. 2001)   
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2.5.3 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis  
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed for Coomassie staining, silver staining and Western blotting.  
 
2.5.3.1 Coomassie Brilliant Blue   
Samples were mixed with Laemmli buffer (Bio-Rad, Hercules, CA). Where analysis was 
to be performed under reducing conditions, dithiothreitol or -mercaptoethanol was 
added to the Laemmli buffer and samples boiled for 3 minutes. Proteins were resolved 
on 4-12% gels (NUPAGE, Invitrogen) and placed in fixative, before being stained with 
Coomassie Brilliant Blue (Bio-Rad) and then washed in destaining solution until bands 
were clearly visible.  
 
2.5.3.2 Silver Stain   
Proteins were separated by SDS-PAGE and treated with fixative as above. The gel was 
placed in 50 ml of sensitisation reagent overnight. After washing, silver solution was 
added and incubated for 45 minutes protected from light, and washed again. Developer 
solution was added, and stop solution added when bands were adequately visible.  
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2.5.4 Immunoblotting  
2.5.4.1 Western Blotting - Protein Purity Testing    
During polyclonal FLC purification, western blotting was used to identify bands on 
SDS-PAGE. Proteins were resolved as above. Proteins were electrophoretically 
transferred to nitrocellulose membranes in a wet tank. Membranes were blocked in 5% 
skim milk and then incubated with primary antibody for 2 hours at room temperature. 
Blots were washed, incubated with HrP conjugated secondary antibody for 1 hour and 
then bands were visualised by incubating with AEC staining reagent until bands were 
developed adequately.  
 
2.5.4.2 Dot Blotting  
Dot blotting was used to probe for the presence of a particular protein of interest in 
chromatography fractions. It involves loading sample of interest directly onto a 
membrane without the need for resolving on a gel and transferring.  
 
A nitrocellulose membrane was marked to form a grid with a pencil. Samples were 
spotted in1-2 µl volumes onto the membrane using a 10 µl pipette tip pressed firmly 
against the membrane, taking care not to rupture the membrane, and allowed to air-dry. 
The membrane was then rehydrated in water, blocked in 5% skim milk and then 
incubated with primary antibody for 2 hours, followed by HrP-conjugated secondary 
antibody for 1 hour, and developed with AEC as above.  
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2.5.5 Endotoxin Assays  
2.5.5.1 Colorimetric Assay  
A quantitative, chromogenic Limulus amoebocyte lysate (LAL) assay kit was used, 
according to manufacturer’s instructions, to test for the presence of endotoxin in 
monoclonal FLC (QCL-1000, Lonza, Walkersville, MD, USA). This assay utilises the 
reaction of endotoxin with LAL to activate an enzyme, which in turn acts on a synthetic 
substrate to produce a yellow colour. A 96-well microplate was warmed to 37 ˚C. At T = 
0 minutes, in duplicate, 50 µl per well of endotoxin standards and samples were pipetted 
into the wells. 50 µl of LAL was then added to each well and incubated until T = 10 
minutes. 100 µl of substrate solution per well was then added. At T = 16 minutes, 100 µl 
per well of stop solution was added. Absorbance was measured using a plate reader at 
405-410 nm.  
 
2.5.5.2 Gel Clot Assay   
Endotoxin in polyclonal FLC was measured using a LAL gel-clot assay (E-TOXATE; 
Sigma-Aldrich). The assay utilises the formation of a gel when LAL interacts with even 
minute quantities of endotoxin.(Bang 1956) Sterile, plugged pipettes and autoclaved, 
new, 10 x 75 mm glass tubes were used. The pH of the FLC solution was measured and 
confirmed to be within the working range of the assay. The LAL reagent and endotoxin 
standards were prepared as instructed. Samples (undiluted) and standards were added to 
tubes, followed by LAL reagent, and incubated at 37 ˚C in a water bath. After 1 hour, 
tubes were gently inverted while observing for evidence of gel formation. A hard gel 
that permits complete inversion without disruption of the gel was taken as a positive 
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result; all other results, including soft gels or turbid solutions were taken as negative 
(Appendix).  
 
2.5.6 Endotoxin Removal   
Endotoxin removal from polyclonal FLC was carried out using polymixin B, 
immobilised onto cross-linked 6% agarose resin (Detoxi-Gel; Thermo Scientific). 
Polymixin B binds to the lipid A portion of endotoxin.(Issekutz 1983) Endotoxin-free 
water (Sigma Aldrich) was used at all times. Resin was degassed by placing slurry in a 
suction filter flask, stirring with a magnetic stirrer, and applying suction for 15 minutes. 
Slurry was then packed into disposable 10 ml centrifuge columns (Thermo Scientific). 
The resin was regenerated by running through 5 bed volumes of 1 % sodium 
deoxycholate (Sigma Aldrich), then washed with 5 bed volumes of water. Columns were 
centrifuged at 100 x g for 30 seconds to remove liquid from resin, and the resin was 
immediately resuspended in the sample (polyclonal FLC). Columns were then incubated 
at room temperature for 2 hours on a roller, centrifuged again and the filtrate collected, 
and the resin resuspended in water. The resin was then washed with deoxycholate and 
water as above to regenerate and elute off bound endotoxin. Samples were then tested by 
E-TOXATE as above, and, if necessary, endotoxin removal repeated.  
 
2.5.7 Monoclonal FLC Preparation   
Monoclonal FLCs used in experiments were previously prepared by Dr Paul W. Sanders 
at the University of Alabama at Birmingham from the urines of patients with multiple 
myeloma.(Sanders et al. 1987) 
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2.5.8 Polyclonal FLC Preparation  
Polyclonal FLCs were extracted from pooled blood donor sera. These were obtained 
from a vendor (Bio Products Laboratories, Elstree, UK) following removal of albumin 
by ethanol precipitation. The final production process for polyclonal FLCs is 
summarised in Chapter Five.   
 
2.5.8.1 Initial Steps 
These initial steps were performed at  Ltd, by Simon Blackmore. Precipitate was 
resuspended in PBS and remaining particulate matter allowed to settle. Using a 
peristaltic pump, the supernatant was dialysed using a membrane with increased 
permeability to molecules up to 60 kDa (HCO-1100, Gambro, Stockholm, Sweden). The 
filtrate was analysed for soluble protein, and found to contain significant quantities of 
IgG and albumin. A significant proportion of this IgG was removed by protein A 
immobilised on agarose (3 loops). The unbound fraction from this step was passed onto 
me for further processing. 
 
2.5.8.2 Coupling of Antibody to Matrix  
An anti- FLC affinity column was manufactured by coupling antibody to Sepharose 
matrix. 500 mg of anti- FLC antibody, raised in sheep, was obtained from  Ltd, along 
with CNBr activated Sepharose matrix (GE Healthcare). The ligand (antibody) was 
dialysed for 24 hours into coupling buffer, and transferred to a temporary column. 
Sepharose matrix was washed under suction in 1 mM HCl, and allowed to pack down 
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under suction to a cake. This was transferred to the temporary column, and gently 
resuspended by shaking, and left to couple through the day and overnight on a roller. 
The outlet was then opened, and the coupling buffer was drained out. The matrix was 
washed with 1 bed volume of acetate buffer, alternating with Tris-HCl, three times, then 
with one bed volume of elution buffer (glycine), then finally with running buffer (PBS).  
 
Protein content of the drained coupling buffer was determined by A280, and discarded 
after confirmation of adequate ligand binding.  
 
2.5.8.3 Affinity Chromatography   
Column chromatography was used extensively during the process of purifying 
polyclonal FLC. The principal methods applied were affinity chromatography and size-
exclusion chromatography.  
 
Affinity chromatography relies on the binding of a molecule of interest in solution (the 
liquid phase) to a molecule immobilised on a matrix (the solid phase) under designated 
conditions (e.g. a given pH), thus removing that molecule of interest from the 
solution.(Scopes 1994) These can be disassociated, by altering conditions (e.g. a 
different pH) with subsequent elution.  Matrix conjugated with relevant antibody was 
packed into a column, and connected to an automated pumped liquid chromatography 
system (AKTAprime plus; GE Healthcare, Uppsala, Sweden). This system enables 
loading of samples and passage of buffers at a range of designated speeds, monitoring of 
solute content of column eluent by an UV light absorption detector, and collection of 
eluent in fractions (Appendix). The buffer volumes, process running time, solution 
  
 91 
conductivity, collected fractions and UV absorption was depicted graphically in real-
time using proprietary software installed on a computer connected to the AKTAprime 
plus.  
 
All samples and buffers were passed through a 0.45 µm filter prior to application to the 
column. The column was washed in three bed volumes of running buffer (usually PBS, 
pH 7.2), elution buffer (usually glycine, pH 3) and then running buffer again. Sample 
was then loaded onto the column, and run through. The unbound fraction was collected 
for further analysis. The bound fraction was then eluted in glycine, and neutralisation 
buffer promptly added (Appendix).  
 
2.5.8.4 Size-Exclusion Chromatography   
Size-exclusion chromatography (SEC) is a process that enables separation of molecules 
according to their size. It relies on the differential speeds at which molecules of different 
sizes in solution (the liquid phase) travel through a porous matrix (the solid phase). 
Smaller molecules will be able to enter every corner of the matrix’s intra-particle pore 
system, and thus its progress will be retarded, causing it to be eluted late. (Lathe and 
Ruthven 1956; Scopes 1994) A larger molecule will permeate the pore system to a lesser 
extent, thus mostly passing through the inter-particle spaces, and will be eluted earlier.  
 
Columns were packed with matrix (GE Healthcare), connected to an AKTAprime 
system as above, and equilibrated with PBS running buffer which had been filtered to 
0.22 µm. Samples were injected via a loop, the buffer was run at 0.5 ml/min and 
fractions collected in 4 ml aliquots. Fractions of interest were then analysed as required.  
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2.5.9 Lyophilisation of Polyclonal FLC for Storage and Transportation  
After confirmation of the absence of endotoxin, polyclonal FLC was dialysed 
extensively for 72 hours into cell culture grade water, and transferred to 10 ml glass 
vials. Proteins were then lyophilised at  Ltd. Following lyophilisation, an aliquot was 
redissolved in buffer to confirm that solubility of protein was retained.  
 
2.6 Uromodulin  
2.6.1 Purification of Uromodulin  
Uromodulin was purified from the urines of healthy volunteers, according to the original 
method of Tamm and Horsfall.(Tamm and Horsfall 1952) Urine from healthy volunteers 
was collected and divided into 40-45 ml aliquots and placed on ice. Sodium chloride was 
added to a final concentration of 0.58 M, and allowed to dissolve on a roller at 4 ˚C. 
Once dissolved, the tubes were left upright, overnight at 4 ˚C. Samples were then 
centrifuged at 10,000 x g at 4 ˚C for 1 hour. The supernatant was discarded, the gel-like 
flocculent pellet redissolved in 10 ml of water, sodium chloride added again to a 
concentration of 0.58 M, and left overnight again. The solution was centrifuged as 
above, and the pellet redissolved in 2 ml of water. This was then dialysed into water for 
24 hours and protein concentration assessed by BCA assay. Protein was concentrated 
until it reached a TSP value of 2 mg/ml. For storage, the proteins could be frozen to -
70˚C.  
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When making dilutions of uromodulin in buffer, stock solutions were made by 
combining the uromodulin solution in water, with equivalent volumes of x 2 strength 
buffer (prepared by diluting x 10 buffer 1:5 in distilled, deionised water) and serially 
diluting this stock solution with x 1 buffer.  
 
2.6.2 Binding of Uromodulin to Polyclonal FLC   
The binding of uromodulin to polyclonal FLC was assessed by ELISA, immunoblotting 
and nephelometry.  
 
2.6.2.1 Indirect ELISA 
Plates were coated with polyclonal FLCs and control proteins (monoclonal FLCs 
purchased from a vendor;  FLC and  FLC, both from Sigma Aldrich; and HSA in 
PBS-T overnight at 4 ˚C. After washing, the wells were blocked with 1% BSA for 30 
min, and incubated with uromodulin for 2 hours, washed, incubated with HrP-
conjugated anti-sheep antibody (The Binding Site) for 1 hour, and developed with TMB 
substrate, and stopped with sulphuric acid, as above. Absorbance was measured at 450 
nm. For background measurement, wells were loaded with buffer only instead of protein 
and probed with primary and secondary antibodies as normal; absorbance values from 
these wells were subtracted from the results from the rest of the plate. No standard curve 
was generated, as the aim of the experiment was a comparison between polyclonal FLC 
and other proteins.  
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Plates were also coated with uromodulin, and then incubated with different dilutions of 
polyclonal FLC, probed with anti- FLC or anti- FLC primary antibodies, followed by 
HrP-conjugated secondary antibody.  
 
2.6.2.2 Sandwich ELISA  
A sandwich ELISA approach was attempted to reduce background signal from indirect 
ELISA. Plates were coated with anti-uromodulin antibody. Uromodulin was then 
applied at fixed concentration and incubated for 2 hours at room temperature. After 
washing, dilutions of polyclonal FLC were added to the wells, and incubated for 2 hours. 
Plates were then washed again, and incubated with HrP-conjugated anti- FLC or anti- 
FLC antibody for 1 hour at room temperature, and developed with TMB substrate as 
above. Background absorbance was measured and subtracted from the results as above.  
 
2.6.2.3 Dot Blot  
Dilutions of polyclonal FLC were made, spotted onto a nitrocellulose membrane, air-
dried, rehydrated with water, and blocked in 5% milk, before being incubated with 
uromodulin. Blots were then incubated with anti-uromodulin primary antibody, followed 
by HrP-conjugated secondary antibody, and developed with AEC.  
 
In other experiments, dilutions of uromodulin were spotted onto membranes, incubated 
with polyclonal FLC, and probed with anti- FLC and anti- FLC antibodies.  
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2.6.2.4 Nephelometry   
The formation of aggregates between polyclonal FLC in free and uromodulin in free 
solution was also investigated by measuring dynamic light scattering.(Sanders et al. 
1990) The instrument (MiniNeph; ) was a bench-top nephelometer with a 670 nm laser, 
using a 1 cm constant path length cuvette, with a reaction volume of 400 µl, and 
detected light scatter at an angle of 18˚ to the incident beam. Results were expressed as 
arbitrary Scatter Units against the reading from a blank cuvette containing buffer only, 
as zero.  
 
Uromodulin was added to the cuvette, and the reaction started by addition of polyclonal 
FLC or control protein, prepared in buffer with different salt concentrations. The open 
end of the cuvette was then promptly covered with plastic film to prevent excess 
evaporation. Scatter readings were taken at intervals and plotted against time.  
 
2.7 Statistical Analyses    
Statistical analysis was carried out using software packages Prism, GraphPad Software, 
La Jolla, CA, USA) and PASW Statistics (SPSS Inc, Chicago, IL, USA). A p-value of < 
0.05 was assigned statistical significance. 
 
2.7.1 Assessment of Normality of Data  
Data was analysed to assess whether they were from a Gaussian distribution, by 
applying both a Kolmogorov-Smirnov test (with Dallal-Wilkinson-Lilliefor p-value) and 
a d’Agostino and Pearson omnibus normality test.  
  
 96 
 
2.7.2 Normalisation of Data   
Where required, data, which was not normally distributed was normalised by log-
transformation.  
 
2.7.3 Correlations  
Linear regression analyses were performed to determine correlations between normally 
distributed data variables. Correlations between data were assessed by Pearson’s test 
(after log-transformation, if required) and Spearman’s calculations, with 2-tailed p-
values. Linear regression stepwise multivariate analysis of these correlations with a 
dependent variable was also performed. 
 
2.7.4 ANOVA  
Where measurements involved the use of ELISA, H2O2 measurement, LDH release, and 
nephelometry, each experiment was performed with at least 3 replicates and results were 
expressed as mean, with standard error of the mean (SEM).  Statistical differences 
between results were assessed by one-way and two-way analysis of variance (ANOVA) 
with Bonferroni post hoc testing.  
 
2.7.5 Test of Intra- and Inter-observer Variability of Image Analysis Data  
To test the validity of data obtained from quantitative image analysis for chronic 
damage, capillary density and macrophage infiltration, intra- and inter-observer 
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variability was tested. Inter-observer variation was assessed by having two observers 
measure 20 specimens independently. One observer was an independent research 
associate, and the other was myself. These 20 specimens were also measured twice, at 
intervals, by myself. This was to test for intra-observer variability. Concurrence was 
tested by the method described by Bland and Altman.(Bland and Altman 1986) This 
method gives the bias, or mean difference between measurements and limits of 
agreement, or 2 SDs either side of the mean, with 95% confidence intervals (CIs) for the 
bias and limits of agreement.  
 
2.7.6 Assessment of Distribution of Casts   
Statistical comparison of distribution of casts between areas with or without chronic 
damage was made with the two-tailed unpaired non-parametric Mann-Whitney test. 
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3. RENAL INFLAMMATION AND FIBROSIS IN MONOCLONAL 
DISEASE: IN SITU STUDIES   
3.1 Introduction  
Renal failure is a common finding in multiple myeloma, and is associated with 
significantly increased morbidity and mortality.(Kyle et al. 2003) The predominant 
histological lesion is myeloma kidney, or cast nephropathy, which is seen in up to 70% 
of cases at biopsy.(Ivanyi 1989; Herrera et al. 2004) Cast nephropathy is characterised 
by the presence of proximal tubular cell injury, interstitial inflammation, and hard, waxy 
casts in the distal tubules. Associated interstitial fibrosis is frequently seen. Currently 
there is no specific treatment for myeloma cast nephropathy, beyond treatment of the 
underlying plasma cell clone with chemotherapy. 
 
Excess circulating FLCs produced by the aberrant plasma cell clone are freely filtered at 
the glomerulus and presented to PTECs where they are taken up via the multi-ligand 
receptors megalin and cubilin and undergo lysosomal degradation.(Batuman et al. 1998; 
Klassen et al. 2005) During this process, signalling events lead to release of 
inflammatory mediators (including MCP-1) from PTECs, resulting in inflammatory cell 
recruitment and progressive interstitial fibrosis.(Sengul et al. 2002; Wang and Sanders 
2007) When the resorptive capacity of the proximal tubule is exceeded, FLCs then 
travel to the distal nephron, where they co-precipitate with uromodulin to form 
casts.(Sanders et al. 1990; Huang et al. 1993) These casts have a hard, waxy appearance 
and are frequently associated with a cellular reaction consisting of macrophage-derived 
giant cells.(Alpers et al. 1985)  
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Despite a wealth of information from in vitro and in vivo studies, little data exists on the 
in situ evolution of renal injury in humans. There has been one previous report of a 
follow-up renal biopsy after the initial diagnostic biopsy showing cast 
nephropathy.(Rose et al. 1987). This patient was treated with chemotherapy and 
initially received haemodialysis, converting to continuous ambulatory peritoneal 
dialysis. The patient became dialysis-independent after 3 months (although renal 
function did not normalize), with an associated reduction in serum paraprotein 
concentration and urinary light chain excretion. A repeat renal biopsy at 8 months 
showed an improvement in the adverse histological features present in the index biopsy.  
 
At our centre, a recent study has analysed treatment for patients presenting with AKI 
secondary to cast nephropathy with the combination of chemotherapy and high cut-off 
haemodialysis.(Hutchison et al. 2009) A number of patients who received this treatment 
and did not achieve independence from dialysis were assessed by a repeat renal biopsy.  
 
The aims of the work reported in this chapter were to: (i) perform a detailed histological 
examination of kidney tissue in these patients; (ii) compare the features seen before and 
after a period of treatment; and (iii) compare histological features which might be 
associated with renal outcomes.  
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3.2 Results 
3.2.1 Patients   
Patients treated by chemotherapy and high-cut off dialysis who remained dialysis 
dependent at six weeks were offered a repeat renal biopsy to assess the potential for 
recovery of independent renal function. Four patients (referred to as A, B, C and D) 
consented to undergo the second renal biopsy. The four patients, who comprised two 
male and two female adult Caucasians, presented with AKI requiring dialysis. None of 
the patients were known to have pre-existing renal disease, or any other significant 
medical history. After a paraprotein was detected in their sera, the patients underwent 
bone marrow biopsies to confirm the diagnosis of multiple myeloma. Serum FLCs were 
measured using the Freelite assay. A renal biopsy was also performed, which in each 
case showed myeloma cast nephropathy.  
 
All four patients received standard chemotherapy according to the local protocol. 
Patients A, B and C received thalidomide and dexamethasone, whilst patient D received 
cyclophosphamide, thalidomide and dexamethasone. Patients A, B and C were treated 
at our centre, while patient D was treated at another centre. As an adjunct, they also 
received high cut-off haemodialysis to maximise extracorporeal removal of light chains 
and minimise renal toxicity. After six weeks of treatment, for the purpose of further 
assessment, including quantification of chronic damage and the potential for recovery of 
independent renal function, each patient underwent a second renal biopsy. 
 
Table 3.1 summarises patient demographics, histological findings and biochemical data. 
All biopsies contained adequate cortical tissue to enable morphometric analysis. 
  
 101 
Significant reductions in light chain concentrations were achieved in all patients 
(median 76.5%, range 63.9-92.9%). Three patients (A, B and C) eventually achieved 
independence from dialysis at 51, 67 and 105 days, respectively. The six-week biopsies 
showed differential changes in the degree of chronic damage and cast numbers.  
 
3.2.2 Histological Diagnosis of Cast Nephropathy  
The initial biopsies fulfilled diagnostic criteria for cast nephropathy. In all four there 
was evidence of vacuolation and desquamation of PTECs, interstitial inflammation and 
fibrosis, and distal tubular casts. There was no evidence of amyloid or light chain 
deposition disease in any of the biopsies. In addition to standard diagnostic assessments, 
renal biopsy specimens were also assessed in detail for chronic damage and light chain 
cast formation. Figure 3.1 shows the initial diagnostic and six-week biopsies for the 
patients.  
 
  
 102 
Table 3.1. Summary of patient demographics, histological findings and biochemical data.  
Patient Age Sex Medication 
Prior to 
Presentation 
FLC 
Isotype  
Treatment 
Regimen 
Serum 
FLC at 
Treatment 
Initiation 
(mg/L) 
Serum 
FLC at 
6 
Weeks 
(mg/L) 
Reduction 
in Serum 
FLC by 6 
Weeks 
(%) 
Index of 
Chronic 
Damage (%) 
Number of 
Tubules with 
Casts (%) 
Interstitial Infiltrate Time to 
Independence 
from Dialysis 
(Days) 
     0 
Weeks 
6 
Weeks 
0 
Weeks 
6 
Weeks 
0 Weeks 6 Weeks 
A 61 F None Free  TD 1,990 334 83.2 % 28.1 40.3 37.5 5.7 Heavy Moderate 51 
B 56 M None IgA  TD 9,918 704 92.9 % 10.7 42.2 37.3 10.0 Moderate Moderate 67 
C 55 F None Free  TD 7,675 2,318 69.8 % 35.7 37.3 21.9 8.3 Moderate Moderate 105 
D 55 M None IgG  CTD 5,870 2,119 63.9 % 28.3 31.7 24.6 24.0 Heavy Light No Recovery 
 
TD, thalidomide and dexamethasone; CTD, cyclophosphamide, thalidomide and dexamethasone.  
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3.2.3 Index of Chronic Damage  
Figure 3.2A shows changes in the index of chronic damage over six weeks. At initiation 
of treatment, the index of chronic damage for patients A-D was 28.1%, 10.7%, 35.7% 
and 28.3%, respectively. At six weeks, patient A had sustained a moderate increase in 
chronic damage, up to 40.3%. Patients C and D showed minimal increases in chronic 
damage, up to 37.3% and 31.7%, respectively. In contrast, patient B sustained a fourfold 
increase in the degree of renal scarring, from 10.7% up to 42.4%, despite a rapid and 
sustained reduction in serum light chain levels to lower than 10% of starting level at six 
weeks.  
 
3.2.4 Number of Tubules with Casts  
Figure 3.2B shows changes in cast numbers over six weeks. The median number of 
tubules counted per biopsy was 368.5 (range 145-1302). Three patients, A, B and C, 
showed major reductions in intratubular cast numbers at six weeks, from 37.5% to 
5.7%, 27.3% to 10.0% and 21.9% to 8.3%, respectively. Patient D continued to have 
high cast formation at six weeks, and there was no renal recovery in this case. 
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 Figure 3.1. Renal biopsies from patients A-D.  
Renal biopsies at initiation of treatement (i) and after six weeks (ii), showing 
observed changes in interstitial inflammation, degree of interstitial scarring and cast 
numbers. (H&E, original magnification x200) 
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Figure 3.2. Changes in the index of chronic damage and cast numbers over six 
weeks.  
Changes in the index of chronic damage (A), and cast numbers (B) at initiation of 
treatment and after six weeks. Patient A sustained a moderate increase in chronic 
damage, while Patients C and D showed minimal increases. Patient B sustained a 
fourfold increase in chronic damage. Patients A, B and C showed major reductions 
in the numbers of intratubular casts seen on biopsy, while patient D continued to 
have high numbers of casts after six weeks.  
A 
 
B 
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3.2.5 Interstitial Infiltrate   
For the purpose of scoring the degree of interstitial infiltrate, sections were anonymised 
and blinded assessment was carried out by two observers independently (Dr  and Dr Dia 
Kamel). The degree of interstitial infiltrate was determined by eye, and graded as heavy, 
moderate or light.  
 
The degree of interstitial infiltrate at six weeks was reduced in patient A from heavy to 
moderate, and markedly reduced in patient D from heavy to light. In patients B and C 
there were moderate interstitial infiltrates on the first biopsy, which had not changed at 
six weeks. 
 
3.3 Discussion  
This is the first series detailing the in situ changes with time in patients with myeloma 
cast nephropathy. The patients who are reported remained dialysis dependent after six 
weeks, which prompted further assessment by a repeat biopsy. The purpose of repeat 
biopsy included assessment of chronic damage and estimation of potential for the 
recovery of renal function. Despite significant reductions in serum FLC levels in all 
cases, chronic damage in situ on repeat biopsy ranged from no change from baseline to 
progression to severe chronic damage. Despite these observations, it was the patient 
who had no progression of chronic damage, but no decrease in cast numbers, who failed 
to recover independent renal function. Those patients who had reductions in cast 
numbers at six weeks did subsequently recover independent renal function. 
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In patients with multiple myeloma and cast nephropathy, failure to become independent 
of dialysis is associated with a worse outcome. A previous histological study indicated 
that the degree of interstitial fibrosis seen in the diagnostic biopsy correlated well with 
the prospect of renal recovery.(Pasquali et al. 1987) Another study has indicated that 
early renal recovery correlated with the severity of chronic damage and cast numbers 
seen in the biopsy.(Pozzi et al. 1987) In this study, some patients with severe tubular 
atrophy and interstitial fibrosis still recovered independent renal function. However, 
there are no other reliable predictors of renal recovery in this setting. In patients who are 
receiving disease-specific treatment for multiple myeloma in the setting of dialysis-
dependent AKI and who have not achieved independent renal function after significant 
reductions in serum FLC levels, a repeat biopsy to assess in situ chronic damage and 
cast numbers may be useful as a guide to further treatment. Reduction in cast numbers 
may also indicate the potential for a late recovery. 
 
Cast formation can also be promoted by increasing the salt concentration, acidification 
or slowing the flow rate of distal tubular fluid, as well as a high load of light chain 
delivered to the distal tubule. These conditions are potentiated by dehydration, 
administration of drugs such as furosemide or non-steroidal anti-inflammatory agents, 
and a higher serum FLC load. Therefore appropriate management of the patient can 
potentially reverse all these factors. Irrespective of any clinical changes, the reduction in 
cast numbers seen in patients A, B and C could reflect the fall in serum FLCs seen in 
these patients. The reason for the persistence of casts in patient D is hypothetical, but 
may be a reflection of the affinity of the clone of light chain in that patient for 
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uromodulin. Also in patient D, an improvement in the degree of interstitial infiltrate was 
not associated with subsequent renal recovery. 
 
In these four patients, serum FLC measurements were taken into account at initiation of 
treatment, and at six weeks. Because the patients described in this study were treated at 
different centres, there were local variations in treatment strategies and serum FLC 
measurement intervals during treatment. As a result it was not known if there were 
differences between patients in serum FLC reductions during this six week period. In 
patients C and D, the reductions in serum FLC levels were less pronounced than in 
patients A and B. Patient C took longer to achieve independence from dialysis than 
patients A or B, while patient D did not recover independent renal function despite 
receiving more intensive chemotherapy than the other three patients. It is therefore also 
possible that better responsiveness to treatment (i.e. earlier, more pronounced reductions 
in serum FLC levels) might account for the differences in clinical outcomes.(Hutchison 
et al. 2009)  
 
The findings presented in this chapter are based on the study of patients who underwent 
a repeat renal biopsy due to their failure to respond adequately to treatment. Patients 
who rapidly recover independent renal function are rarely offered a repeat biopsy. 
Therefore the data are gathered from a biased cohort, and may not necessarily be 
representative of in situ histological changes in all patients with myeloma kidney.  
 
Studies using myeloma light chains purified from the urine of different patients have 
demonstrated that different species of light chains have differing degrees and patterns of 
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toxicity in the kidney, in both the proximal tubule and the distal tubule. Some light 
chains tend to cause more proximal tubular damage, while others have a strong 
tendency to co-precipitate in the distal nephron with uromodulin, to form casts.(Sanders 
et al. 1988a; Sanders et al. 1990; Sanders and Booker 1992) Sanders and co-workers 
have shown that it is the CDR3 region of both  and  FLCs that interacts with a single, 
9 amino acid binding domain on uromodulin.(Huang et al. 1993; Huang and Sanders 
1997; Ying and Sanders 2001) Both the degree of proximal tubular inflammation and 
avidity for binding to uromodulin varies from light chain to light chain.(Sanders et al. 
1988a) In addition, although a link to progression of renal fibrosis has not been 
established, uromodulin is capable of activating macrophages through TLR4,(Saemann 
et al. 2005) a phenomenon which may in part account for the giant cell reaction 
frequently seen around myeloma casts. 
 
The development of interstitial fibrosis leading to established chronic damage is 
associated with and dependent on the release of cytokines from PTECs in response to 
light chain endocytosis and the subsequent recruitment of inflammatory cells. One 
explanation for these differing degrees of toxicity may derive from the fact that light 
chains are coded for multiple gene segments which have a huge number of possible 
combinations, thus giving rise to extreme primary structure heterogeneity.(Bradwell 
2006) These differences in primary structure and subsequent post-translational 
modifications can give an individual light chain unique physicochemical properties.  
 
A recent, elegant study from the laboratory of Sanders showed that different 
monoclonal FLCs are capable of generating varying quantities of H2O2 in solution, a 
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property not exhibited by non-immunoglobulin derived proteins.(Wang and Sanders 
2007) H2O2 was also detected in PTEC culture supernatants after exposure to FLCs, and 
subsequent release of cytokines was dependent on this H2O2. H2O2 acts as a second 
messenger in many signaling pathways, and so this finding had significant implications 
in terms of potential downstream inflammatory signaling following FLC endocytosis. It 
was possible that the inflammatory potential of FLCs was related to their ability to 
generate H2O2.  
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4. RENAL INFLAMMATION AND FIBROSIS IN MONOCLONAL 
DISEASE: IN VITRO STUDIES  
4.1 Introduction  
In the previous chapter, a detailed histological examination of renal biopsies was 
presented. In one of the patients, the degree of interstitial fibrosis was noted to have 
advanced rapidly, compared to the other three patients. The development of fibrosis is 
dependent on the activation of PTECs following FLC exposure, resulting in activation 
of MAPKs and NF-B and downstream release of inflammatory cytokines such as 
MCP-1.(Sengul et al. 2002) One possible contributory factor is the differential toxicity 
of each clone of FLC. Two consistent findings in studies performed in vitro have been 
that (i) FLCs are more potent inducers of cytokines than other proteins commonly 
implicated in renal inflammation and (ii) the quantity of cytokines produced varies from 
one FLC to another.  
 
A possible explanation for this phenomenon may lie in the ability of light chains to 
generate H2O2 in a catalytic fashion.(Wentworth et al. 2000; Wentworth et al. 2001) 
Recently, it was shown that myeloma FLCs also possess this ability, and that the release 
of MCP-1 from PTECs in response to FLC was dependent upon this.(Wang and Sanders 
2007) These data pointed to a key role played by H2O2 in the signal transduction 
cascades that are set in motion after internalisation of excess light chain. The single 
initiating event for signal transduction, however, has remained elusive. H2O2 is known 
to act as a second messenger in signalling pathways.(Rhee 2006) If H2O2 were to 
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activate a molecule acting as a central signalling hub, the potential effects of H2O2 
generation in monoclonal FLC related kidney disease might be far-reaching.  
 
One potential candidate early signalling molecule was c-Src. c-Src is a member of the 
Src tyrosine kinase family, which plays a role in signal transduction in response to 
many external stimuli and its activity is under tight redox control (figure 4.1).(Parsons 
and Parsons 2004) When reduced by phosphorylation at Y527, it is inactive.(Cooper 
and Howell 1993) However, when oxidised at cysteine residues C245 & C487, it is 
dephosphorylated at Y527, undergoes conformational change, is autophosphorylated at 
Y416, and becomes active.(Brown and Cooper 1996; Xu et al. 1997) This process of 
activation has been shown to be dependent on ROS.(Cooper and Howell 1993; 
Giannoni et al. 2005) This chapter presents results from investigations into the 
relationship between H2O2, c-Src and the release of MCP-1 from PTECs in response to 
two monoclonal FLCs, referred to here as 2 and 2. These two monoclonal FLCs were 
purified from the urines of two patients with multiple myeloma.(Wang and Sanders 
2007) Both patients had clinical evidence of significant renal damage, which was 
presumed to be cast nephropathy. However renal biopsy was not routinely performed in 
these patients. Endotoxin levels in both FLCs were shown to be below the detection 
limit of the QCL-1000 colourimetric assay (see Chapter 2). Both these FLCs had 
previously been shown to cause generation of H2O2 in HK-2 cell culture, and the 
production of this H2O2 was an integral step in the release of MCP-1 from cells.(Wang 
and Sanders 2007) The methods that were used to perform these experiments are 
presented in Chapter 2.  
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Figure 4.1. The c-Src molecule, and its activation. 
In the inactive, reduced state, c-Src is phosphorylated at Y527. Oxidation at C245 & C487 results in dephosphorylation at Y527, 
subsequent conformational change, and autophosphorylation at Y416, causing the molecule to becomes active. This process has been 
shown to be dependent on ROS. SH, Src homology domains.  
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4.2 Results  
4.2.1 Immunoglobulin Light Chains Activate c-Src 
c-Src activation by phosphorylation (phospho-c-Src) was detected by Western blot 
analysis of cell lysates using a primary antibody that specifically detects 
phosphorylation at Y416. The amount of active c-Src in cells exposed to light chain (1 
mg/ml) relative to the amount of GAPDH in the lysate were determined by 
densitometry (figure 4.2). After exposure to both 2 and 2 light chains, phospho-c-Src 
levels increased rapidly, representing activation of this enzyme, in a time-dependent 
manner, with a peak being observed at 12 h and declining thereafter. At this point they 
were up to 8-fold to 9-fold higher than the amounts seen in cells treated with vehicle 
alone. No time-dependent change in phospho-c-Src levels were seen in cells exposed to 
vehicle alone. After 12 h, phospho-c-Src concentrations declined, reducing to less than 
50% of the peak levels by 24 h. There were no significant differences in the relative 
increase of phospho-c-Src between the two species of light chains at each time point. 
 
4.2.2 DMTU Inhibits c-Src Activation  
Co-incubation of HK-2 cells with either light chain and 1,3-dimethyl-2-thiourea 
(DMTU, 30 mM) a cell permeable chemical trap for H2O2, prevented activation of c-
Src, as determined by the ratio of phospho- c-Src to total c-Src in the lysate obtained 
(Figure 4.3). Compared with 2 alone, the increase in the relative amount of phospho-c-
Src induced by the 2 light chain was inhibited (P < 0.05) by DMTU (0.28 +-/- 0.04 for 
vehicle alone; 0.96 +/- 0.07 for light chain alone; 0.28 +/- 0.04 for light chain plus 
DMTU). Compared with 2 light chain alone, the increase in phospho-c-Src induced by  
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the 2 light chain was inhibited (P < 0.05) by DMTU (0.46 +/- 0.04 for vehicle alone; 
0.80 +/- 0.12 for light chain alone; 0.41 +/- 0.02 for light chain plus DMTU).  
 
Figure 4.2. Immunoglobulin free light chains activate c-Src. 
Time dependent activation of c-Src by light chains. Exposure to both 2 and 2 light 
chain resulted in an increase in phosphorylation at Y416, representing activation of 
this enzyme, when compared with lysates of cells exposed to vehicle alone. 
Densitometric analysis of bands shows the increase was similar for both light chains 
and occurred in a time-dependent manner, reaching a peak at 12 hours, and declining 
thereafter. N = 3 experiments in each group.  
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4.2.3 Inhibition of c-Src Suppresses MCP-1 Production but does not Suppress  
H2O2 Production 
Overnight incubation of HK-2 cells with both 2 and 2 light chains (1 mg/ml) 
increased production of MCP-1 and H2O2 in the cell culture supernatant, when 
compared to medium alone, as measured by sandwich ELISA and Amplex Red, 
respectively (figure 4.4). When 10 µM 4-amino-5-(4-chlorophenyl)-7-(t-
butyl)pyrazolo[3,4-d]pyramidine (PP2), an inhibitor of c-Src activity, was added to the 
Figure 4.3. DMTU inhibits c-Src activation. 
Addition of DMTU inhibits light chain-induced activation of c-Src in HK-2 cells, as 
determined by the ratio of phospho-c-Src to total c-Src in the lysate obtained 
following overnight incubation. Compared with K2 alone, the increase in the relative 
amount of phospho-c-Src induced by the K2 light chain was inhibited (P < 0.05) by 
DMTU (0.28 +-/- 0.04 for vehicle alone; 0.96 +/- 0.07 for light chain alone; 0.28 +/- 
0.04 for light chain plus DMTU). Compared with L2 light chain alone, the increase 
in phospho-c-Src induced by the L2 light chain was inhibited (P < 0.05) by DMTU 
(0.46 +/- 0.04 for vehicle alone; 0.80 +/- 0.12 for light chain alone; 0.41 +/- 0.02 for 
light chain plus DMTU). N = 4 experiments in each group. 
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culture medium, MCP-1 concentrations in the supernatant remained at baseline levels. 
However PP2 did not have such an effect on H2O2 in the supernatant.  
 
Figure 4.4. Inhibition of c-Src suppresses MCP-1 production but not H2O2 
production.  
Inhibition of c-Src prevents light chain-induced production of MCP-1, but not 
H2O2. There is a rise in H2O2 after exposure of HK-2 cells to both 2 (top) and 2 
(bottom) light chains. This is unaffected by the addition of 10 µM PP2, an inhibitor 
of c-Src activity, indicating that the production of H2O2 takes place upstream of c-
Src. There is also an increase in MCP-1 release into the supernatant. Inhibition of c-
Src activity by PP2 returns MCP-1 levels to baseline, indicating that c-Src activation 
is necessary for the release of MCP-1. n = 6 experiments in each group. 
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4.2.4 Removal of Extracellular H2O2 by Catalase has no Impact on MCP-1 
Production 
To investigate whether H2O2 involved in signaling was produced intracellularly or 
extracellularly, catalase was added to the medium.  As a powerful extracellular 
scavenger of H2O2, exogenously applied catalase would quickly destroy any H2O2 in the 
supernatant. Cells exposed to medium containing catalase produced MCP-1 at a rate of 
302.8±10.3 pg/day.  Addition of catalase to the medium along with 2 and 2 light 
chains did not prevent the increase in MCP-1 (672.5±37.3 and 1018.3±28.7 pg/day, 
respectively; P < 0.05 compared to control).  
 
4.2.5 Silencing of c-Src Expression Suppresses MCP-1 Production in Response 
to Light Chain Exposure 
c-Src expression was silenced by transfecting HK-2 cells with siRNA specifically 
targeted to c-Src. Western blot analysis of cell lysates confirmed successful silencing of 
total-c-Src production (figure 4.5A). Densitometry relative to GAPDH expression 
showed an approximate 80% reduction in c-Src expression when compared to lysates 
from cells exposed to the non-targeting siRNA. When HK-2 cells were incubated with 
2 and 2 light chains, cells in which c-Src expression was reduced did not release 
MCP-1 into the supernatant above baseline levels (figure 4.5B). 
 
4.2.6 c-Src is Oxidised Following Light Chain Treatment 
To determine whether oxidation of c-Src occurs in response to exposure to light chain in 
HK-2 cells, N-(biotinoyl)-N’-(iodoacetyl)ethylenediamide (BIAM), a thiol-reactive  
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 Figure 4.5. Silencing of c-Src expression suppresses MCP-1 production in 
response to light chain exposure. 
Silencing c-Src expression in HK-2 cells abrogates the MCP-1 response that follows 
exposure to either 2 or 2 light chains. Cells were transfected with siRNA specific 
for c-Src. (A) Successful knockdown of c-Src expression was confirmed by Western 
blot analysis, normalized to a GAPDH loading control. Densitometric analysis 
shows an approximate 80% reduction compared with negative control. Bars 
represent means of four individual experiments. (B) MCP-1 release from transfected 
cells after light chain challenge. Knockdown of c-Src expression abrogates the 
MCP-1 response, indicating that the presence of c-Src is necessary for signal 
transduction, leading to MCP-1 release. N = 8 experiments in each group. 
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biotinylating reagent for proteins, was used. BIAM specifically identifies the thiolate 
form of cysteine residues when they are in the reduced state, making it a very useful 
tool to detect redox-regulation of proteins.(Dominici et al. 1999; Kim et al. 2000) Using 
this method, we measured reduced-c-Src levels in HK-2 cells after exposure to 2 and 
2 light chains (figure 4.6). There was a time-dependent reduction in reduced-c-Src 
levels, when compared to those treated with vehicle alone.  Data in the bottom panels 
show that total c-Src levels in the samples did not differ among the groups. These data 
confirm that c-Src is directly oxidised when cells are treated with light chains.  
 
4.2.7 Silencing of Megalin and Cubilin Suppresses MCP-1 Production 
To confirm that MCP-1 production was dependent on cellular uptake of light chain 
through interaction with megalin and cubilin, expression of these two proteins was 
silenced by transfecting HK-2 cells with specific siRNAs. Successful knockdown was 
confirmed by Western blot analysis for both proteins (figure 4.7A). Silencing of 
megalin and cubilin significantly reduced MCP-1 release by HK-2 cells in response to 
exposure to 2 and 2 light chains (figure 4.7B). MCP-1 production between controls, 
where cells were transfected with non-targeting sequence siRNA or exposed to vehicle 
alone, did not differ. MCP-1 production increased when cells were exposed to light 
chains, the response being stronger with 2 compared with 2. After megalin and 
cubilin knockdown, this response was markedly reduced, by approximately 60% with 
2 and 63% with 2, but remained slightly above production levels seen in the control 
samples.  
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4.3 Discussion  
In the setting of renal disease attributable to monoclonal FLCs, renal fibrosis can 
progress rapidly despite treatment in this condition, as indicated in the previous chapter. 
Understanding pathways to inflammation driven by cytokine release from the proximal 
tubule becomes important from a translational point of view, if ways of preventing the 
resulting irreversible renal fibrosis are to be found.  
 
The purpose of the studies reported here was to investigate the links between light 
chains, oxidative stress, c-Src activation and production of MCP-1, a key chemokine in 
inflammation. The data from this series of experiments show that two unique light 
chains, in concentrations relevant to levels exposed to proximal tubule cells in vivo,  
Figure 4.6. c-Src in oxidised following light chain treatment. 
Incubation of HK-2 cells with the two light chains oxidizes c-Src. Cells were 
exposed to either 2 or 2 light chain, and c-Src oxidation was assessed at 2-, 6-, 12-
, and 24-hour time points. Cells were lysed and reduced c-Src was labelled with 
BIAM and immunoprecipitated before detection by immunoblotting. Half of each 
sample was probed with an anti-total-c-Src antibody for the purpose of 
normalization. Reduced-c-Src levels declined during the time course of the 
experiment, indicating that direct oxidation and activation of c-Src was taking place. 
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Figure 4.7. Silencing of megalin and cubilin suppress MCP-1 production. 
Silencing megalin and cubilin expression inhibits light chain-induced MCP-1 
production by HK-2 cells. Megalin and cubilin expression was silenced by specific 
siRNAs. (A) Successful knockdown was confirmed by Western blot analysis, 
normalized to a GAPDH loading control. Lane 1, control; lane 2, vehicle; lane 3, 
addition of nontargeting siRNA; lane 4, addition of siRNA targeted for megalin; 
lane 5, addition of siRNA targeted for cubilin; and lane 6, addition of siRNA 
targeted for both megalin and cubilin. Densitometric analyses showed a greater than 
85% reduction in megalin and an approximate 95% reduction in cubilin. (B) MCP-1 
release is significantly reduced after knockdown, compared with nontargeting 
scramble sequence siRNA. However, the response was not completely abrogated, 
indicating ongoing signal transduction likely due to incomplete knockdown of the 
machinery involved in transport of the light chains into the cell. N = 6 experiments 
in each group.  
 
 
 
  
 123 
induce activation of c-Src, a tyrosine kinase known to be involved in several signal 
transduction pathways. Sengul et al. demonstrated that NF-B is activated in HK-2 cells  
 
when they are exposed to and internalise light chains, resulting in the release of MCP-
1.(Sengul et al. 2002) Findings in the present study agree with these data and 
complement the previous findings that production of MCP-1 was also dependent on 
H2O2 and NF-B, because inhibition of ROS with 1,3-dimethyl-2-thiourea (DMTU) and 
inhibition NF-B with pyrrolidine dithiocarbamate (PDTC) suppressed MCP-1 
release.(Wang and Sanders 2007) The present data further demonstrate that c-Src is 
integrally involved in production of MCP-1 by proximal tubule cells following 
exposure to light chains.  
 
Because of the observed capability of FLC to generate H2O2,(Wang and Sanders 2007) 
the present study therefore focused on activation of c-Src as an intermediate in the 
signal transduction process that produced MCP-1 by FLC.  The addition of PP2 
abrogated the MCP-1 response quite effectively, indicating that activation of c-Src plays 
a key role in MCP-1 production. To reaffirm that c-Src was necessary for the production 
of MCP-1 after light chain exposure, c-Src synthesis was silenced with the use of 
siRNA. After successful knockdown, the release of MCP-1 into the supernatant in 
response to light chains was abolished. This was further evidence that as well as H2O2 
and NF-B, c-Src served as a vital link in the chain of events leading to MCP-1 release. 
Experiments then investigated whether the H2O2 generated after light chain challenge 
led to oxidation of c-Src. The data show that c-Src in the reduced state (as detected by 
BIAM labeling) is depleted in a time-dependent fashion temporally associated with c-
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Src activation. These observations are consistent with previous results demonstrating 
the presence of intracellular oxidative stress within HK-2 cells.(Wang and Sanders 
2007) The data are also supported by the results published by Giannoni et al.(Giannoni 
et al. 2005) showing that intracellular oxidative stress causes direct oxidation of c-Src at 
Cys245 and Cys487, thereby facilitating c-Src activation.  
 
Inhibition of c-Src by PP2 however had no effect on H2O2 levels in the supernatant. 
This would suggest that H2O2 generation occurs independently of c-Src activation. 
Although the major source of H2O2 is likely from the light chain itself,(Wang and 
Sanders 2007) the precise intracellular location where H2O2 was produced in these 
experiments remains unclear. However, an elegant series of experiments by DeYulia et 
al. has revealed that the interaction of receptor and its ligand can generate H2O2, 
independent of subsequent signal transduction.(DeYulia et al. 2005) This ability was 
conserved even when cells were fixed, or purified receptor and ligand interacted in the 
absence of cells. Although this phenomenon has not been shown when megalin-cubilin 
receptors interact with light chains, it is yet another possible source of H2O2.  
 
In a fashion similar to immunoglobulins,(Wentworth et al. 2001) Sanders et al have 
previously shown that light chains alone in solution are capable of catalysing the 
production H2O2.(Wang and Sanders 2007) Although all proteins have the intrinsic 
ability to do this, the effect is usually quickly saturable, resulting in low levels of 
production of ROS. In contrast, light chains are much more efficient and have a much 
higher capacity for catalysing this reaction when compared to non-immunoglobulin-
derived proteins. While the ability of immunoglobulins to generate H2O2 may improve 
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the ability of the antibody to destroy pathogens, the present series of experiments show 
that the generation of H2O2 by light chains may have deleterious effects on the kidney 
proximal tubule by initiating inflammatory signaling pathways.  
 
A recent study by Li et al. from the laboratory of Batuman has shown that by silencing 
the expression of megalin and cubilin with siRNAs, endocytosis of light chains could be 
blocked, resulting in the amelioration of toxic effects, cytokine release such as that of 
MCP-1, and epithelial-to-mesenchymal transition (EMT).(Li et al. 2008a) The findings 
from the current study were in agreement with the role of megalin and cubilin in these 
processes. Along with the lack of efficacy of extracellular catalase, these data indicate 
that endocytosis of light chains is an important step in signal transduction leading to 
cytokine release.  
 
The inhibitory agents PP2 and siRNAs are highly specific inhibitors of their respective 
targets. In addition to H2O2, other intracellular ROS such as peroxynitrite may activate 
c-Src in response to pro-inflammatory stimuli.(Mallozzi et al. 1999) Although the role 
of peroxynitrite in the pathogenesis of myeloma cast nephropathy has not been 
described, it is conceivable that this form of ROS also plays a role. The inhibitory agent 
for ROS used in the studies presented in this chapter, DMTU, is capable of blocking the 
activity of peroxynitrite as well as H2O2, thus dissecting any individual contributions of 
each of these ROS is not possible by this approach alone.(Whiteman and Halliwell 
1997) Wentworth et al have shown that immunoglobulins can generate H2O2, and 
Sanders et al have demonstrated that myeloma FLCs also possess this 
ability.(Wentworth et al. 2000; Wang and Sanders 2007) In the studies presented in this 
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chapter, the Amplex Red assay which is highly specific for H2O2 was used.(Zhou et al. 
1997; Mohanty et al. 1997) It is therefore clear from the studies presented in this 
chapter, and previous studies from the laboratory of Sanders, that H2O2 is indeed 
generated in response endocytosis of FLCs by PTECs, leading to the inference that this 
is the primary ROS involved in signaling. Additional studies in the future would be 
required to distinguish between the contributions of H2O2 and peroxynitrite in the 
setting of myeloma cast nephropathy. The peroxynitrite decomposition catalyst 
5,10,15,20-tetrakis-[4-sulfonatophenyl]-porphyrinato-iron[III] (FeTPPS) would be a 
suitable inhibitory agent is this setting.(Misko et al. 1998)  
 
Other proteins such as albumin have been shown to stimulate MCP-1 production in 
PTECs.(Wang et al. 1999; Morigi et al. 2002) However, it has been repeatedly observed 
that the ability of light chains to induce cytokine production in PTECs far exceeds that 
of other such filtered proteins implicated in proximal tubule inflammation.(Sengul et al. 
2002; Wang and Sanders 2007) These proteins share a common route of entry into 
PTECs via megalin and cubilin, suggesting that there is another mechanism for 
generation of oxidative stress aside from ligand-receptor interaction. In the context of 
inflammation in the proximal tubule, the intrinsic ability of light chains to generate 
H2O2 and the highly efficient manner in which they do this puts them in a class of 
proteins quite separate from non-immunoglobulin-derived proteins. The data presented 
here show that in order for PTECs to reach an inflammatory state in response to light 
chains, the activation of the tyrosine kinase c-Src is necessary. The generation of H2O2 
occurs upstream of c-Src activation, which in turn is dependent on H2O2. Indeed, this 
event appears to be mediated by H2O2 directly oxidising this enzyme.  
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Because the rate of clearance of FLCs is linked to GFR, in CKD, where there is gradual 
loss of functioning nephrons, the serum concentrations of polyclonal FLCs rise, 
presenting the remaining nephrons with increased levels of filtered FLC.(Hutchison et 
al. 2008c) Given the findings with monoclonal FLCs, I hypothesised that the polyclonal 
FLCs in CKD might exert a pro-inflammatory biological effect on PTECs, as well as in 
distal tubules with uromodulin.  
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5. PURIFICATION OF POLYCLONAL FREE LIGHT CHAINS 
5.1 Introduction   
In the setting of plasma cell dyscrasias (PCDs), free light chains (FLCs) have been 
shown to activate PTECs and effect the release of cytokines such as MCP-1, IL-6 and 
IL-8, resulting in inflammatory cell infiltration and established interstitial 
fibrosis.(Sengul et al. 2002; Wang and Sanders 2007) In distal tubules, FLCs co-
precipitate with uromodulin to form casts, which are also associated with inflammatory 
cell invasion of the interstitium and tubules.(Sanders and Booker 1992) Because FLCs 
are cleared from the circulation by the kidneys, serum FLC levels are dependent upon 
glomerular filtration rate (GFR). Consequently, both serum  and  FLCs are present at 
concentrations in patients with CKD, that are several orders of magnitude higher than in 
healthy controls.(Hutchison et al. 2008c) I set out to purify polyclonal FLCs, to perform 
experiment to assess if they exert similar biological effects in chronic kidney disease, as 
monoclonal FLCs do in PCDs. This chapter presents the development and optimisation 
of methodology for the purification of polyclonal  and  FLCs.  
 
5.2 Choice of Source of Polyclonal Free Light Chains   
Broadly speaking, previous studies of FLCs have utilised proteins derived from two 
sources: urine from patients with PCDs or dialysis effluent. Urine has several 
advantages. The glomerular filtration barrier acts as a natural sieve, preventing the 
passage of larger proteins like whole immunoglobulin. In myeloma, where the serum 
concentration of monoclonal FLC can be very high, FLC is often the main protein in the 
urine, which helps simplify the purification process. However in CKD, urinary FLC 
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levels are elevated to a lesser extent, and there are often other proteins such as albumin 
present. Due to the effect of receptor-mediated endocytosis reclaiming proteins in the 
proximal tubule, urinary FLCs from patients with CKD might not have been entirely 
representative of the serum FLC population. In addition, patients with CKD have 
elevated levels of cytokines in their urine, which might affect downstream in vitro 
assays.(Morii et al. 2003; Eardley et al. 2006) These factors mean that large quantities 
of urine from patients with CKD, and rigorous screening for and removal of cytokines, 
would have been needed to produce an adequate yield of FLC.  
 
In the published literature, polyclonal FLCs have been extracted from dialysis effluent 
for experimental use by one group.(Cohen et al. 1995) FLCs were successfully purified 
from both haemodialysis and peritoneal dialysis effluent. In this case, as with urine, the 
dialyser and peritoneal membranes would act as filters. One major disadvantage of 
using dialysis effluent is the presence of cytokines, found both in peritoneal dialysis and 
haemodialysis.(Wong et al. 2003; Catalan et al. 2003; Goldfarb and Golper 1994) 
Again, as with urine from patients with CKD, the use of dialysis fluid would have 
required large volumes of fluid to be processed, along with detection and, if necessary, 
removal of cytokines.  
 
Therefore, for the purpose of purifying polyclonal FLCs for in vitro studies, pooled, 
precipitated sera from blood donors was chosen. These originated from the national 
blood transfusion service, and had undergone large scale fractionation during which the 
majority of albumin had been removed for therapeutic applications. This source had a 
number of advantages: (i) it represented a large cohort of healthy donors, translating 
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into increased diversity of FLCs and thus a true polyclonal pool; (ii) it was a good bulk 
product to work with as a large quantity was available; (iii) it was obtained after a 
significant quantity of the albumin had been removed, which was the contaminating 
protein present in the highest concentration.  
 
5.3 Analysis of Resuspended Sera  
Initial steps in purification were performed by Simon Blackmore, in the Subclass 
Antisera department at . Precipitated sera were resuspended, filtered through a 
membrane with an effective MW cut-off of 60 kDa (HCO-1100; Gambro), the filtrate 
subjected to immunoglobulin removal by repeated loops through a protein A column, 
and the unbound fraction was then provided to me for further processing. This will be 
referred to as the starting sample. Table 5.1 summarises the quantities of TSP and FLC, 
as well as the final quantities of FLCs recovered from the batches.   
 
For an indication of the different types and sizes of proteins which required removal in 
order to obtain pure FLC, an initial assessment of the protein content was made by 
separating 5-20 µl of protein A affinity unbound fractions and pre-protein A treated 
samples, on 4-12% SDS-PAGE (Figure 5.1). The results showed a broad range of 
proteins in solution, of differing MWs, representing contaminants, which would need to 
be removed. Bands representing IgM, IgA and IgG were observed. A band just above 
the 66 kDa standard indicated significant albumin levels. A large, broad band, likely to 
represent multiple overlapping bands was seen between the 55 kDa and 42 kDa 
standards. Multiple overlapping bands were also seen at the level of the 42 kDa 
standard, in the region where dimeric FLCs would be expected, indicating that there  
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Table 5.1. Batches of resuspended sera received after filtration and passage through protein A column. 
Batch Volume  Total Soluble Protein FLC 
(Freelite) 
FLC Final 
Yield  
(Freelite) 
FLC Final 
Yield  
(BCA) 
 (ml) Conc 
(mg/ml) 
Total (mg) Conc (mg/ml) Total (mg)  (mg) 
            
1 1350 27.6 37260 0.244 0.393 33 53 - - 7 23.7 
2 1330 - - 0.266 0.359 353.3 477 92.5 117.7 50.5 82.2 
3 1726 - - 0.479 0.134 827.2 231.9 16.5 72.2 2.1 28.4 
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were multiple other protein contaminants of similar MW. Two discreet bands were seen 
just below the level of the 27 kDa standard, where monomeric FLC would be expected. 
Bands were noted to be weaker in samples after passage through the protein A column. 
However, this could have been a result of dilution in buffer after repeated passages 
through the column; TSP was not measured in the sample prior to protein A. The 
presence of contaminants of similar size to FLC meant that a combination of affinity 
and size-exclusion techniques would be necessary to purify FLC.  
 
Figure 5.1. Electrophoretic (SDS-PAGE) analysis of the FLC extract after 
passage through the protein A column. 
There are a broad range of contaminant proteins in solution of differing MWs, 
including immunoglobulins and albumin. FLCs are present, among other proteins, at 
the level of the 42 kDa and 27 kDa standards. Coomassie Brilliant Blue. Lanes L-R, 
and volume loaded: 1: standard; 2: post protein-A, 20µL; 3: post protein-A, 10µL; 4: 
post protein-A, 5µL; 5: blank; 6: pre protein-A, 20µL; 7: pre protein-A, 10µL; 8: pre 
protein-A, 5µL.  
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5.4 Extraction of Proteins Containing Light Chains from Starting Sample   
Proteins containing light chains (Immunoglobulins as well as FLCs) were extracted 
from the starting sample using affinity chromatography, with antibodies which 
recognise both free and bound light chains () immobilised on a Sepharose bead matrix, 
packed into columns. Matrix for both columns had been previously coupled to antibody 
at . Figure 5.2 summarises the polyclonal FLC purification process.  
 
5.4.1 Anti- Light Chain Matrix – Assessment of Suitability     
In order to assess the suitability of the anti- light chain matrix, a small volume of 
matrix (10 ml) was assessed initially. 200 ml of start sample was run through the 
column. Fractions were collected during the loading phase and elution phase. The 
chromatogram summarising this process is shown in figure 5.3. These fractions were 
then assessed for presence of light chain by dot blot (figure 5.4) and SDS-PAGE (figure 
5.5).  The chromatogram showed an increase in UV absorbance after around 90 ml, due 
to an abrupt rise in protein concentration, indicating that the capacity of the column had 
been exceeded at that point. The dot blot showed no detectable light chain in the 
unbound fractions 1-8. From fraction 9 onwards, there is a detectable signal, indicating 
the “breakthrough” of light chain containing proteins. This coincides with the rise in 
UV absorbance seen on the chromatogram. The Elution fractions show strong signals. 
Coomassie brilliant blue staining after SDS-PAGE shows that this affinity step has 
successfully removed a large quantity of contaminants, particularly the non-
immunoglobulin derived proteins. However there are still significant quantities of 
higher MW contaminants. Upon reduction, these resolve to bands corresponding to the  
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 Figure 5.2. Polyclonal FLC purification protocol. 
 
 
  
 135 
 
 
MWs of light chain and heavy chain, indicating that these contaminants are 
immunoglobulin. A faint band is also seen in the reduced samples just above the 66 kDa 
standard, which may represent incomplete separation of light chain and heavy chain.  
 
This experiment showed that the anti- matrix has adequate capacity to separate  light 
chain containing proteins from the starting sample. The eluate from the column 
consisted mostly of immunoglobulin and free light chain. 10 ml of matrix would 
remove all the  light chain containing proteins from around 80-90 mls of starting 
Figure 5.3. Chromatogram of assessment of suitability of anti- light chain 
matrix. 
Two hundred millilitres of start sample was run through the column. An increase in 
UV absorbance after 90 ml (arrowed) indicates a rise in protein concentration, 
indicating the limit of the column’s capacity. Red line, conductivity; blue line, UV 
absorbance; green line, % elution buffer. U, unbound; E, elution.   
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sample. A decision was therefore made to manufacture additional anti- matrix and 
increase the column size to 100 ml.  
 
 
5.4.2 Anti- Light Chain Matrix – Assessment of Suitability   
An initial assessment of the anti- light chain matrix was carried out with 65 ml of 
matrix. Five hundred mls of starting sample was run through the column, and fractions 
collected during the loading and elution phases. The chromatogram for this process is 
shown in figure 5.6. This chromatogram shows a rise in UV absorbance at around 200 
ml, indicating when the capacity of the column had been exceeded. Dot-blotting was 
performed on unbound and elution samples (figure 5.7). This shows breakthrough of 
light chain containing proteins at fraction 6, at around 210 ml, coinciding with the rise 
in UV absorbance seen on the chromatogram. Strong signals are seen in the elution 
Figure 5.4. Dot blot demonstrating anti- light chain matrix capacity. 
Numbers represent fractions. The blot has been probed with anti- light chain 
antibody. No detectable  light chains are present in unbound fractions 1 – 8. From 
fraction 9 onwards, there is detectable signal, showing “breakthrough” of  light 
chain containing proteins, indicating the capacity of the column had been exceeded. 
This coincides with the rise in UV absorbance seen in the chromatogram (Figure 
5.3).  
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fractions. Coomassie brilliant blue staining after SDS-PAGE (figure 5.8) showed the 
presence of higher MW contaminants likely to represent IgG. A double-band at the 
level of the 42 kDa standard representing dimeric  FLC was seen, while no band was 
seen at the level of the 27 kDa standard. Upon reduction, these bands resolve to just 
above 55 kDa and around 27 kDa, corresponding to the MWs of heavy chain and 
monomeric FLC. An additional unidentified faint band was seen in the reduced lane 
between the 66 and 97 kDa standards.  
 
Figure 5.5. SDS-PAGE analysis of pooled elutions from the anti- column. 
A large proportion of contaminants have been removed, compared with starting 
sample (lanes 2 and 5). Many of the bands representing non-immunoglobulin 
derived proteins are no longer present in the elutions. Significant quantities of higher 
MW contaminants persist. These resolve upon reduction to molecular weights which 
correspond to heavy chain and light chain, indicating the contaminants are 
immunoglobulins. Lanes L-R and volumes loaded: 1, standard; 2, starting sample 
(non-reduced); 3 elution (non-reduced) 20 µl; 4, elution (non-reduced) 10 µl; 5 
starting sample (reduced); 6, elution (reduced) 20 µl; 7, elution (reduced) 10 µl.  
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This experiment showed that the anti- light chain matrix has adequate capacity to 
separate light chain containing proteins from the starting sample. The eluate consisted 
mostly of intact immunoglobulin and free light chain. 65 ml of matrix will remove all of 
the light-chain containing proteins from around 200 ml of starting sample. The 
remaining matrix was incorporated into the column, increasing the column size to 80 
ml.  
 
 
Figure 5.6. Chromatogram of assessment of suitability of anti- light chain 
matrix. 
Five hundred millilitres of starting sample was run through the column. There is a 
rise in UV absorbance at 200 ml (arrowed), indicating the limit of the column’s 
capacity. Red line, conductivity; blue line, UV absorbance; green line, % elution 
buffer. U, unbound; E, elution. .  
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Figure 5.7. Dot blot demonstrating anti- light chain matrix capacity. 
Numbers represent fractions. The blot has been probed with anti- light chain 
antibody. No detectable  light chain containing proteins are seen in unbound 
fractions 1 – 5. From fraction 6 onwards, there is detectable signal, indicating 
“breakthrough” of  light chain containing proteins. This coincides with the rise in 
UV absorbance seen in the chromatogram (Figure 5.6).  
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5.4.3 Extraction of -Light Chain Containing Proteins From Starting Sample   
Following the initial assessment of the capacity of the matrix, the entire starting sample 
was applied to the anti- column by loading in five 200 ml aliquots, and two 150 ml 
aliquots. This process is summarised in the chromatograms in figure 5.9. Elutions were 
collected in fractions, which were pooled, dialysed into PBS and concentrated down to a 
volume of 130 ml in spin columns (Vivaproducts). TSP concentration in the eluate was 
measured by BCA assay to be 0.73 mg/ml, giving a total of 94.9 mg of TSP.  
 
 
Figure 5.8. SDS-PAGE analysis of pooled elutions from the anti- column. 
There are persistent higher molecular weight contaminants, which resolve to bands 
corresponding to the MWs of heavy chain and light chain upon reduction, indicating 
that these represent IgG. Lanes L-R and volumes loaded: 1, standard; 2, elution 
(non-reduced); 3 blank; 4, elution (reduced)  
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Figure 5.9. Chromatograms showing extraction of -light chain containing 
proteins from the starting sample. 
Starting sample was loaded onto the anti- column in five 200 ml aliquots (A) and 
two 150 ml aliquots (B). Each loading step was followed by an elution, to regenerate 
the column before the next loading step. Elutions were collected in fractions, which 
were pooled. Red line, conductivity; blue line, UV absorbance; green line, % elution 
buffer. U, unbound; E, elution. 
 
A 
 
B 
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Western blotting was then performed on the elution pool, probing for light chain as well 
as intact immunoglobulin (figure 5.10). The anti- and anti- light chain blots showed a  
signal at the bases of the wells in the stacking region and these corresponded to the 
presence of IgM.  and  signals above the 225 kDa standard corresponded to the 
presence of IgA. A  and a  signal just above the 150 kDa standard corresponded to 
the presence of IgG as well as IgA, possibly in the form of fragments or monomer. A  
signal was seen at the level of the 102 kDa standard, which was not seen in the whole 
immunoglobulin blots, indicating that this might be oligomeric FLC. Signals were seen 
in both the  and the  blots between the 38 and 52 kDa standards, representing dimeric 
FLC. A faint  signal was seen at the level of the 24 kDa standard, representing 
monomeric FLC. Very little signal was seen at this level in the  FLC blot.  
 
5.4.4 Anti- Light Chain Matrix Manufacture   
Additional anti- matrix for affinity extraction of  light chain containing proteins was 
manufactured by coupling 500 mg of anti- light chain antibody (AU015; The Binding 
Site) to 100 ml of CNBr activated Sepharose beads. The antibody was supplied at 4.5 
mg/ml. After dialysis into coupling buffer, A280 analysis measurement showed the 
protein concentration to be 4.6 mg/ml, meaning that antibody concentration was 
maintained during dialysis. Following coupling, BCA assay showed that only 3 mg of 
protein had not bound to the matrix. This represented 0.6% of the total protein, meaning 
that 99.4% of antibody had bound to the beads. The matrix was washed in PBS and 
packed into a column for use.  
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5.4.5 Anti- Light Chain Column – Assessment of Capacity   
The capacity of the new anti- column was tested by loading 500 ml of the unbound 
fraction from the anti- column. Fractions of unbound and elutions were collected 
during the loading and elution phases, respectively, as shown in the chromatogram in 
figure 5.11. These fractions were assessed for the presence of  light chain by dot 
Figure 5.10. Western blots of anti- elution pool. 
Western blotting, probing for  and  light chains in lanes 1 and 3 show high MW 
signals at the base of the wells, corresponding to the presence of IgM. There are also 
high MW  and  signals, corresponding to the presence of IgA and IgG. A signal in 
the  FLC blot (lane 1) at the level of 102 kDa is present, which is not seen in the 
whole immunogloblulin blots (lanes 5, 7 and 9) indicating the possible presence of 
oligomeric FLCs. A signal in both the  and  blots (lanes 1 and 3) between the 38 – 
52 kDa represents dimeric FLC. Lanes L-R (2 µg per lane): 1, anti- light chain; 2, 
standard; 3, anti- light chain; 4, standard; 5, anti-IgM; 6, standard; 7, anti-IgA; 8, 
standard; 9, anti IgG. Arrow shows the protein of interest, lambda FLC (nearly all 
dimer here) 
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blotting (figure 5.12). This showed that no  light chain was detectable in any of the 
unbound fractions up to 500 ml, indicating that the capacity of the column had not been 
exceeded. The elutions were pooled and stored for further downstream processing.  
 
 
 
 
Figure 5.11. Chromatogram of assessment of suitability of manufactured anti- 
matrix. 
Five hundred millilitres of the unbound fraction from the anti- column was passed 
through the new anti- column. The UV absorbance during the running phase 
remained unchanged, indicating that the capacity of the column was not exceeded. 
Both unbound and elution phases were collected in fractions. Red line, conductivity, 
blue line, UV absorbance, green line, % elution buffer. U, unbound; E, elution.   
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5.4.6 Extraction of -Light Chain Containing Proteins From the Anti- 
Unbound Fraction   
After the starting sample had been processed through the anti- column, the entire 
unbound fraction was then applied to the new anti- column by loading in three 450 ml 
aliquots and one 530 ml aliquot. Chromatograms for this process are shown in figure 
5.13. Elution fractions were pooled, dialysed into PBS, and concentrated in spin 
columns down to a volume of 130 ml. TSP  concentration in the eluate was measured 
by BCA assay and found to be 1.2 mg/ml, giving a total of 156 mg of TSP.   
 
Western blotting was performed on the elution pool, probing for light chain as well as 
intact immunoglobulin (figure 5.14). This Western blot shows the enrichment of  light 
Figure 5.12, Dot blot demonstrating capacity of the manufactured anti- light 
chain matrix. 
Numbers represent fractions. The blot has been probed with anti- light chain 
antibody. No  light chain containing proteins were detected in any of the elutions (1 
– 12), confirming that the capacity of the column was not exceeded. Strong signals 
were detected in the elution fractions.  
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chain containing proteins including FLC and intact immunoglobulins, while the 
amounts of  light chain containing proteins was significantly reduced. The anti- and 
anti-  blots showed multiple signals at the base of the wells in the stacking region, 
above the 225 kDa standard, and at the level of the 150 kDa marker. These 
corresponded to the presence of IgM, IgA and IgG respectively. In addition, an 
unidentified signal was detected at the level of the 102 kDa standard in the anti- blot, 
with a much weaker signal in the anti- blot. A signal between the 52 and 38 kDa 
standards represented dimeric  FLC. No monomer signal was detected. There was no 
detectable contamination with  FLC.  
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Figure 5.13. Chromatograms showing extraction of -light chain containing 
proteins from the anti- unbound fraction. 
The unbound portion from the anti- column was onto the anti- column in three 
450 ml aliquots (A) and one 530 ml aliquot (B). Each loading step was followed by 
an elution, to regenerate the column before the next loading step. Elutions were 
collected in fractions, which were pooled. Red line, conductivity; blue line, UV 
absorbance; green line, % elution buffer. U, unbound; E, elution. 
A 
B  
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5.5 Removal of Intact Immunoglobulin and Higher Molecular Weight 
Contaminants   
5.5.1 Protein G   
Protein G was used to remove IgG from the samples. Five ml of protein G immobilised 
on Sepharose beads (Calbiochem, Merck, Darmstadt, Germany) was packed into a 
column. This volume of matrix was known to have a capacity to bind around 50 mg of 
Figure 5.14. Western blot showing enrichment of -light chain containing 
proteins in the anti-total  elutions. 
Western blot of elutions from anti-total kappa column, showing enrichment of -
light chain containing proteins, including FLC and intact immunoglobulin. There is 
a reduction in the quantity of  light chain containing proteins. Significant quantities 
of immunoglobulin contaminants persist. Arrow shows the protein of interest, -
FLC, nearly all dimer here. Lanes L-R: 1, anti-IgG; 2, standard; 3, anti-IgA; 4, 
standard; 5, anti-IgM; 6, standard; 7, anti- LC; 8, standard; 9, anti- light chain; 10, 
standard.  
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IgG. Quantification of IgG by nephelometric assay performed at The Binding Site 
showed that the elution fractions from the anti- and anti- columns contained 21.87 
mg and 10.73 mg of IgG respectively. The anti- elution was applied to this column by 
loading in two 45 ml aliquots and one 40 ml aliquot, while the anti- elution was 
applied in two equal aliquots of 65 ml, as shown in figure 5.15. The unbound fraction 
volumes were 180 ml for the  sample and 230 ml for the  sample.  
 
Repeat analysis of the unbound fractions for immunoglobulin was performed at The 
Binding Site. The results are summarised in table 5.2, showing that the samples still 
contained significant quantities of immunoglobulin. A decision was made to proceed to 
removal of IgA and IgM by affinity chromatography. This step was to be followed up 
with size exclusion chromatography (SEC).  
 
5.5.2 Removal of IgA and IgM  
Two columns, one containing 10 ml of anti-IgA matrix, and the other containing 20 ml 
of anti-IgM matrix (both previously manufactured at The Binding Site), were connected 
in series. These columns were known to have capacities for binding of around 10 mg of 
IgA and 20 mg of IgM respectively. The  FLC containing sample was applied to these 
columns by loading in three 60 ml aliquots (figure 5.16), while the  FLC containing 
sample was applied to the columns by loading in two 115 ml aliquots as shown in the 
chromatograms in figure 5.17.  
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Protein concentration in the unbound fractions (, 233 ml; , 270 ml) was measured by 
BCA assay to be 0.11 mg/ml and 0.09 mg/ml, giving TSP values of 25.63 mg and 24.30 
mg respectively. Samples were concentrated down to 7.5 ml, to maintain protein 
stability and in preparation for size-exclusion chromatography (SEC).  
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Figure 5.15. Chromatograms showing anti- and anti- elutions applied to 
protein G column. 
Protein G was used to remove IgG from the elutions from the anti- and anti- 
columns. The anti- elution was applied to the protein G column in two 45 ml 
aliquots and one 40 ml aliquot (A). The anti- elution was applied to the protein G 
column in two 65 ml aliquots (B). Each loading step was followed by an elution, to 
regenerate the column before the next loading step. Red line, conductivity; blue line, 
UV absorbance; green line, % elution buffer. U, unbound; E, elution.  
 
A 
 
B 
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Table 5.2. Nephelometric analysis of immunoglobulin content of fraction unbound 
to protein G. 
  Sample 
(180 ml) 
 Sample 
(230 ml) 
 Conc (mg/ml) Total (mg) Conc (mg/ml) Total (mg) 
IgG 0.012 2.16 <0.011 - 
IgA 0.13 23.4 0.065 14.95 
IgM <0.024 - 0.034 7.82 
 
 
Figure 5.16. Chromatogram showing the -FLC sample applied to anti-IgA and 
anti-IgM columns. 
The -FLC containing sample was applied to anti-IgA and anti-IgM columns in 
series, in three 60 ml aliquots. Each loading step was followed by an elution, to 
regenerate the columns. Red line, conductivity; blue line, UV absorbance; green 
line, % elution buffer. U, unbound; E, elution. 
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Figure 5.17. Chromatograms showing the -FLC sample applied to anti-IgA 
and anti-IgM columns. 
The -FLC containing sample was applied to anti-IgA and anti-IgM columns in 
series, in two 115 ml aliquots. Each loading step was followed by an elution, to 
regenerate the columns. Red line, conductivity; blue line, UV absorbance; green 
line, % elution buffer. U, unbound; E, elution. 
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5.5.3 Size Exclusion Chromatography   
Concentrated  and  samples were loaded separately onto a 300 ml Superdex S200 
SEC column and run overnight at 0.5 ml/min. Chromatograms for these processes are 
shown in figure 5.18. Fractions corresponding to the peaks on the chromatograms were 
collected for analysis. In the  sample, peaks B and C, and E and F were pooled as they 
were overlapping significantly. In the  sample, peaks B and C were pooled. To 
ascertain which peaks contained FLC, aliquots were sent to The Binding Site 
quantification using the Freelite assay (table 5.3).  
 
TSP was measured separately by BCA assay, which showed the protein concentrations 
to be 0.32 mg/ml in the  sample and 0.85 mg/ml in the  sample. The  sample was 
concentrated to a volume of 25 ml, while the  sample was concentrated to 36 ml in 
order to preserve protein stability.  
 
5.6 Assessment of Polyclonal FLC Purity   
Purity of polyclonal FLC was measured at this point by SDS-PAGE and Western 
blotting. Coomassie blue staining (figure 5.19A) revealed a strong band in the  FLC 
lane, corresponding to dimer and a weaker monomer band. In addition, there was a 
broad, smudge-like band at the level of the 55 kDa standard. Higher MW bands were  
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Figure 5.18. Chromatograms showing removal of impurities from  and  FLC 
samples by size-exclusion chromatography. 
Removal of residual impurities from the -FLC sample (A) and the -FLC sample 
(B) by size-exclusion chromatography. Samples were loaded onto a 300 ml 
Superdex S200 SEC column and run overnight at 0.5 ml/min. Peaks are labelled 
alphabetically on the chormatograms. Fractions corresponding to these peaks were 
collected. Red line, conductivity; blue line, UV absorbance; green line, % elution 
buffer. U, unbound; E, elution.  
 
A 
 
B 
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seen at the level of the 158 kDa standard. Upon reduction, the bands resolve to two 
main bands, just below the 55 kDa standard and the 27 kDa standard, representing 
heavy chain and light chain, respectively. This indicated that the attempts to remove all 
the IgG from the  sample had been unsuccessful. The  FLC lane showed the presence 
of a strong dimer band and a weaker monomer band, which resolved upon reduction to 
a double band just below 27 kDa standard, indicating that the  sample is relatively 
pure.  
 
Table 5.3. Nephelometric analysis of FLC content of  and  samples after SEC. 
Peak Volume  
(ml) 
 FLC  FLC 
  Conc 
(mg/ml) 
Total 
(mg) 
Conc 
(mg/ml) 
Total 
(mg) 
 A 20 0.00012 0.0024   
 B+C 40 0.0021 0.08   
 D 28 0.00278 0.08   
 E+F 100 0.0777 7.77 0.00114 0.11 
 A 24   0.00263 0.06 
 B+C 36   0.0568 2.04 
 D 72 0.0078 0.56 0.202 14.54 
Performed using a commercial nephelometric assay (Freelite) using a Dade-Behring 
BNII analyser at The Binding Site. Peaks containing FLC of interest have been 
highlighted. 
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Silver staining was carried out for a more sensitive assessment of the bands seen on 
Coomassie staining (Figure 5.19B). This confirmed the presence of a significant band in 
the  FLC lane at the 158 kDa level, most likely to be IgG. Other, faint bands were also 
seen, including one just above the 66 kDa standard, which could be albumin. The 
presence of small quantities of transferrin could not be excluded. Upon reduction, these 
bands resolved to mainly heavy chain and light chain, with three other very faint bands. 
The  lane showed two very faint bands just above and below the dimer band. Upon 
reduction, there appeared a very faint band just below the 55 kDa standard, and another 
band at the 14 kDa level, which were unidentified. This indicated that the  FLC sample 
contained only very small quantities of unidentified contaminants.  
 
Western blotting was then performed (figure 5.19C). The  FLC sample showed that the 
bands seen on silver staining were immune reactive with anti- antibody, confirming 
that  FLC sample was highly pure. No further purification steps would be necessary 
for the  sample. Higher MW signals were seen in the  sample, confirming the 
presence of significant contamination, most likely due to the presence of IgG.  
 
Further Western blots were performed on the  sample, probing for the presence of two 
other possible contaminants: albumin and transferrin (figure 5.20). These blots 
identified both albumin and transferrin as contaminants of the  sample. These would 
need to be removed, in addition to the excess IgG present.  
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5.7  FLC – Removal of IgG, Human Serum Albumin and Transferrin   
An initial assessment was undertaken to determine whether it was feasible to remove 
IgG, albumin and transferrin from the  FLC sample. Small aliquots of sample were 
incubated in spin columns containing (i) Sepharose matrix with immobilised anti-
human albumin antibody, (ii) a mixture of immobilised anti-human albumin and anti-
human transferrin antibodies, or (iii) protein G immobilised of a glass matrix (Prosep G, 
Millipore). The unbound fractions were evaluated by silver staining (figure 5.21). This 
showed that both albumin and IgG could effectively be removed using these methods. 
There was some loss of intensity of the FLC bands after incubation with protein G, 
however it was decided to sacrifice some FLC in order to remove most of the IgG. The 
entire  sample was incubated first with anti-human albumin and transferring matrix, 
and the unbound then incubated with protein G for three hours at room temperature. As 
the incubations were performed in spin columns, which were loaded manually, no 
chromatograms were generated.  
 
The unbound fraction was re-assessed for purity by silver staining (figure 5.22A). This 
showed that the IgG band had been greatly attenuated. A very weak band at 14 kDa was 
noted, which intensified on reduction. This band was noted to be immune reactive to 
anti- light chain antibody on western blotting (figure 5.22B), showing that it 
represented FLC or FLC fragment.  
 
TSP was measured by BCA assay showed a total of 7 mg of  FLC and 23.7 mg of  
FLC.  
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Figure 5.19. SDS-PAGE analysis of the purity of  and  FLC samples. 
SDS-PAGE analysis of  and  FLC samples. Coomassie staining (A) and silver 
staining (B) revealed a strong band in the -FLC lane at 42 kDa, corresponding to 
dimer, and a weaker monomer band below 27 kDa. There is a broad band at 55 kDa 
in the  sample which resolves on reduction. There is also a higher MW band 158 
kDa, which resolves upon reduction indicating it is IgG. The -FLC lane showed the 
presence of a strong dimer band and a weaker monomer band, which resolved upon 
reduction to a double band just below 27 kDa. Other faint bands were also seen, 
including one above 66 kDa, which could be albumin. Lane L-R: 1, standard; 2, -
FLC (non-reduced); 3, -FLC (reduced); 4, -FLC (non-reduced); 5, -FLC 
(reduced). Western blotting (C) showed that in the  sample, bands seen on silver 
staining were immune reactive to anti- antibody, confirming that the -FLC sample 
was highly pure. The presence of IgG was also confirmed in the  sample, as well as 
a band above 97 kDa, which may represent oligomeric FLC.  
A     B     C 
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5.8 Detection and Removal of Endotoxin  
As the proteins were to be used in an experimental setting it was critical that the 
proteins would be free of bacterial endotoxin. Samples were filtered through 0.22 µm 
filters and testing for endotoxin was then performed using the E-TOXATE gel-clot 
assay. Both  and  samples tested positive. The samples were therefore treated by 
incubating with immobilised polymixin B (Detoxi-Gel). Repeat testing with E-
TOXATE showed that the samples had successfully been cleared of endotoxin to levels 
below the detection limit of the assay. 
 
 
Figure 5.20. Western blots showing the presence of albumin and transferrin 
contaminants in the -FLC sample. 
Western blotting for albumin (A) and transferrin in the -FLC sample shows the 
presence of contamination by these proteins (arrowed). HSA, human serum albumin; 
TF, transferrin. Lanes L-R: 1, standard; 2, HSA positive control; 3, -FLC, anti-
HSA probe; 4, standard; 5, transferrin positive control; 6, -FLC, a-TF probe. 
A   B 
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5.9 Assessment of Solubility After Lyophilisation   
Three aliquots of  FLC (0.4 mg) were dialysed into water and sent to The Binding Site 
for lyophilisation. Each lyophilised sample was dissolved in 1 ml of PBS, and TSP 
measured by BCA (table 5.4). Recovery rate was between 100% and 85%. The samples 
were also analysed by SDS-PAGE with Coomassie staining (figure 5.23), which 
showed that the proteins appeared identical before and after lyophilisation. The 
remainder of the samples were then dialysed extensively (48 h) into water, and sent to 
The Binding Site for lyophilisation.  
Figure 5.21. SDS_PAGE analysis of unbound fractions after incubation with 
anti-HSA, anti-HSA+anti-TF and protein G. 
Silver staining showed that albumin and transferrin could be effectively removed by 
incubating the sample with anti-HSA (lane 4) and anti HSA+anti-TF matrices (lane 
5). IgG could be removed by incubation with protein G matrix, although this method 
leads to loss of some protein (lane 6). Lanes L-R: 1, standard; 2, -FLC (non-
reduced); 3, -FLC (reduced); 4, post anti-HSA (non-reduced); 5, post anti-
HSA+anti-TF (non-reduced); 6, post protein G (non-reduced).  
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Table 5.4. FLC  recovery after lyophilisation. 
Sample TSP Before 
Lyophilising (mg) 
TSP After 
Lyophilising (mg) 
% Recovery 
A 0.4 0.4 100 
B 0.4 0.34 85 
C 0.4 0.39 98 
Figure 5.22. SDS-PAGE analysis of -FLC sample, after incubation with anti-
HSA+anti-TF and protein G. 
Silver stain (A) sowing that the IgG band in the -FLC sample has been greatly 
attenuated, indicating effective removal. Lanes L-R: 1, standard; 2, -FLC (non-
reduced); 3, -FLC (reduced). Western blot (B) confirms effective removal of IgG, 
with only a very weak band appearing after prolonged development of the blot 
(arrowed “IgG”). The weak band at 17 kDa is immune reactive to anti- FLC 
antibody, indicating it is FLC or FLC fragment. Lanes L-R: 1, standard; 2, FLC.  
A     B 
    
 
IgG 
FLC 
fragment 
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5.10 Discussion  
The polyclonal FLCs obtained as a result of the above processes were shown to be 
highly pure. The FLCs were shown to exist as monomers and dimers mainly, but higher 
oligomeric forms were also seen. The ability of FLCs to aggregate into higher MW 
forms has previously been described with myeloma FLCs.(Sanders et al. 1987)  
 
Figure 5.23. SDS-PAGE analysis of  FLC recovery after lyophilisation. 
Comparison of -FLC pre and post lyophilisation, showing that proteins appear 
identical before and after lyophilisation on SDS-PAGE analysis. Coomassie brilliant 
blue, lanes L-R: 1, standard; 2, pre-lyophilisation (non-reduced); 3, post-
lyophilisation, sample A (non-reduced); 4, post-lyophylisation, sample B (non-
reduced); 5, post-lyophilisation, sample C (non-reduced); 6, pre-lyophilisation 
(reduced); 7, post-lyophilisation, sample A (reduced); 8, post-lyophilisation, sample 
B (reduced); 9, post-lyophilisation, sample C (reduced).   
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An initial assessment of the starting sample revealed that it contained a very large 
number of different proteins. The FLC content of the starting sample represented only a 
very small proportion of the TSP. In batch 1, for example, FLC constituted just 0.23 % 
of TSP. The starting sample contained significant quantities of immunoglobulin, as well 
as albumin. These were the main contaminants that needed to be removed. The 
efficiency of affinity chromatography declines as the concentration of the protein of 
interest relative to the concentration of other proteins in the solution is reduced. (Scopes 
1994) The initial approach of choice was to apply affinity chromatography to the 
starting sample, thus extracting those proteins that contained light chain – FLC and 
immunoglobulin. Dot-blotting confirmed that the anti- and anti- columns extracted 
all detectable light chain containing proteins. From here, immunoglobulin could be 
removed by further affinity chromatography.  
 
The polyclonal  FLC sample was much more readily purified than the  sample. All 
the bands seen on SDS-PAGE in the non-reduced lanes were immune reactive to anti-
light chain antibody, indicating that these were FLC. On the silver stained gel, on 
reduction, two faint bands appeared in the  sample, one between the 42 and 55 kDa 
standards, and one at 14 kDa. These were not seen on Coomassie staining, however, and 
remained unidentified.  
 
The polyclonal  sample had persistent IgG and albumin impurities, despite multiple 
further attempts to remove them. The major disadvantage of repeated chromatography 
processes is the loss of protein at each step.(Scopes 1994) The requirement to process 
the  sample in this way was reflected in the very poor recovery rates. The incubation of 
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the  sample with protein G resulted in additional protein loss, suggesting protein G 
binding of  FLC, as demonstrated by the weakening of the band seen on silver stained 
SDS-PAGE. In the final analysis of the  sample, there was still a faint band seen on 
silver staining and Western blotting which represents IgG contamination. Similar to the 
 sample, a faint band was seen in the  sample at around 14 kDa. This is shown to be 
FLC on the corresponding Western blot.  
 
As the degree of contamination was small, a decision was made not to pursue any 
further removal of contaminants from the FLC samples in the interests of preserving 
protein.  
 
There was some disagreement between FLC readings measured using the Freelite assay 
and the TSP measured in the final purified samples by BCA assay. Despite the final 
products being near-pure FLC, in solution at around 1 mg/ml, the Freelite readings were 
consistently higher than TSP measured by BCA. However, in early steps, Freelite was 
used to provide an indication of how much FLC was present in the start samples. In the 
final stages, BCA assay was used to determine volumes to which samples needed to be 
concentrated. In the downstream application of polyclonal FLC in vitro, protein 
concentration was ascertained by weighing lyophilised protein and adding to cell culture 
medium to make a stock, this being more robust than the above measurements.  
 
In conclusion, the proteins obtained from the processes described in this chapter were 
were highly purified FLCs. The endotoxin-free lyophilised final product was suitable 
for application in vitro, as described in the next chapter.  
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6. TISSUE DISTRIBUTION OF POLYCLONAL FREE LIGHT 
CHAINS IN CHRONIC KIDNEY DISEASE: IN SITU STUDIES  
6.1 Introduction  
Results from the investigations presented in the preceding chapters have shown that in 
the setting of myeloma, monoclonal FLCs are responsible for the development of 
tubulointerstitial inflammation and fibrosis. These effects are mediated by the release of 
inflammatory cytokines, especially MCP-1, from PTECs in response to endocytosis of 
FLCs, via mechanisms which are unique to FLCs. In addition, there is a contributory 
effect from cast formation with uromodulin in the distal nephron, resulting in tubular 
obstruction, stasis and leakage of tubular contents into the interstitium. Tubular casts are 
a common finding in acute kidney injury (AKI) that has not been caused by cast 
nephropathy. (Patel et al. 1964; Abuelo 2007) The presence of tubular casts is also 
recognised in chronic kidney disease (CKD), a phenomenon sometimes referred to as 
“thyroidisation”, and has been considered non-specific (figure 6.1).(Walker 2003) 
Because the clearance of FLCs from serum is dependent on GFR, elevated polyclonal 
FLC levels are observed in the setting of CKD, even in the absence of plasma cell 
dyscrasia.(Hutchison et al. 2008c) This raises the question of whether polyclonal FLCs 
exert a direct biological effect at tissue sites. However there is little data on the 
pathogenicity of polyclonal FLCs in CKD. This may be an important deficit in the 
literature: in CKD, as the functioning nephron mass declines, the remaining 
hyperfiltering nephrons will be exposed to higher concentrations of FLCs and other low 
molecular weight proteins over prolonged periods. Furthermore nephrons may  
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experience reduced tubular fluid flow and dysregulation of concentrating and 
acidification processes, thus favouring cast formation. 
 
The distribution of FLCs within renal tissues in the setting of CKD may provide an 
indication of the targets for potential injury. This chapter presents data from a detailed 
investigation into the distribution of FLCs in the kidney, in the setting of CKD, 
followed by a study of in situ distribution of casts in CKD, and their relationship to 
known markers of progression for CKD.   
 
 
Figure 6.1. A proteinaceous cast in a renal biopsy from a patient with CKD. 
Intratubular proteinaceous precipitates in a renal biopsy specimen (arrowed), taken 
from a patient with chronic kidney disease. PAMS, original magnification x 400.  
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6.2 Patients  
Following approval from the local Ethics Committee, all patients who had undergone a 
renal biopsy at University Hospital Birmingham between 2005 and 2008 were screened. 
Patients with a histological diagnosis of “ischaemic/hypertensive nephropathy” were 
chosen for this study, the aim of which was to investigate the relationship between 
tubulointerstitial fibrosis in CKD and increased serum polyclonal FLCs as a result of 
decreased GFR.  
 
The disease group of ischaemic/hypertensive nephropathy was chosen and other 
diagnostic groups were excluded, to control for other mechanisms that may contribute 
to progressive CKD, such as diabetes, and selective proteinuria in the 
 Figure 6.2. Uromodulin is produced in the distal nephron and is present in 
casts. 
Uromodulin is expressed on apical surfaces of cells of the distal tubules (A) and seen 
in proteinaceous precipitates (B). Confocal laser scanning microscope, original 
magnification x 400.  
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glomerulonephritides. Furthermore I excluded conditions such as systemic lupus 
erythematosus and vasculitides, where serum FLCs might be elevated as a result of 
increased B-cell activity, independent of GFR. After exclusion criteria were applied, 
tissue was available for study from 102 patients.  
 
6.3 Results  
6.3.1 Immunofluorescence   
An immunofluorescence study was initially undertaken on renal biopsies from 20 
patients, to assess the overall pattern of polyclonal FLC distribution at tissue sites. 
Tissue sections were probed with fluorochrome-labelled polyclonal antibodies against  
and  FLC. Images were acquired using a confocal laser scanning microscope. 
Uromodulin, which is transcribed exclusively by the cells of the thick ascending limb of 
the loop of Henle, expressed apically and subsequently present in tubular filtrate distal 
to this point, was used both as a marker for casts, as well as to help differentiate 
between proximal and distal tubules (figure 6.2).  
 
No staining was seen in control sections for isotype antibody, immunoglobulin controls, 
and intra-species cross-reactivity controls. Thus, no non-specific binding of sheep IgG 
to human kidney tissue, to other sheep IgG, and to human immunoglobulins was 
demonstrable, and any staining seen truly represented polyclonal FLC.  
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6.3.2 Polyclonal FLCs are Present in PTECs   
Positive staining for both  and  FLCs were seen co-localising within the cytoplasm of 
cells of many tubules (figure 6.3). These tubular cells did not stain positively for 
uromodulin, thus identifying them as PTECs. Strong staining was demonstrated near the 
apical surfaces of these cells, indicating where FLCs were concentrated by binding to 
the cell-surface receptors megalin and cubilin, prior to endocytosis. Staining near the 
basal surfaces of these cells was weaker, which may be explained by proteolytic 
breakdown of FLCs after endocytosis within lysosomes, which would result in 
diminished reactivity to the antibodies.  
 
Tubules where cells stained positively for uromodulin were taken to represent the thick 
ascending limb of the Loop of Henle and distal tubule. Both  and  FLC staining was 
seen to co-localise with uromodulin in these tubules, but the distribution was noted to 
be almost exclusively apical (figure 6.4). This supports the conclusion that polyclonal 
FLCs interact with and bind to uromodulin in the distal nephron, but endocytosis and 
subsequent proteolytic digestion does not take place.  
 
6.3.3 Polyclonal FLC Co-localise with Uromodulin in Distal Tubules 
As described above, the presence of uromodulin was used as a marker to identify 
tubules of the distal nephron. Uromodulin staining was also used to identify the 
presence of casts. Both  and  polyclonal FLC staining was seen co-localising with 
uromodulin in distal tubules, supporting the hypothesis that polyclonal FLC do indeed 
interact with and bind to uromodulin in CKD (figure 6.5). Where casts were identified, 
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Figure 6.3. Free light chains in the proximal tubule in CKD. 
Positive staining for , in green, (A) and , in blue, (D) FLCs was seen co-localising within epithelial cell cytoplasms. The absence of 
uromodulin (B) confirms that this is a proximal tubule. C, nuclei; E, combined image. Confocal laser scanning microscope, original 
magnification x 400.  
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Figure 6.4. Confocal image of proximal and distal tubules showing distribution of -FLC, -FLC and uromodulin. 
In proximal tubules, , in green, (A) and , in blue, (D) FLCs were seen colocalising in proximal tubule epithelial cell cytoplasms. The 
absence of co-localising uromodulin staining confirms that these were proximal tubule cells. Distal tubules are indicated by uromodulin 
staining, in red (B). C, nuclei; E, combined image. Confocal laser scanning microscope, original magnification x 200.  
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Figure 6.5. Confocal image of casts in a renal biopsy from a patient with CKD. 
Intratubular casts in a biopsy from a patient with chronic kidney disease. Both , in green, (A) and , in blue, (D) FLCs are seen co-localising with 
uromodulin, in red (B). C, nuclei; D,   FLC; E, combined image. Confocal laser scanning microscope, original magnification x 100.  
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Figure 6.6. High-power confocal image of a cast in a renal biopsy from a patient with CKD. 
High-power image of a cast in CKD, showing that staining for -FLC, in green, -FLC, in blue, and uromodulin, in red appears stronger in 
the periphery, compared to the central area. A,  FLC; B, uromodulin; C, nuclei; D,  FLC; E, combined image. Confocal laser scanning 
microscope, original magnification x 400.  
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the intensity of staining was usually more intense peripherally than centrally (figure 
6.6). These appearances might suggest that FLCs are not present in these casts in the 
same relative quantities that they are in myeloma cast nephropathy.   
 
6.4 Measurement of Cast Numbers, Index of Chronic Damage, Interstitial 
Capillary Density and Macrophage Numbers 
Following the finding of polyclonal  and  FLCs within renal tubular casts, a formal 
quantification of cast numbers, as well as other markers of progression of CKD, was 
undertaken for the 102 patients in the cohort. For the purpose of quantifying the index 
of chronic damage, sections routinely stained with PAMS were retrieved from the 
pathology archive at University Hospital Birmingham. The method is summarised in 
figure 6.7. Cast numbers were quantified using the same sections, and the process is 
summarised in figure 6.8. For capillary density and macrophage numbers, separate 
sections were stained for CD34 and CD68. Data was collected using Aequitas image 
analysis software, as described in the Chapter 2. The methods are summarised in figures 
6.9 and 6.10 respectively.  
 
6.4.1 Test of Normality of Data   
The data failed to pass normality testing for skewness, as determined by applying the 
D'Agostino and Pearson omnibus normality test. The data variables were therefore 
normalised by log transformation. In the case of cast numbers, because some values 
were equal to 0, 1 was added to each data value in the set, prior to log transformation.  
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 Figure 6.7. Quantification of the index of chronic damage. 
The cortex is outlined and selected using Aequitas image analysis software (A). 
Areas of chronic damage are then encircled by freehand drawing (B). This image is 
then exported as a screen-grab for cast counting using ImageJ software. In Aequitas, 
areas of chronic damage are quantified and expressed as a percentage of the total 
cortical area (C). Original magnification x 100.  
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Figure 6.8. Quantification of cast numbers. 
After marking out areas of chronic damage using the Aequitas software, the image is 
exported to ImageJ software. Using the cell counting function in ImageJ, casts were 
counted in areas with and without chronic damage. Original magnification x 100.  
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Figure 6.9. Quantification of interstitial capillary density. 
The image has been converted to a two-colour scale image using Aequitas software. 
A threshold was then applied so that the areas of staining were detected (A). Using 
Aequitas software, areas of staining were then quantified and expressed as a 
percentage of total area (B). Note that the glomerulus has been ignored in the 
measurement. Original magnification x 200.  
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Figure 6.10. Quantification of macrophage numbers. 
The image has been converted to a two-colour scale image using Aequitas software. 
A threshold was then applied so that the areas of staining were detected (A). Using 
Aequitas software, area of staining were then quantified and expressed as a 
percentage of total area (B). Original magnification x 200.  
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6.4.2 Assessment of Validity of Quantification Methods  
To assess the validity of the methods used in quantifying the data, variability between 
intra-observer results and inter-observer results were determined. All the specimens 
were measured by myself first. For inter-observer variation, 20 specimens were 
measured again by a second observer independently. This observer was a research 
associate who had assisted in developing the method. For the purpose of testing intra-
observer variability, the same 20 specimens were measured again, after an interval, by 
myself.  
 
Agreement between the different measurements was assessed using the method 
described by Bland and Altman.(Bland and Altman 1986) Because the difference in 
measurements was proportional to the mean, log transformation was carried out prior to 
testing, as described above. The Bland-Altman method calculates the bias (the mean 
difference between measurements) and limits of agreement (2 SDs two-tailed) with 95% 
CIs for the bias, which are expressed as ratios when back-transformed. The results are 
shown in table 6.1. There was no significant bias detected between inter- and intra-
observer results obtained for cast numbers, capillary density, index of chronic damage 
or macrophage numbers.  
 
6.4.3 Casts in CKD are Situated in Areas of Established Chronic Damage   
By light microscopy, most of the casts were distributed within areas of established 
fibrosis. Cast numbers were counted within areas of chronic damage, and areas deemed 
to be normal. There was a significant difference between the median percentages of  
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Table 6.1. Assessment of agreement between two observers by the Bland-Altman method. 
 Index of Chronic Damage Capillary Density Macrophages % Casts 
 Obsv 1 vs 
Obsv 1 
Obsv 1 vs 
Obsv 2 
Obsv 1 vs 
Obsv 1 
Obsv 1 vs 
Obsv 2 
Obsv 1 vs 
Obsv 1 
Obsv 1 vs 
Obsv 2 
Obsv 1 vs 
Obsv 1 
Obsv 1 vs 
Obsv 2 
Bias  
(SD) 
1.023 
(1.083) 
1.014 
(1.116) 
1.040 
(1.097) 
0.994 
(1.078) 
0.983 
(1.090) 
0.980 
(1.070) 
0.992 
(1.074) 
 
0.992 
(1.059) 
95% CI of 
Bias 
0.986-1.061 0.963-1.067 0.996-1.086 0.960-1.030 0.945-1.024 0.950-1.012 0.960-1.026 0.965-1.019 
 
95% LoA 0.876-1.195 0.818-1.256 0.867-1.248 0.858-1.152 0.831-1.164 0.860-1.118 0.863-1.141 0.886-1.111 
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tubules containing casts in normal areas compared to the median in areas of established 
chronic damage (0 and 35, n=98, p <0.0001), as shown in figure 6.11.  
 
6.4.4 Capillary Density Correlates with the Index of Chronic Damage and 
Macrophage Numbers  
By univariate analysis, interstitial capillary density showed a negative correlation with 
the index of chronic damage (r = -0.539; p <0.0001; n = 98) and a negative correlation 
with interstitial macrophage numbers (r = -0.444; p <0.0001; n = 100). These data are 
summarised in table 6.2 and linear regression is shown in figure 6.12.  
 
Figure 6.11. Comparison of cast numbers between areas with or without 
chronic damage. 
Most of the casts counted were present in areas of established chronic damage. The 
median percentage of tubules containing casts in areas without chronic damage was 
0, while in areas of established chronic damage, the median percentage of tubules 
containing casts was 35. ***p = < 0.0001 
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Table 6.2. Univariate analyses of cast numbers, index of chronic damage, capillary 
density and macrophage numbers. 
 
 Cast No    
Cast No 
 
1.000 
(Correlation; p 
value) 
<0.0001; 
n = 98 
 
Index of 
Chronic 
Damage 
  
Index of 
Chronic 
Damage 
0.736; 
<0.0001 
98 
 
1.000; 
<0.0001 
98 
Capillary 
Density 
 
Capillary 
Density 
-0.471; 
<0.0001 
98 
 
-0.539; 
<0.0001 
98 
1.000; 
<0.0001 
102 
Macrophage 
Infiltration 
Macrophage 
Infiltration 
 
0.515; 
<0.0001 
96 
0.695; 
<0.0001 
96 
-0.444; 
<0.0001 
100 
1.000; 
<0.0001 
100 
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Figure 6.12. Correlations of capillary density with index of chronic damage and 
macrophage numbers. 
Linear regression analysis of capillary density with index of chronic damage (A) and 
macrophage numbers (B), indicated inverse relationships, which were confirmed by 
univariate analyses. Negative correlations of capillary density were were shown with 
chronic damage (r = -0.539; p <0.0001, n = 98) and macrophages (r = -0.444; p 
<0.0001; n = 100).  
 
 
 
  
 185 
6.4.5 Macrophage Numbers Correlate with Index of Chronic Damage 
Macrophage numbers, as quantified by image analysis, correlated positively with the 
index of chronic damage (r = 0.695; p <0.0001; n = 96). These data are summarised in 
table 6.2 and linear regression is shown in figure 6.13.  
 
 
6.4.6 Cast Numbers Correlate with Index of Chronic Damage, Capillary 
Density and Macrophage Numbers   
The percentage of tubules counted in each biopsy that contained casts showed a positive 
correlation with the index of chronic damage (r = 0.736; p <0.0001; n = 98), a negative 
correlation with interstitial capillary density (r = -0.471; p <0.0001; n = 98), and a 
positive correlation with infiltrating interstitial macrophage numbers (r = 0.515; p 
<0.0001; n = 96). These data are summarised in table 6.2 and linear regression is shown 
in figure 6.14.  
 
Figure 6.13. Correlation of macrophage numbers with index of chronic 
damage. 
Linear regression analysis of macrophages with chronic damage indicated a positive 
relationship, confirmed by univariate analysis, which showed a positive correlation 
(r = 0.695; p <0.0001, n = 96). 
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 Figure 6.14. Correlations of cast numbers with index of chronic damage, 
capillary density and macrophage numbers. 
Linear regression analyses of cast numbers with index of chronic damage (A), 
capillary density (B) and macrophage numbers (C). Univariate analyses showed a 
positive correlation with chronic damage (r = 0.736; p <0.0001; n = 98), a negative 
correlation with interstitial capillary density (r = -0.471; p <0.0001; n = 98) and a 
positive relationship with macrophage numbers (r = 0.515; p <0.0001; n = 96). 
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Table 6.3. Multivariate analysis of correlations between index of chronic damage, 
capillary density, macrophage numbers and cast numbers. 
 
 Dependent Variable 
  Index of 
Chronic 
Damage 
Capillary 
Density 
Macrophages % Casts 
Index of 
Chronic 
Damage 
 
Correlation;   
p value 
n.a. n.s. 0.741; 
< 0.0001 
0.703 
< 0.0001 
Capillary 
Density 
 
 n.s. n.a. n.s. n.s. 
Macrophages 
 
 
 0.522; 
< 0.0001 
n.s. n.a. n.s. 
% Casts  0.446; 
< 0.0001 
n.s. n.s. n.a. 
 
n.a., not applicable; n.s., not statistically significant  
 
 
6.4.7 Multivariate Analysis of Correlations  
Linear regression stepwise multivariate analysis of these correlations with a dependent 
variable was performed for correlations between cast numbers, interstitial capillary 
density, macrophages and the index of chronic damage (table 6.3) In this analysis, the 
index of chronic damage and macrophage numbers were independent predictors of each 
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other. The index of chronic damage and the percentage of tubules containing casts were 
also independent predictors of each other. However no other significant relationships 
were shown.  
 
6.5 Discussion 
In this chapter, results are presented outlining the in situ tissue distribution of polyclonal 
FLCs seen in chronic kidney disease. The presence of positive staining for FLCs in 
proximal tubules confirmed that in CKD, polyclonal FLCs that are filtered at the 
glomerulus are indeed processed by PTECs. The presence of these polyclonal FLCs in 
increased concentrations in the serum would translate to increased exposure of PTECs 
to these proteins. Because of the nature of recovery of filtered proteins from the tubular 
lumen by the multi-ligand, tandem endocytic receptors, megalin and cubilin, PTECs are 
a preferential target for injury by filtered proteins.(Birn and Christensen 2006) Although 
in this study, co-localisation with megalin and cubilin was not investigated, the 
increased intensity of staining at the apical surfaces of cells indicated that there may be 
concentration of polyclonal FLCs at these sites as a result of engagement with these 
receptors. Staining within the cytoplasm weakened towards the basal aspect of PTECs, 
possibly due to lysosomal degradation of endocytosed FLCs rendering them less 
immune reactive.  
 
Uromodulin was chosen as the marker not only because of its utility in differentiating 
proximal tubules from those of the distal nephron, but also because it is an important 
component of casts. The co-localisation of both  and  polyclonal FLC with 
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uromodulin in distal tubular casts confirms that in CKD, polyclonal FLCs do indeed 
interact with and bind to uromodulin. In myeloma cast nephropathy, the casts have a 
characteristic hard appearance, often fractured. Invasion of the tubule by macrophages 
and giant cells is seen. In the casts associated with CKD, the appearance is different. 
The intensity of immunofluorescence staining was stronger at the periphery, indicating 
that the cast might be denser at the periphery than the centre, and indeed may be patent 
centrally. These appearances may be the result of different mechanisms of formation. In 
myeloma, cast formation is often precipitated rapidly by high concentrations of FLC 
delivered to the tubule, in conjunction with other factors such as dehydration or drugs. 
In CKD the formation of casts is likely to be a slower process, which occurs as tubules 
are surrounded by fibrotic tissue, lose their capillary blood supply and become 
senescent, tubular fluid flow decreases, stasis occurs, with dysregulation of electrolyte 
control and acidification. Proximal tubular dysfunction may also play a role, with 
reduced reabsorption of filtered proteins having the effect of increasing FLCs delivered 
to the distal nephron, thus promoting cast formation.  
 
Along with quantification of cast numbers in the patient group described, other 
histological parameters associated with progression of CKD were studied. The index of 
chronic damage has been established as a rigorous predictor of renal outcome in 
CKD.(Howie et al. 2001) Eardley et al have shown that in addition, infiltrating 
macrophage numbers and interstitial capillary density are also predictors of renal 
outcomes, and that these parameters are inter-related.(Eardley et al. 2006; Eardley et al. 
2008) I hypothesised that, if polyclonal FLCs did indeed have a biological effect in the 
progression of CKD, histological features associated with polyclonal FLCs would be 
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correlated with the index of chronic damage, interstitial capillary density and infiltrating 
macrophage numbers. The identification of polyclonal FLCs within PTECs, although a 
good qualitative measure, is not a robust quantitative measure, due to variances in 
staining intensity, and the fact that all PTECs would be exposed to at least some FLC. 
Casts, however, were easily identifiable and could be easily counted. It was therefore 
chosen as the parameter of interest. In the studies reported by Eardley et al, 
quantification methods for capillary density and macrophage numbers were shown to be 
robust and reproducible, a feature seen in my own studies presented here.  
 
In order to validate results obtained from morphometric analyses of renal biopsy 
material, the results were analysed for intra-observer as well as inter-observer 
variability with an independent, blinded second observer. In order for the results to be 
valid, high levels of agreement needed to be demonstrated. One suitable method for 
testing inter-observer agreement is the Cohen’s kappa calculation.(Cohen 1960) 
However, in my studies, an additional aspect was the intra-observer variability. Kappa 
can qualitatively test whether there is inter-observer variability or not. However, as a 
quantitative tool, there are limitations to kappa, in that it is not a true chance-corrected 
measurement, and that its value can often be low, despite high levels of 
agreement.(Feinstein and Cicchetti 1990; Cicchetti and Feinstein 1990) The Bland-
Altman method, although primarily designed to measure agreement between different 
methods, is able to give the bias, or mean difference between measurements, and limits 
of agreement, or 2 standard deviations either side of the mean, with 95% CIs for the 
bias and limits of agreement. This methods has been successfully used to quantitatively 
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demonstrate high levels of both inter-observer and intra-observer variability by Eardley 
et al, and therefore was chosen for my own studies.(Eardley et al. 2006)  
 
Despite CD68 being a consistent macrophage marker, accurate histological 
characterisation of macrophages in the kidney is complex and the precise identity of 
cells staining positively for CD68 has been questioned. A recent study by Segerer et al 
has indicated that in certain forms of kidney disease, a proportion of interstitial CD68 
positive cells in renal biopsies from patients with a range of glomerulonephritides were 
in fact dendritic cells, rather than macrophages.(Segerer et al. 2008) In order to 
distinguish true macrophages, it would be necessary to demonstrate either the absence 
of dendritic cell markers or to show co-localisation with a macrophage marker, usually 
using immunofluorescence. In my studies, this approach was not taken. First, the study 
by Segerer et al focussed on a population of patients with glomerulonephritis; such 
patients were excluded from my study. Second, Eardley et al have shown that the 
correlations CD68 positive cell number with interstitial capillary density and index of 
chronic damage are robust.  
 
Although immunofluorescence has a distinct advantage over conventional 
immunohistochemistry where co-localising targets are concerned, it is difficult to gain 
an appreciation of overall morphology, limiting its utility when quantifying casts and 
chronic damage. Therefore both these quantifications were carried out using light 
microscopy. Additionally, the methods used for these two measurements were 
interlinked.  
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My investigations confirmed at an early stage, that casts were predominantly present in 
tubules in areas of chronic damage, suggesting that cast numbers would be correlated 
positively with the index of chronic damage and macrophage numbers, whilst being 
inversely correlated with capillary density. This was confirmed by the subsequent 
statistical analyses performed. In my studies, univariate analyses of the index of chronic 
damage, capillary density and macrophage numbers were in agreement with the 
findings of Eardley et al, confirming that these data would be suitable for correlation 
analyses with cast numbers. Univariate analyses also showed that cast numbers were 
associated with increased interstitial fibrosis, increased interstitial macrophage numbers, 
and decreased capillary density, indicating that cast formation may be favoured by an 
ischaemic microenvironment.  
 
In multivariate analyses, the index of chronic damage and macrophage numbers were 
shown to be independent predictors of each other. This was consistent with the previous 
findings of Eardley et al. The index of chronic damage and the percentage of tubules 
containing casts also had a similar relationship.  
 
The observation of polyclonal FLC at two specific tissue sites in the kidney in the 
setting of CKD – the PTEC and the distal nephron – raises the possibility of biological 
effects exerted by these polyclonal FLCs at these sites, contributing to ongoing 
interstitial inflammation and progression of fibrosis. Following these detailed in situ 
studies the next chapter will focus on using in vitro models to identify potential 
mechanisms of injury.  
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7. BIOLOGICAL EFFECTS OF POLYCLONAL FREE LIGHT 
CHAINS: IN VITRO STUDIES  
7.1 Introduction  
Results presented in the preceding chapter have demonstrated that in CKD, polyclonal 
FLCs can be seen co-localising with PTECs in situ. In addition, in the distal tubules, 
proteinaceous precipitates are seen which are composed of uromodulin, and contain 
polyclonal FLCs. In multiple myeloma, both the proximal tubule and distal tubule are 
well recognised sites of injury from FLCs, by PTEC activation and cast formation by 
co-precipitation with uromodulin respectively.(Sanders 2005) The mechanism of PTEC 
activation is initiated by the generation of H2O2 following receptor-mediated 
endocytosis, which then activates the redox-sensitive tyrosine kinase c-Src, which in 
turn is integrally involved in downstream signalling resulting in nuclear translocation of 
NF-B and transcription, leading to the release of inflammatory cytokines.(Wang and 
Sanders 2007; Basnayake et al. 2010) In the distal tubule, monoclonal FLCs co-
precipitate with uromodulin, forming casts, which obstruct tubules and are associated 
with invasion of the tubules by inflammatory cells, although a direct inflammatory 
effect of FLC on distal tubular epithelium has not been investigated to date. 
 
Although the presence of polyclonal FLCs at the same sites where monoclonal FLCs 
cause injury to the kidney has been demonstrated in CKD, a causative link between 
polyclonal FLCs and the inflammation seen in CKD has not been found to date. In this 
chapter, results from in vitro studies are presented, which test the hypothesis that 
polyclonal FLCs contribute to the inflammation seen in CKD: (i) contributing to 
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activation of PTECs and effecting inflammatory cytokine release from these cells, and 
(ii) by co-precipitation with uromodulin, thus leading to cast formation in tubules and 
further potentiating inflammation.  
 
7.2 PTEC Culture 
HK-2 cells (Ryan et al. 1994) were used for in vitro experiments investigating the 
effects of polyclonal FLCs on PTECs. Cells were grown on 6-well plates coated with 5 
µg/cm
2
 rat tail collagen. Where measurements of H2O2 and MCP-1 were taken, the total 
quantity present per well was calculated by multiplying by the volume of medium in 
each well, and expressed as “per day”.  
 
7.2.1 Effect of Polyclonal Free Light Chains on Inflammatory Signalling  
HK-2 cells were incubated with polyclonal FLCs at 1 mg/ml or 5 mg/ml, or equimolar 
concentrations of delipidated HSA, or medium alone, for 24 hours (n = 6 per group). 
Harvested supernatants were promptly assayed for H2O2 and MCP-1. The results did 
not show significant differences in the quantities of H2O2 produced (figure 7.1A). In 
addition, there were no significant differences in the quantities of MCP-1 released from 
these cells (figure 7.1B).  No increases in H2O2 or MCP-1 production were seen in wells 
incubated with HSA, even as high as 15 mg/ml. Positive controls were included using 
the same monoclonal FLCs used in experiments presented in Chapter 4, which are 
known to have pro-inflammatory effects on PTECs. These wells showed significantly 
raised concentrations of H2O2 and MCP-1, when compared to wells incubated with 
polyclonal FLCs or HSA. Given the poor response to HSA as well as polyclonal FLCs, 
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it may be possible that endocytosis of these proteins was not taking place. Endocytosis 
has previously been shown to be a key step in inflammatory signalling both in the 
results presented in Chapter 4 and in studies from the laboratory of 
Batuman.(Basnayake et al. 2010; Li et al. 2008a) However, endocytosis of HSA or 
polyclonal FLCs was not formally demonstrated in the studies presented here. Thus it 
cannot be conclusively proven in these experiments that polyclonal FLCs do not have 
pro-inflammatory effects on PTECs.  
 
7.2.2 Cytotoxic Effects of Polyclonal Free Light Chains on Proximal Tubule 
Epithelial Cells  
LDH activity in the supernatant was used as a measure of cytotoxicity of polyclonal 
FLCs. HK-2 cells were incubated with polyclonal FLCs at 1 mg/ml or 5 mg/ml, or 
equimolar concentrations of HSA, or medium alone, for 24 hours (n = 6 per group). 
Supernatants were assayed for LDH activity as described. The LDH activity for each 
well was expressed as a percentage of maximum LDH release, as assessed by lysis of 
cells by repeated freeze-thawing in a control plate. There was no significant difference 
between LDH release from cells treated with polyclonal FLC, HSA, or medium alone 
(figure 7.2). In positive controls using the same monoclonal FLCs used in Chapter 4, 
significant increases in supernatant LDH concentrations were detected. As in the 
previous experiments, these results must be interpreted in the context of endocytosis of 
HSA and polyclonal FLCs not being formally demonstrated. Thus, as with the previous 
experiments, it cannot be conclusively proven in these experiments that polyclonal 
FLCs do not have cytotoxic effects on PTECs. 
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7.3 Uromodulin 
7.3.1 Uromodulin is Highly Aggregated in High Salt Solutions 
Uromodulin was extracted from pooled urines obtained from healthy volunteers as 
described. The purified protein was assessed at that stage by SDS-PAGE. Silver 
staining showed a faint band in the non-reduced lanes, with a broad band above, and 
Figure 7.1. Effect of polyclonal free light chains on inflammatory signalling. 
Exposure of HK-2 cells to polyclonal FLCs at 1 mg/ml or 5 mg/ml did not result in 
an increase in H2O2 or MCP-1 release into the supernatant, when compared to HSA 
or vehicle. In addition, there was no increase in H2O2 or MCP-1 release into the 
supernatant when cells were treated with delipidated HSA, up to 15 mg/ml when 
compared to vehicle alone. Monoclonal FLCs (2 and 2) known to initiate H2O2 
and MCP-1 release from HK-2 cells were used as positive controls. Treatment of 
cells with these positive control proteins showed significant increases in the 
quantities of H2O2 and MCP-1 in the supernatants. ****p <0.0001; n = 6 per group.  
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some staining at the bases of the wells (figure 7.3A). This confirms that at high salt 
concentrations, uromodulin is highly aggregated. Upon reduction, the proteins resolve 
to a single band between the 102 and 76 kDa standards. Western blotting confirmed that 
the bands seen on the non-reduced silver stained lanes were in fact uromodulin (figure 
7.3B)  
 
7.3.2 Uromodulin Aggregation is Reduced in Water and by Alkaline pH    
Figure 7.2. Cytotoxic effects of polyclonal free light chains on proximal tubule 
cells. 
Exposure of HK-2 cells to polyclonal FLCs at 1 mg/ml or 5 mg/ml did not result in 
an increase in LDH release into the supernatant, when compared to HSA or vehicle. 
In addition, there was no increase in LDH release into the supernatant when cells 
were treated with delipidated HSA, up to 15 mg/ml, when compared to vehicle 
alone. Monoclonal FLCs (2 and 2) were used as positive controls. Treatment of 
cells with these positive control proteins showed significant increases in the 
quantitiy of LDH in the supernatants. **p <0.01; n = 6 per group.  
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The uromodulin sample was dialysed into distilled, deionised water for 24 hours. To 
test the effects of pH manipulation, two 36 µl aliquots were taken, and each mixed with 
either 4 µl of 0.5 M acetate buffer, pH 4.0, or 0.5 M Tris, pH 8.5 (pH values of 4.0 and 
8.5 were confirmed by universal indicator paper testing), and incubated at 4˚C 
overnight. The next day, samples were separated by SDS-PAGE and visualised by 
silver staining (Figure 7.4). Uromodulin from a small retained aliquot in PBS (150 mM 
 
Figure 7.3. Uromodulin from healthy volunteer urines prior to dialysis. 
Silver staining (A) demonstrates the highly aggregated nature of uromodulin in 
saline solutions. In non-reduced lanes (5 and 6), a faint band is seen corresponding 
to monomeric uromodulin, with a broad band above. These resolve when reduced to 
a single band (lanes 2 and 3). Lanes L-R 1, standard; 2 & 3, uromodulin (reduced); 
4, blank; 5 & 6, uromodulin (non-reduced). Western blotting (B) confirms that the 
bands seen on silver staining are indeed uromodulin, and that uromodulin exists in 
highly aggregated states in saline solutions. Lanes L-R 1, standard, 2 & 3, 
uromodulin (non-reduced).  
 
A       B 
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NaCl) was also loaded onto the gel. The results show that when compared to sample in 
PBS or at acidic pH 4 (lanes 8 and 9, non-reduced), samples dialysed into distilled, 
deionised water and at alkaline pH 8.5 show intensification of bands (lanes 10 and 11, 
non-reduced). This indicates that reducing salt concentration in the solution and 
alkalinisation of pH leads to reduced uromodulin aggregation. A slight upward mobility 
shift was noted in the lanes representing reduced protein (lanes 2 - 5), a phenomenon 
that remains unexplained.  
 
Figure 7.4. Uromodulin aggregation is reduced by dialysis into water and by 
alkaline pH. 
Uromodulin aggregation is reduced by dialysis into water and by alkaline pH, as 
shown by SDS-PAGE with silver staining. When compared to sample in PBS or 
acid pH (lanes 8 and 9), samples dialysed into water or at alkaline pH (lanes 10 and 
11) show intensification of bands, indicating that reducing salt concentration and 
alkalinisation leads to reduced uromodulin aggregation. Lanes L-R: 1, standard; 2, 
PBS (reduced); 3, pH 4 (reduced); 4, water only (reduced); 5, pH 8.5 (reduced); 6, 
blank; 7, standard; 8, PBS (non-reduced); 9, pH 4 (non-reduced); 10, water only 
(non-reduced); 11, pH 8.5 (non-reduced) 
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7.4 Polyclonal Free Light Chains Interact with Uromodulin: Dot Blotting  
Dot blotting was used in initial experiments to assess the interaction between polyclonal 
FLCs and uromodulin. In one approach, polyclonal FLCs were spotted at different 
concentrations onto nitrocellulose membranes and the blots were incubated with either 
uromodulin diluted to 20 µg/ml in PBS, or PBS alone (figure 7.5). The blots were then 
probed with HrP conjugated antibodies against either  or  FLC, or an anti-uromodulin 
antibody that was detected by an HrP conjugated secondary antibody. Blots A and B 
were probed with anti-FLC antibodies, and confirm the presence of FLCs on the blot. 
Blot C was probed with PBS alone, without uromodulin, and shows that in the absence 
of uromodulin, there is no cross-reactivity between the polyclonal FLCs and the anti-
uromodulin antibody. Blot D shows that uromodulin localises to the polyclonal FLCs 
spots, showing that there has been binding of uromodulin to polyclonal FLCs. Blot D 
also shows that the strength of binding is much stronger with polyclonal  FLCs than 
with  FLCs. In this experiment, despite different quantities of polyclonal FLCs being 
spotted onto the blots, in blot A there was no obvious variation in the intensity of dots, 
indicating a lack of dose-response to the quantity of polyclonal FLC spotted onto the 
membrane, such as seen in blot B.  
 
In a second approach, uromodulin and HSA were spotted onto nitrocellulose 
membranes at varying concentrations and incubated with either polyclonal  or  FLCs 
at 25 µg/ml, or PBS alone (figure 7.6). Blots were then incubated with HrP conjugated 
anti- or anti- FLC antibodies. Blot A shows, as in the previous experiment, that there 
is binding between polyclonal FLCs and uromodulin on the blot. Blot B shows that 
there appears to be some cross-reactivity between the uromodulin on the membrane and 
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the anti- or anti- FLC antibodies. It was possible that this cross-reactivity was a result 
of contamination of the uromodulin with immunoglobulin in the urine, and this was 
addressed in the next experiment (see below). Blot C shows that in this experimental 
approach, no binding could be demonstrated between uromodulin and polyclonal  
FLC, in contrast to the previous experiment. No reactivity was seen between 
uromodulin and the HSA control spots.  
 
Following the above experiment, a repeat dot blot was performed by spotting polyclonal 
FLCs onto nitrocellulose membranes at serial dilutions (figure 7.7). Uromodulin was 
incubated for 15 minutes with immobilised protein G (Prosep G) The blots were then 
incubated with uromodulin diluted to 20 µg/ml, and probed with HrP conjugated anti- 
or anti- FLC antibody, or anti-uromodulin antibody which was detected with a 
secondary antibody, as indicated in the figure.  
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Figure 7.5. Dot blot showing binding of polyclonal FLCs to uromodulin 
(polyclonal FLC dots). 
Blots A and B were probed with anti- and anti- FLC antibodies, to demonstrate 
the presence of polyclonal FLC on the membranes. Blots C and D were probed with 
anti-uromodulin antibody. Blot C was incubated with PBS alone, without 
uromodulin, and shows no signal with anti-uromodulin antibody, confirming that in 
the absence of uromodulin, there is no cross-reactivity between polyclonal FLCs and 
this antibody. Blot D was incubated with uromodulin, then probed with anti-
uromodulin antibody. This blot shows that uromodulin has localised to the 
polyclonal FLC spots, indicating binding. Binding of uromodulin to polyclonal -
FLC appeared stronger than binding to polyclonal -FLC. Polyclonal FLCs dotted 
onto membrane, and incubated with uromodulin (20 µg/ml). Secondary antibodies 
are indicated on the right. Uro +Ctrl, uromodulin positive control.  
 
 
 
  
 203 
 
Blot A confirmed the presence of polyclonal FLC on the membrane. Blot B confirmed 
that there is binding of uromodulin to polyclonal FLC under these experimental 
conditions. Blot C showed that in the absence of uromodulin, there is no binding of 
anti-uromodulin antibody to the polyclonal FLCs. In blot D, uromodulin was spotted 
onto the membrane (1 µg). When probed with anti- and anti- FLC antibodies, no 
Figure 7.6. Dot blot demonstrating binding of polyclonal FLC to uromodulin 
(uromodulin dots). 
In these blots, uromodulin and HSA have been spotted onto the membranes. Blot A 
was incubated with polyclonal -FLC, then probed with anti- FLC antibody. This 
blot shows that there is binding between uromodulin and polyclonal FLC on the 
blot. Blot B was incubated with PBS alone, then probed with anti- and anti- FLC 
antibodies. This blot shows that there is cross-reactivity between uromodulin and the 
antibodies. Blot C was incubated with polyclonal -FLC before being probed with 
anti- FLC antibody. No signal is This blot shows no signal, in contrast to Figure 
7.5. Probes and secondary antibodies are indicated on the right.  and  polyclonal 
FLCs were diluted to 25 µ/ml.  
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signal was seen, confirming that the cross-reactivity seen in the previous experiment 
was most likely due to contamination with immunoglobulin.  
 
 
Figure 7.7. Dot blot (repeated) demonstrating binding of polyclonal FLC to 
uromodulin (FLC dots). 
In these blots A-C, polyclonal FLC has been dotted onto the membranes. 
Uromodulin was incubated with protein G prior to use. Polyclonal -FLC has been 
spotted onto the membranes to the left of the vertical dotted line and polyclonal -
FLC has been spotted to the right. Blot A has been incubated with uromodulin, then 
probed with anti- FLC antibody on the left and anti- FLC antibody on the right. 
This blot confirms the presence of FLCs on the membranes. Blot B was incubated 
with uromodulin, then probed with anti-uromodulin antibody. This blot shows 
uromodulin localising to the FLC spots, indicating that there is binding between 
these proteins. Blot C was incubated with PBS alone, then probed with anti-
uromodulin antibody. No signal is seen, confirming that in the absence of 
uromodulin, there is no cross-reactivity between polyclonal FLCs and anti-
uromodulin antibody. In blot D, uromodulin has been spotted onto the membrane 
and probed with anti- FLC antibody on the left, and anti- FLC antibody on the 
right. No signal is seen, confirming that there is no cross-reactivity between 
uromodulin and the anti-FLC antibodies. Uromodulin, 20 µg/ml. Where uromodulin 
spotted onto membrane = 1 µg.   
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7.5 Polyclonal Free Light Chains Interact with Uromodulin: ELISA   
Following the immunoblotting experiments described above, binding of uromodulin to 
polyclonal FLCs was assessed further by ELISA. Three approaches were used: (i) plate 
coated with uromodulin, (ii) plate coated with polyclonal FLCs (iii) plate coated with 
anti-uromodulin antibody and Sandwich type ELISA performed. Wells on each plate 
were loaded in triplicate, and averages of the absorbance was taken. Each plate 
experiment was repeated three times.  
 
7.5.1 Plate Coated with Uromodulin  
Plates were coated with uromodulin diluted to 1 µg/ml in distilled, deionised water, 
overnight. The next day, plates were incubated with polyclonal  and  FLCs as well as 
monoclonal  and  FLCs (Sigma Aldrich), all serially diluted, starting at 1 mg/ml. 
Equimolar HSA was also applied, serially diluted, starting from 3 mg/ml. The results 
are shown in figure 7.8. The results showed that both the monoclonal and polyclonal  
and  FLCs tested had similar binding patterns to uromodulin on the plates (figure 7.8A 
and 7.8B). Significant binding of HSA was noted in the ELISAs. At dilutions of 1:8 and 
higher, there was no significant difference between binding of HSA and both the 
polyclonal and monoclonal FLCs. At a dilutions of 1:4 and less however, there was 
significantly more binding detected with both the monoclonal and polyclonal FLCs, 
compared to HSA. At high concentration (dilution 1:1), there was significantly more 
binding of polyclonal  than polyclonal .  
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7.5.2 Plate Coated with Polyclonal Free Light Chains  
Plates were coated with monoclonal and polyclonal  and  FLCs diluted to 1 µg/ml, or 
HSA 3 µg/ml, overnight. The next day, serial dilutions of uromodulin were prepared, 
starting at 1 mg/ml, and ELISA procedure was carried out. The results are shown in figure 
7.9. No significant differences were seen between binding of polyclonal or monoclonal 
FLCs, or with HSA. Moreover, there were considerable variations in the readings. Readings 
at higher concentrations of uromodulin were not significantly different from those at lower 
concentrations, suggesting that there was no significant binding occurring in the wells. One 
other possible explanation for these results is that the coating step failed. However, in these 
experiments, positive controls for coating, using anti-FLC antibodies, were not included.  
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Figure 7.8. Assessment of binding of polyclonal FLC to uromodulin by ELISA: 
Plate coated with uromodulin. 
A: Greater binding of polyclonal -FLC to uromodulin was seen when compared to 
HSA, at dilutions of 4 (**p <0.01). No difference was seen between polyclonal and 
monoclonal -FLCs. B: Similarly, greater binding of polyclonal -FLC to 
uromodulin as seen when compared to HSA, at dilutions of 4 (*p <0.05). No 
difference was seen between polyclonal and monoclonal -FLCs. C: Polyclonal -
FLC showed greater binding to uromodulin than polyclonal -FLC at high 
concentration (dilution factor 1, ***p <0.001). mFLC, monoclonal FLC; pFLC, 
polyclonal FLC.  
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Figure 7.9. Assessment of binding of polyclonal FLC to uromodulin by ELISA: 
Plate coated with FLC. 
ELISA procedure was carried out with the plate coated with monoclonal and 
polyclonal FLCs, or HSA. Incubation with even high concentrations of uromodulin 
showed no significant differences between the proteins were seen, and the 
absorbance values were low, indicating that no binding had taken place using this 
approach. mFLC, monoclonal FLC; pFLC, polyclonal FLC.  
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7.5.3 Sandwich ELISA  
In order to address the poor binding in the above experiment, and in an attempt to reduce 
any background so as to improve the specificity of the assay, a sandwich approach was 
adopted. Anti-uromodulin antibody was diluted to 1/5000 and coated onto the plate. The 
next day, uromodulin was diluted to 100 µg/ml and applied to the plate, followed by serial 
dilutions of monoclonal and polyclonal FLCs, starting at 1 mg/ml, as well as HSA, starting 
at 3 mg/ml (figure 7.10). The results from this experiment were similar to the previous one. 
There were no significant differences between binding of polyclonal or monoclonal FLCs, 
or with HSA. Again, considerable variations in readings were seen. There was no dilution-
dependent change in readings, suggesting, in this setting as well, that no significant binding 
had taken place in the wells. As with the previous experiment, one possible explanation for 
these results was that the coating step failed. However, a positive control, using an anti-
sheep antibody, was not included.  
 
7.6 Polyclonal Free Light Chains Interact with Uromodulin: Nephelometry   
Following the findings of the ELISAs presented above, the association of polyclonal 
FLCs and formation of higher MW aggregates with uromodulin was assessed by 
nephelometry. The binding of uromodulin to proteins, can promote the formation of 
aggregates with an effective increase in molecular size and diameter. These larger 
aggregated molecules cause light to be scattered to a greater extent as it passes through 
the cuvette. The degree of light scatter, and therefore the degree of binding, can be 
assessed by means of a nephelometer (see Chapter 2).  
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Uromodulin was diluted to 200 µg/ml and added to equal volumes of solutions of 
polyclonal and monoclonal  and  FLCs at 500µg/ml. In this setting the final 
concentrations of uromodulin and FLCs were 100 µg/ml and 250 µg/ml, respectively.  
 
The effect of altering salt concentration was assessed by using three strengths of NaCl 
in the PBS buffer: 50 mM, 100 mM and 150 mM. Each experiment was repeated three 
times. A significant amount of background scatter was detected, with PBS alone. This 
background scatter was not constant, and increased with time. One possibility was that 
gas bubbles were forming as the cuvette sat in the nephelometer for prolonged periods. 
However, degassing the buffer under suction prior to experiments made no difference to 
this background scatter (data not shown). This background was subtracted from the 
results presented below.  
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Figure 7.10. Assessment of binding of polyclonal FLC to uromodulin by 
ELISA: Sandwich ELISA. 
Plates were coated with anti-uromodulin antibody, and then incubated with 
uromodulin at 100 µg/ml. Serial dilutions of monoclonal and polyclonal FLCs and 
HSA were then incubated in the plates. No significant differences between the 
proteins were seen, and the absorbance values were low, indicating that no binding 
had taken place using this approach. mFLC, monoclonal FLC; pFLC, polyclonal 
FLC.  
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7.6.1 Experiments in Buffer Containing 50 mM NaCl  
Experiments were performed with PBS containing 50 mM NaCl. Formation of higher 
molecular weight aggregates was detected as increases in light scatter. There were no 
differences between monoclonal and polyclonal  or  FLCs (figure 7.11). However, 
there were significant increases in light scatter in cuvettes containing both  and  
polyclonal FLCs, compared to uromodulin alone (figure 7.12). No differences were 
detected between polyclonal FLCs and HSA.  
 
7.6.2 Experiments in Buffer Containing 100 mM NaCl  
When the concentration of NaCl was increased to 100 mM, again, there was no 
difference between the monoclonal and polyclonal FLCs in their binding to uromodulin, 
as indicated by light scatter (figure 7.13). There were significant increases in light 
scatter, indicating formation of higher molecular weight aggregates in cuvettes 
containing polyclonal FLCs with uromodulin, compared to those containing HSA with 
uromodulin, or uromodulin alone (figure 7.14). Differences were significant at 360 
minutes, as indicated in the figure. 
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Figure 7.11. Nephelometric assessment of the formation of higher molecular 
weight aggregates with uromodulin; comparison of polyclonal and monoclonal 
FLCs; 50 mM NaCl.  
Assessment of the formation of higher molecular weight aggregates, as determined 
by increased light scatter, with uromodulin in the presence of monoclonal and 
polyclonal and  FLC (A) and  FLC (B), at 50 mM NaCl. At this concentration of 
NaCl, no differences were seen between monoclonal and polyclonal -FLCs or 
between monoclonal and polyclonal -FLCs. mFLC, monoclonal FLC; pFLC, 
polyclonal FLC. 
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Figure 7.12. Nephelometric assessment of the formation of higher molecular 
weight aggregates with uromodulin; comparison of polyclonal FLCs with HSA 
and uromodulin; 50 mM NaCl.  
Formation of higher molecular weight aggregates with uromodulin, as determined 
by increased light scatter, at 50 mM NaCl. Comparison of polyclonal and  FLC (A) 
and  FLC (B) with HSA and uromodulin alone. At 360 minutes, there were 
significantly increased light scatter readings in cuvettes containing polyclonal -
FLC with uromodulin, when compared to uromodulin alone (**p < 0.01), but no 
difference when compared to HSA. Similarly, at 360 minutes, there were 
significantly increased light scatter readings in cuvettes containing polyclonal -
FLC when compared to uromodulin alone (*p < 0.05), but no difference when 
compared to HSA.  
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Figure 7.13. Nephelometric assessment of the formation of higher molecular 
weight aggregates with uromodulin; comparison of monoclonal and polyclonal 
FLCs; 100 mM NaCl. 
Formation of higher molecular weight aggregates with uromodulin, as determined 
by increased light scatter, in the presence of monoclonal and polyclonal and  FLC 
(A) and  FLC (B), at 100 mM NaCl. At this concentration of NaCl, no differences 
were seen between polyclonal and monoclonal -FLCs or between polyclonal and 
monoclonal -FLCs. mFLC, monoclonal FLC; pFLC, polyclonal FLC. 
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7.6.3 Experiments in Buffer Containing 150 mM NaCl  
When the concentration of NaCl was increased further to 150 mM, a significant 
increase in aggregate formation, as indicated by increase in light scatter, was seen with 
polyclonal  FLCs, compared to monoclonal  FLCs (figure 7.15). The development of 
light scatter was accelerated with a significant difference seen at 120 minutes There 
were also significant increases in light scatter in cuvettes containing uromodulin with 
Figure 7.14. Nephelometric assessment of the formation of higher molecular 
weight aggregates with uromodulin; comparison of polyclonal FLCs with HSA 
or uromodulin alone; 100 mM NaCl.  
Formation of higher molecular weight aggregates with uromodulin, as determined 
by increased light scatter, at 100 mM NaCl. Comparison of polyclonal and  FLC 
(A) and  FLC (B) with HSA, or uromodulin alone. At 360 minutes, there were 
significantly higher readings in cuvettes containing polyclonal -FLC when 
compared to compared to HSA (***p < 0.001), or uromodulin alone (*p < 0.05). 
pFLC, polyclonal FLC; HSA, human serum albumin. 
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both polyclonal  and polyclonal  FLCs, compared to those containing uromodulin 
with HSA, or uromodulin alone (figure 7.16). These differences were significant at an 
earlier stage in 150 mM NaCl than at 100 mM NaCl.  
 
7.7 Discussion  
This chapter presents results from detailed in vitro studies investigating the potential 
biological effects of polyclonal FLCs in the kidney. The results from my experiments 
have not demonstrated that polyclonal FLCs have a direct pro-inflammatory effect on 
PTECs. However, there does appear to be an interaction between polyclonal FLCs and 
uromodulin, which in some experiments was comparable in magnitude to that of 
monoclonal myeloma FLCs. 
 
Generation of H2O2 after receptor mediated endocytosis has been established as the 
initiating event for pro-inflammatory signalling following exposure of PTECs to 
monoclonal FLCs.(Wang and Sanders 2007) The result of this signalling is transcription 
and release of inflammatory cytokines from PTECs, leading to recruitment of 
inflammatory cells and subsequent fibrosis. Intra-renally produced MCP-1 plays a key 
role in the development of fibrosis in the kidney.(Grandaliano et al. 1996; Prodjosudjadi 
et al. 1995) In the experiments presented here, H2O2 and MCP-1 in the supernatants of 
HK-2 cells was not increased, in contrast to the monoclonal FLCs used as positive 
controls, as well as demonstrated in Chapter 4.  
 
Previous studies using monoclonal FLCs have demonstrated the cytotoxic potential of 
these proteins, by detecting increased release of LDH after exposure to these 
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FLCs.(Pote et al. 2000) Experiments performed with polyclonal FLCs in the present 
study did not show increased LDH release into the cell culture supernatants, when 
compared to HSA controls.  
 
However, there were a number of limitations in the experimental designs, making a 
definitive conclusion impossible. In studies investigating the potential of polyclonal 
FLCs to initiate inflammatory signalling and cytotoxicity in PTECs, no increases in 
H2O2, MCP-1 or LDH levels were detected in supernatants of cells treated with 
polyclonal FLCs. Similar results were obtained when cells were treated with delipidated 
HSA, up to 15 mg/ml. These poor responses to HSA raises the possibility that 
endocytosis of these proteins was not taking place. Endocytosis is a key step in the 
pathway to the release of inflammatory mediators such as MCP-1; this is demonstrated 
by the abrogation of these responses when megalin and cubilin expression was silenced 
with siRNA, in Chapter 4. The presence of megalin and cubilin (demonstrated by 
Western blotting in Chapter 4) and robust responses to the monoclonal FLCs seen 
indicate that the endocytic machinery of the HK-2 cells used were functioning normally. 
Other laboratories have shown that delipidated albumin can induce MCP-1 release from 
PTECs.(Wang et al. 1999) However, independent studies from the laboratories of 
Batuman as well as Sanders have noted a lack of response from PTEC lines (SV40 
transfected PTECs and HK-2 cells respectively) to delipidated HSA, at doses of up to 
15 - 30 mg/ml.(Sengul et al. 2002; Wang and Sanders 2007) Both these laboratories 
have performed studies to demonstrate endocytosis of monoclonal FLCs, but have not 
formally shown endocytosis of HSA. As endocytosis of HSA or polyclonal FLCs was 
not formally demonstrated in my own studies presented in this chapter, it cannot be 
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conclusively proven in these experiments that polyclonal FLCs do not have pro-
inflammatory effects on PTECs.  
 
The in vitro studies presented in this chapter utilised type 1 collagen from rat tail 
tendons for thin-coating of containers, to facilitate HK-2 cell anchorage and 
proliferation. This type of collagen was chosen for consistency, as it has previously 
been used for the same purpose at independent laboratories.(Pote et al. 2000; Wang and 
Sanders 2007) However, type 4 collagen is a more physiological thin-coating agent for 
epithelial cells, being more abundant in basement membranes, while type 1 collagen is 
more abundant in the interstitium. A recent study has also indicated that type 1 collagen 
may promote EMT in epithelial cells, including HK-2 cells, thus raising the possibility 
that some of the inflammatory effects seen were attributable to the choice of thin-
coating agent.(Medici and Nawshad 2010) However, low levels of H2O2, MCP-1 and 
LDH seen when cells were treated with vehicle alone indicate that the pro-inflammatory 
effects of the thin-coating agent were minimal.   
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Monoclonal FLCs which are associated with inflammatory potential exert these effects 
by activating specific post-receptor signalling pathways.(Sengul et al. 2009) In 
successive studies, the inflammatory potential both in vitro and in vivo has been shown 
Figure 7.15. Nephelometric assessment of the formation of higher molecular 
weight aggregates with uromodulin; comparison of monolconal and polyclonal 
FLCs; 150 mM NaCl. 
Formation of higher molecular weight aggregates with uromodulin, as determined 
by increased light scatter, in the presence of monoclonal and polyclonal  FLC (A) 
and  FLC (B), at 150 mM NaCl. At this concentration of NaCl, a dramatic increase 
in light scatter was seen with polyclonal  FLC, compared to monoclonal -FLC, 
which was evident at 40 minutes, and was significant by 120 minutes (***p < 
0.001). No differences were seen between polyclonal and monoclonal -FLCs. 
mFLC, monoclonal FLC; pFLC, polyclonal FLC. 
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to vary from one FLC species to another.(Pote et al. 2000; Sengul et al. 2002; Sanders 
et al. 1988a; Wang and Sanders 2007) An explanation for this phenomenon may lie in 
the fact that due to the extreme primary structure heterogeneity of FLCs, no two FLCs 
are physicochemically identical.(Sanders 2005) In addition, mutations leading to 
Figure 7.16. Nephelometric assessment of the formation of higher molecular 
weight aggregates with uromodulin; comparison of polyclonal FLCs with HSA 
or uromodulin alone; 150 mM NaCl. 
Formation of higher molecular weight aggregates with uromodulin, as determined 
by light scatter, at 150 mM NaCl. Comparison of polyclonal and  FLC (A) and  
FLC (B) with HSA, or uromodulin alone. At 120 mintues, significantly increased 
light scatter was noted with polyclonal -FLC, compared with HSA (***p < 0.001), 
or with uromodulin alone (***p < 0.001). Significant increases in light scatter were 
noted with polyclonal -FLC, compared with HSA (***p < 0.001), or uromodulin 
alone (***p < 0.001) at 280 minutes. pFLC, polyclonal FLC; HSA, human serum 
albumin. 
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abnormal FLC primary structure are well described in plasma cell dyscrasias,(Stevens 
2000) although precise associations between the physicochemical properties of the 
proteins and patterns of PTEC injury in myeloma cast nephropathy have not been 
established. However, a link between primary structure and pathology is also supported 
by the observation that some patients with multiple myeloma develop progressive renal 
failure, while there are others who excrete large quantities of urinary FLCs with little or 
no disturbance in renal function.(DeFronzo et al. 1978)   
 
Uromodulin is a glycoprotein secreted apically by cells of the thick ascending limb of 
the Loop of Henle. It is initially GPI-anchored, but once this is cleaved, free uromodulin 
passed down the nephron, and in health, is the most abundant urinary protein.(Kumar 
and Muchmore 1990) Increasing the ambient NaCl or calcium ion concentrations as 
well as acidic pH is associated with aggregation of uromodulin molecules, and the 
enhanced binding of uromodulin to many low MW proteins.(Porter and Tamm 1955; 
Sanders et al. 1990; Kobayashi and Fukuoka 2001) The results presented in this 
chapter, of the initial analyses of uromodulin purified from healthy volunteers are in 
agreement with past studies, showing that aggregation of uromodulin was reduced by 
dialysing the protein into water, and by alkalinisation of the solution. It was therefore 
decided to store uromodulin in water, but mix with buffers to form physiological 
solutions immediately prior to use in experiments.  
 
The binding of polyclonal FLCs to uromodulin was initially confirmed by the dot-
blotting experiments. In these experiments, it appeared that the binding of polyclonal  
FLC was stronger than that of  FLC. This was a phenomenon which had not been 
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described in previous studies investigating the interactions between monoclonal FLCs 
and uromodulin, although the numbers of proteins studied in these situations were 
small.(Sanders et al. 1990) In the initial dot-blotting experiment, one of the control blots 
(Figure 7.5, Blot A) failed to demonstrate a dose-response with the quantity of 
polyclonal  or  FLC dotted onto the membrane. This blot was not probed with 
uromodulin, therefore the result is not a reflection of interaction between uromodulin 
and polyclonal FLCs. The observed result was most likely explained by a method error, 
such as excessive exposure to HrP substrate during the development step, because 
subsequent blots showed that there were dose-responses.  
 
In order to apply a more quantitative approach to these findings, ELISA was employed. 
The results from these experiments confirmed a dose-dependent binding relationship 
between polyclonal FLCs and uromodulin, when the plate was coated with uromodulin. 
When polyclonal FLCs were immobilised on plates, or the sandwich method was used, 
these experiments produced no significant results. One explanation for this might have 
been the fact that uromodulin in the assays was prepared in a salt-containing buffer 
(standard PBS with 150 mM NaCl), which might have caused significant aggregation 
between uromodulin molecules, a phenomenon which is known to interfere with assays 
where uromodulin is in the liquid phase, often necessitating treatment of the protein 
with strong denaturing agents prior to an ELISA-type assay.(Kjellsson et al. 1987; 
Reinhart et al. 1989; Kobayashi and Fukuoka 2001) One approach would have been to 
lower the NaCl concentration of the buffer; however, this was not performed, as a hypo-
osmolar solution was likely to result in sub-optimal binding. In my own experiments, 
the degree of binding between polyclonal  and polyclonal  FLCs did not differ, 
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except at high concentration (1 mg/ml). Also of note was the observation that there was 
no difference between polyclonal and monoclonal FLCs in their binding to uromodulin 
in this assay.  
 
An alternative explanation for the latter two ELISA methods (plate coated with 
polyclonal FLC and the sandwich method) not showing significant results was that the 
coating step had failed. Whilst this question was not addressed formally in my 
experiments, future studies should include a positive control step, using anti-FLC 
antibodies and anti-sheep antibodies respectively, to prove that polyclonal FLCs and the 
sheep-anti-human uromodulin antibody had been successfully coated onto the 
microplates.   
 
Nephelometric assays were performed for two reasons: (i) to assess binding of 
polyclonal FLCs with uromodulin in the free liquid phase, where neither protein is 
tethered to a membrane or a plate; (ii) to assess the formation of higher MW aggregates. 
The concentrations of polyclonal FLCs used in the nephelometric experiments were 
within the range that would be expected in patients with CKD.(Hutchison et al. 2008a) 
The results indicate that there is indeed aggregation of uromodulin in the presence of 
polyclonal FLCs. This was enhanced by increasing the concentration of NaCl, and this 
finding was consistent with past studies.(Sanders et al. 1990) There was considerable 
background light scatter in these experiments from buffer alone, which was not constant 
for the duration of the experiment, and indeed increased significantly. In previous 
studies with monoclonal FLCs, significant light scatter due to higher MW aggregates 
was detectable within minutes of starting the reactions.(Sanders et al. 1990) In my 
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experiments, however, no significant differences in light scatter were detectable for up 
to 3 hours. This may have been a result of the different methods used, including 
different preparation methods of proteins, and different instrument. In addition, the 
proteins used in the study by Sanders et al were myeloma proteins, extracted from 
patients known to have myeloma related kidney failure. In some experiments, the 
scatter values were very high, approaching the upper detection limit of the 
nephelometer, thus explaining the flattening of curves at these values, and the minimal 
variation between individual results in this range.  
 
In the proximal tubule, toxicity appears to be related to the physicochemical property of 
each FLC clone. In a large pool of polyclonal FLCs such as that used in the experiments 
described here, the importance of the toxicity of an individual FLC may be diminished. 
In the distal nephron however, the presence of uromodulin and ambient conditions such 
as NaCl and calcium concentrations, as well as pH, may play a more important role. In 
conclusion, in my studies, the results indicate that in the distal tubule the interaction of 
polyclonal FLCs might contribute to the formation of casts. Further studies would need 
to be undertaken to dissect out these effects in more detail. Further detailed studies are 
also required to assess whether polyclonal FLCs and delipidated HSA are endocytosed 
by HK-2 cells. 
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8. GENERAL DISCUSSION, IMPLICATIONS FOR FUTURE 
RESEARCH AND THERAPEUTIC STRATEGIES 
8.1 Introduction 
The experiments reported in this thesis were designed to provide further data on the 
pathogenic potential of monoclonal FLCs (derived from patients in myeloma) and to 
perform a comprehensive evaluation of the biological effects of polyclonal FLCs in the 
kidney and, specifically, to evaluate their potential role in the development and 
progression of fibrosis in the setting of CKD. The findings of these investigations 
further elucidated the signalling pathways that are activated by monoclonal FLCs and 
showed that in the distal tubule, there appears to be a detectable interaction between 
polyclonal FLCs and uromodulin, a ubiquitous protein, which has been shown to have 
potentially far-reaching biological effects.(Weichhart et al. 2005)  
 
8.2 Histological Examination in Cast Nephropathy 
In Chapter 3, results were presented from in situ measurements that were made by 
examining renal biopsy tissue from patients with multiple myeloma and AKI due to cast 
nephropathy. Historically, studies that included patients with multiple myeloma and 
kidney injury have not utilised histological examination of kidney tissue as a matter of 
routine. Indeed, there has traditionally been a reluctance to perform percutaneous 
biopsies in these patients. There are perhaps two reasons for this. First, the procedure of 
percutaneous renal biopsy, although generally considered safe in the absence of a 
bleeding diathesis, still carries a not inconsiderable risk of serious haemorrhage.(Parrish 
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1992) This risk is theoretically increased in patients with multiple myeloma.(Magee 
2006; Clark et al. 2005) However, a recent retrospective study of 1993 patients has been 
reported, which showed that renal biopsy posed no excess risk in patients who had 
multiple myeloma.(Fish et al. 2010) This observation may well be explained at least in 
part by improved techniques, equipment, the use of ultrasound in real time, and 
improved after care of patients.  
 
Second, to date there is no direct therapy to target the renal injury component of 
multiple myeloma, specifically cast nephropathy. Thus some physicians argue that a 
renal biopsy is only of academic interest and does not provide any useful additional 
information for diagnosis and/or treatment modification. However, as our knowledge of 
renal diseases associated with PCDs expands and as novel therapies become 
established, histological diagnosis is likely to carry increasing importance in the 
consideration of treatment selection and modification, as well as in stratifying risk and 
prognosis. For example, specific targeted therapies for cast nephropathy would require a 
confirmed diagnosis, in order to balance the benefit of treatment against its potential 
risks. One such example is the ongoing EuLITE trial, where a renal biopsy diagnosis is 
part of the inclusion criteria.(Hutchison et al. 2008b) Therefore, renal biopsies are likely 
to be performed with increasing frequency in this setting. Indeed, patients with cast 
nephropathy receiving targeted therapy may well undergo an initial diagnostic renal 
biopsy, with one or more subsequent biopsies performed to monitor response to 
treatment, direct future treatment, and determine renal prognosis.  
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8.3 Histological Markers of Renal Outcome in Cast Nephropathy 
Two previous published studies have indicated that in the setting of myeloma cast 
nephropathy and acute kidney injury, the degree of chronic damage on the renal biopsy, 
and cast numbers are adverse determinants of renal prognosis.(Pasquali et al. 1987; 
Pozzi et al. 1987)  
 
In my own investigations, a patient with persistently elevated cast numbers in a repeat 
biopsy did not become independent of dialysis. In the study by Pozzi et al, renal tissue 
was assessed from 24 patients, but only 16 were reported has having “myeloma 
kidney”. In this series, fewer casts in the biopsy were associated with a more favourable 
renal outcome.  
 
However, no study has so far dissected out in detail, the relationships between cast 
numbers, chronic damage, renal outcomes, and other predictors of progression of renal 
fibrosis, such as interstitial capillary density and interstitial macrophages. The degree of 
chronic damage seen on the biopsy has been well established as a rigorous predictor of 
renal prognosis and is relatively straightforward to perform and reproduce.(Howie et al. 
2001). Such a study performed in a series of patients at might demonstrate whether or 
not cast numbers are a good measure of treatment efficacy and a predictor of prognosis. 
In my own studies, the measurement of cast numbers was shown to be relatively 
straightforward, and reproducible. However, it is a time consuming task. One possible 
alternative, not assessed in this thesis, would be to use automated or semi-automated 
image analysis, performed on uncounterstained sections with the intensity of staining 
measured as described. An appropriate choice of antibody target for staining would be 
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uromodulin, as this would be present in all casts. There is likely to be adequate archived 
tissue held within many centres, for such a study to be undertaken. The emergence of 
future therapies and an increased number of biopsies might permit a more robust, 
prospective analysis, where tissue from repeat biopsies might also be available and 
could be incorporated into the study. 
 
8.4 Proximal Tubular Damage in Cast Nephropathy 
In the setting of multiple myeloma and cast nephropathy, the mechanisms of proximal 
tubular injury have already been elucidated in some detail. In PTECs, endocytosis of 
monoclonal FLCs occurs through a receptor-mediated process. FLCs are delivered to 
the proximal tubule, where they bind to the tandem receptors megalin and 
cubilin.(Batuman et al. 1998; Klassen et al. 2005) Following endocytosis, the FLCs, 
like many other proteins, are processed within the lysosomal system, where proteolytic 
degradation takes place.(Batuman and Guan 1997) In the case of monoclonal FLCs 
which are toxic to the proximal tubule, a study from the laboratory of Sanders showed 
that an early event following endocytosis is the generation of H2O2 and intracellular 
oxidative stress, and that generation of this H2O2 was linked integrally to the 
downstream activation of NF-B, transcription and release of MCP-1 from cells.(Wang 
and Sanders 2007) This property was not shared with non-immunoglobulin derived 
proteins such as albumin, which has been implicated in proximal tubule activation in 
other settings.(Wang et al. 1997; Burton et al. 1999)  
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8.4.1 The Role of c-Src in Signal Transduction 
The tyrosine kinase c-Src, the 60 kDa product of the c-src gene is a redox sensitive 
enzyme, the activity of which is under tight redox control. It is a central hub in 
intracellular signalling networks, linking receptors to intracellular signalling 
cascades.(Parsons and Parsons 2004; Kim et al. 2009) It is involved in regulation of 
crucial cellular processes, such as growth, shape, differentiation, migration and survival. 
Interest in the involvement of c-Src in proximal tubule inflammation caused by 
monoclonal FLCs arose from these observations. Results from my own experiments 
performed at the laboratory of Sanders, using the same monoclonal FLCs, showed that 
the single initiating event for signal transduction was the activation of c-Src, and that 
this activation was dependent upon receptor-mediated endocytosis, as detailed in 
Chapter 4.(Basnayake et al. 2010)  
 
How the activation of c-Src by H2O2 is linked to downstream activation of NF-B is not 
yet known. The activation of NF-B takes place through complex processes, and 
several pathways to activation of NF-B have been described.(Sanz et al. 2010) 
Currently, there are over 800 compounds, both naturally occurring and synthetic, which 
exert their effects through activation of NF-B.(Gilmore and Herscovitch 2006) In the 
canonical pathway, activating stimuli result in engagement and phosphorylation of the 
inhibitor complex of B kinase (IKK). This complex phosphorylates the inhibitor 
subunit of B (IB), resulting in its ubiquitination, targeting it for degradation by 
proteasomes. This permits nuclear translocation of NF-B subunits, resulting in 
transcription. This is a rapid and transient response. In what is referred to as the atypical 
pathway, tyrosine phosphorylation of IB can also activate NF-B, without 
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involvement of the IKK complex.(Imbert et al. 1996) Therefore the potential 
implications for exposure of PTECs to monoclonal FLCs resulting in the increased 
activity of an intracellular tyrosine kinase such as c-Src could be far-reaching. The 
activation of NF-B by multiple pathways would go some way towards explaining the 
excessive pro-inflammatory effects on PTECs of H2O2 generating monoclonal FLCs, 
compared to non-immunoglobulin derived proteins such as albumin. There are also 
potential roles for other ROS other than H2O2 which have yet to be explored in the 
setting of cast nephropathy.  
 
8.5 Distal Tubular Damage in Cast Nephropathy 
Studies from the laboratory of Sanders have also elucidated the process of cast 
formation in distal tubules by the co-precipitation of monoclonal FLCs with 
uromodulin. Cast formation has been shown to be favoured by reducing extracellular 
fluid volume, increasing calcium ion and sodium chloride concentrations and acidic pH; 
in addition, modification of the carbohydrate moiety of uromodulin by reducing the 
number of sialic acid residues, was shown to reduce aggregation uromodulin, but 
without affecting the actual binding of FLCs to uromodulin.(Sanders et al. 1990; 
Sanders and Booker 1992; Huang et al. 1993) Subsequently, it was shown that the 
CDR3 region of cast-forming monoclonal FLCs bound to a common peptide segment 
on uromodulin.(Ying and Sanders 2001)  
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8.6 Potential Therapeutic Approaches to Cast Nephropathy 
8.6.1 Reduction of FLC Load Delivered to Nephrons 
Work done to date has identified several potential therapeutic approaches to patients in 
whom multiple myeloma is complicated by kidney injury due to cast nephropathy. The 
quantity of monoclonal FLCs delivered to each nephron could be reduced. Two 
practical approaches to this exist: reduction of tumour load by chemotherapy and 
extracorporeal removal. If there is significant kidney injury, even if FLC production is 
reduced, considerable delay will be seen in the removal of the remaining FLCs from the 
circulation. This is because FLCs (like other low molecular weight proteins) are widely 
distributed in the extravascular compartment.(Hutchison et al. 2007) Therefore the toxic 
effects of FLCs may be sustained for several weeks and renal recovery might be further 
compromised, despite reduced production. The extravascular distribution of FLCs 
might also explain why clinical outcomes with the use of plasma exchange have been 
disappointing.(Clark et al. 2005) The use of extended, high cut-off haemodialysis is 
therefore under evaluation, as this allows longer treatment with the subsequent 
redistribution of FLCs from the extravascular to the intravascular compartments. 
Results from a pilot study have been encouraging and a multi-centre, randomised, 
controlled trial is currently under way.(Hutchison et al. 2009; Hutchison et al. 2008b)  
 
8.6.2 Prevention of PTEC Damage 
8.6.2.1 Prevention of Endocytosis 
One therapeutic option to reduce damage sustained by PTECs would be to prevent 
endocytosis. Two approaches are possible here; (i) blocking binding sites on the ligand, 
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thus preventing it from interacting with the receptor and (ii) blocking binding sites on 
the receptor, thus preventing it from interacting with the ligand. Blocking the binding of 
ligand to receptor may be more technically challenging than the opposite, because of 
ongoing production of monoclonal FLCs, the wide distribution of these FLCs into 
extravascular compartments, which might not be accessible to a therapeutic agent and 
the large number of FLC molecules involved might require administration of large 
quantities of such an agent. 
 
On the other hand, binding of receptor to ligand might be preventable. However, several 
milestones will need to be achieved before this becomes possible. Both megalin and 
cubilin have large ligand binding domains, making chemical inhibition potentially 
difficult.(Christensen and Nielsen 2006) Currently, the inhibitors available for 
preventing binding to megalin or cubilin are limited to neutralising antibodies. Receptor 
associated protein (RAP) has a chaperone-like function to megalin, and RAP deficient 
mice have been shown to have significantly reduced cell surface expression of 
megalin.(Birn et al. 2000) Manipulation of this protein may be another potential 
approach to preventing endocytosis. Finally, endocytosis might be prevented by the 
silencing of gene expression and transcription of megalin and cubilin. Because these 
receptors form part of an essential physiological recovery mechanism, permanent 
silencing might be deleterious in the medium to long term. In the short term, this may 
prove to be an effective strategy. The use of siRNA would be an ideal post-
transcriptional, temporary approach to silencing of megalin and cubilin expression. 
Effective gene silencing by this method has been described in vivo for oncogenes.(Li et 
al. 2008d) However, as megalin and cubilin are continuously recycled and not rapidly 
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degraded, gene silencing alone will not be sufficient to prevent endocytosis, especially 
in the acute phase of treatment.  
 
8.6.2.2 Reduction of Intracellular Oxidative Stress 
A second therapeutic approach to protect PTECs may be through reduction of 
intracellular oxidative stress; as this is a key factor in activation of c-Src, it could be 
hypothesised that the administration of antioxidants might mitigate activation of c-Src. 
No in vitro or in vivo studies have been reported to date that use this approach to 
myeloma kidney. If such studies were undertaken, the method of delivery of such 
antioxidants to the cell cytoplasm would require careful consideration. Albumin-bound 
antioxidants such as ascorbic acid might be successfully administered orally, and enter 
the cells via megalin and cubilin. DMTU is a highly membrane diffusible scavenger of 
H2O2, as well as other ROS such as peroxynitrite, which has been used safely in vivo, 
and may be another potential means of ameliorating renal damage in cast nephropathy. 
However, because H2O2 is an important intracellular messenger in many cell types in 
response to many stimuli, careful assessments of safety in humans would be required. 
One notable drawback may be the interference of anti-oxidants with neutrophil 
function, in a group of patients already suffering form immunoparesis caused by 
multiple myeloma.(Jackson et al. 1988)  
 
8.6.2.3 c-Src Inhibition 
A third potential therapeutic approach, which may have a protective effect on PTECs, is 
c-Src inhibition. A number of inhibitors of Src family kinases exist, and have been used 
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safely in vivo in the treatment of malignant tumours.(Kim et al. 2009) No in vivo data 
have been published to date on their safety and efficacy with myeloma FLCs, however. 
The in vitro results with PP2 in my experiments were encouraging; the excess 
production of MCP-1 in response to monoclonal FLCs was reduced to baseline when 
PP2 was used, without any discernible toxicity to the cells. If its efficacy can be 
demonstrated in vivo, human studies could be undertaken. Therapy with siRNA to 
silence c-Src expression might also prove beneficial.  
 
8.6.2.4 MAPK Inhibition 
A further approach is through MAPK inhibition. Batuman and co-workers have shown 
that p38 MAPK is particularly important in renal inflammation in response to 
monoclonal FLCs.(Sengul et al. 2002) PACAP38 has been shown to inhibit the 
activation of p38 MAPK and ameliorate the pro-inflammatory effects of monoclonal 
FLCs on PTECs. This chemical compound, which acts by binding to any of three 
closely related G-protein coupled receptors on PTECs (PAC1, VPAC1 and VPAC2), is 
effective even in subnanomolar quantities both in vitro and in vivo.(Li et al. 2008c) 
mRNA for these receptors have also been detected in malignant plasma cells in multiple 
myeloma and the bone marrow stromal cells they grow on, while administration of 
PACAP38 was shown to attenuate myeloma cell growth in vitro.(Arimura et al. 2006) It 
was also safely used in one human, without any observed adverse effects.(Li et al. 
2007) Further studies are now needed to determine if it can be established as an 
effective therapy not just for cast nephropathy, but also in other settings involving 
multiple myeloma.  
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8.6.2.5 Proteasome Inhibition 
An additional consideration is proteasome inhibition. This mode of therapy would help 
prevent inflammatory cytokine release from PTECs by interfering with activation of 
NF-B. The proteasome inhibitor bortezomib is already a well established treatment for 
multiple myeloma and good renal response rates have been reported when renal injury 
is present.(Ludwig et al. 2010) In this study, patients had eGFR measurements of  50 
ml/min at the start of the study. An improvement in renal function was seen in 62% of 
patients. A good response, defined as a GFR of  60 ml/min, was achieved in only a 
minority of this subset (31%), the rest achieving a partial or minor improvement. The 
use of bortezomib in patients with cast nephropathy may confer an added benefit in 
mitigating renal fibrosis, although there may be good reasons why a response was not 
seen in more patients in this study. Firstly, the onset of renal failure is often insidious 
and in de novo patients who are not under surveillance, there may be significant 
established renal fibrosis by the time a diagnosis is made. Secondly, the inhibition of 
cytokine release from PTECs by bortezomib might be incomplete, because tyrosine 
phosphorylation by c-Src might activate NF-B independently of IKK.  
 
8.6.3 Uromodulin as a Therapeutic Target 
In the distal tubule, co-precipitation of monoclonal FLCs with uromodulin as casts is 
associated with physical damage to the nephron, including obstruction of flow and 
invasion of the tubule by inflammatory cells.(Weiss et al. 1981; Sanders et al. 1990) 
Damage to the tubule may result in spillage of tubular contents into the interstitium. 
Casts may therefore underlie additional inflammatory processes within the kidney that 
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contribute to fibrosis. Central to the formation of casts is uromodulin.(Sanders et al. 
1990) in which two distinct but related processes must be considered. First, the binding 
of monoclonal FLCs to uromodulin and second, the aggregation of uromodulin 
molecules, which is influenced by environmental factors. The binding of monoclonal 
FLC to uromodulin has been shown to be preventable in vitro by a peptide with a 
sequence corresponding to CDR3 of FLC.(Ying and Sanders 2001) No in vivo data has 
been published to date, but it is a potentially attractive strategy for preventing cast 
formation. The importance of supportive care cannot be overstated here. Aggregation of 
uromodulin is promoted by slow tubular flow, increased NaCl and calcium ion 
concentrations, acidic pH, and the presence of drugs such as furosemide.(Sanders and 
Booker 1992; Huang and Sanders 1995) Many of these factors, which are all reversible, 
will be present in patients with cast nephropathy at diagnosis. Finally, it has also been 
shown that colchicine alters the carbohydrate moiety of uromodulin, and reduces 
aggregation. Administration of colchicine over long periods of time is not practical, 
especially in the setting of acute kidney injury. However, short-term administration 
might be another strategy to reduce cast formation, but has yet to be tested in humans.  
 
It is a major undertaking to assess the utility of a new therapy in clinical practice; 
careful pilot studies are required and followed by well-designed randomised controlled 
trials. However, all the approaches outlined above may be applicable to improving 
outcomes in people with myeloma cast nephropathy and even CKD.  
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8.7 The Inflammatory Role of Filtered Proteins in CKD  
In both cast nephropathy and CKD, the release of cytokines from PTECs in response to 
activating stimuli, may result in the recruitment of inflammatory cells and progressive 
fibrosis. Whilst cast nephropathy is predominantly caused by monoclonal FLCs, in 
CKD there are a number of factors including the leakage of low molecular weight 
proteins (<40 kDa) and some intermediate molecular weight proteins (40–100 kDa) 
from the glomerulus, which are then presented to PTECs and may be activating these 
cells.(D'Amico and Bazzi 2003) As CKD progresses, the number of functioning 
nephrons declines. This appears to lead to compensatory hypertrophy and 
hyperfiltration occurring in the remaining healthy nephrons.(Kriz and LeHir 2005) This 
leads to the PTECs in these remaining nephrons being exposed to increased quantities 
of low molecular weight proteins and intermediate molecular weight proteins also. The 
most abundant intermediate molecular weight protein is albumin; polyclonal FLCs also 
constitute a significant proportion of low molecular weight proteins filtered. PTECs 
endocytose and process these proteins, and this protein overloading leads to intracellular 
pro-inflammatory signalling, resulting in activation of NF-B and transcription of 
cytokines, notably MCP-1. Thus a self-perpetuating vicious circle is established in 
CKD, which ensures that once nephron loss and fibrosis begins, it is likely to continue.  
 
8.8 The Role of Polyclonal FLCs in CKD 
8.8.1 The Effects of Polyclonal FLCs on PTECs 
One aim of the experiments presented in this thesis was to determine whether 
polyclonal FLCs had a similar pro-inflammatory effect to monoclonal FLCs. Whilst 
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there were no responses to polyclonal FLCs in the experiments, this observation may 
well be due to failure of the cells to endocytose these proteins. The studies presented in 
this thesis have shown that the endocytic receptors of HK-2 cells were functioning 
normally with respect to monoclonal FLCs. However, as the polyclonal FLCs used were 
demonstrated to be pure proteins, produced without the use of any denaturing processes, 
it was presumed that these proteins were handled no differently to any other class of 
protein. In fact the immunofluorescence studies performed on renal biopsies from 
patients with CKD demonstrated that polyclonal FLCs localised to the cytoplasms of 
PTECs. The lack of response of HK-2 cells to delipidated HSA was another factor 
which indicated a problem with endocytosis. While there are studies in the literature 
which demonstrate definite responses of PTECs to delipidated HSA, my own findings 
are not inconsistent with those from previous studies reported by Batuman and Sanders. 
However, it cannot be concluded from my findings that polyclonal FLCs do not have 
pro-inflammatory potential in PTECs without undertaking an endocytosis study, by 
fluorochrome-labelling polyclonal FLCs and observing their co-localisation with cells 
after exposure.  
 
It could be hypothesised that, because the potential toxicity of FLCs varies from one 
light chain clone to another and is caused by the differential ability to generate H2O2, 
which is most likely related to differences in primary structure, polyclonal FLCs may 
well not possess the same pro-inflammatory potential as monoclonal FLCs. Indeed, 
different monoclonal FLCs generated different quantities of H2O2 and induced MCP-1 
release to different degrees in vitro.(Wang and Sanders 2007) It is therefore possible 
that polyclonal FLCs, despite being found in increased concentrations in sera in CKD, 
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do not exert an excess biological effect when compared to other filtered proteins 
because they do not produce H2O2 in the same way as some monoclonal FLCs and 
therefore do not initiate inflammatory signalling. 
 
8.8.2 The Interaction of Uromodulin and Polyclonal FLCs in CKD 
My experiments demonstrated a link in the distal tubule between polyclonal FLCs and 
uromodulin. I observed in CKD, proteinaceous precipitates, similar to casts. The 
distribution of these casts were largely limited to areas of chronic damage. 
Immunofluorescence showed that these proteins consisted of uromodulin, and contained 
polyclonal FLCs. Polyclonal FLCs were shown to bind to uromodulin in vitro with 
more avidity than HSA. The relationship between these casts and markers of 
progression of CKD were examined in detail. It has previously been shown that the 
index of chronic damage, interstitial macrophage numbers and peritubular capillary 
density are interrelated.(Eardley et al. 2006; Eardley et al. 2008) The findings of my 
own studies showed that cast numbers were correlated positively with the index of 
chronic damage and interstitial infiltrating macrophage numbers, and negatively 
correlated with interstitial peritubular capillary density.  
 
These findings raise two broad hypotheses. First, as chronic damage becomes 
established and progresses, the loss of capillary density leads to an ischaemic tubular 
microenvironment. This in turn causes reduced tubular flow and dysregulation of both 
proximal and distal tubular function. There may also be impairment of resorptive 
capacity of PTECs, leading to increased delivery of polyclonal FLCs to the distal 
tubule. Dysregulation of distal tubular function may alter electrolyte content and pH of 
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tubular fluid, perhaps aided in part by medications such patients will be taking, such as 
angiotensin converting enzyme inhibitors and loop diuretics. These factors may 
combine to facilitate cast formation in such tubules. The intra-nephronal obstruction 
then accelerates nephron loss and may represent an important component of the CKD 
pathway. 
 
Second, the presence of these casts in CKD have traditionally not been considered to 
have pathophysiological relevance, and to represent incidental findings in areas of the 
kidney which have already been scarred to a degree beyond functional recovery. 
However, the presence of uromodulin in these casts may be important as uromodulin is 
a molecule which has a complex relationship with the immune system.(Weichhart et al. 
2005) It is capable of activating macrophages via TLR4.(Saemann et al. 2005) and it 
has also been shown that infiltrating macrophages are concentrated in areas of chronic 
damage, where casts were also found in the present studies.(Eardley et al. 2008) 
Tubules in areas of chronic damage may have weakened epithelia and basement 
membranes, permitting the leakage of uromodulin into the interstitium. This might then 
have an additive chemoattractant and activating effect on macrophages. This is 
supported by a recent study, which showed that in CKD, diminishing eGFR was 
associated with increased concentrations of uromodulin in blood and that addition of 
uromodulin to whole blood led to release of inflammatory cytokines.(Prajczer et al. 
2010) Uromodulin has also been shown to facilitate transmigration of neutrophils across 
epithelial membranes.(Schmid et al. 2010) Furthermore, Eardley et al have indicated 
that once significant chronic damage is established, factors other than albuminuria alone 
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may play a part in macrophage recruitment to the kidney.(Eardley et al. 2008) It is 
possible that one such factor is uromodulin.  
 
Additional evidence that uromodulin might be related to development of CKD exists in 
the form of genomic studies. Kottgen et al have shown that single nucleotide 
polymorphisms (SNP) at the UMOD gene locus, which encodes uromodulin, are 
associated with an increased incident risk of CKD.(Kottgen et al. 2009) They 
subsequently also showed that urinary uromodulin concentrations were associated with 
incident risk of CKD.(Kottgen et al. 2010)  
 
8.9 Conclusion 
Collectively, the results presented in this thesis indicate that polyclonal FLCs in CKD 
might promote cast formation in the distal tubules, leading to uromodulin interacting 
with macrophages and thereby promoting fibrosis. This conclusion has considerable 
implications, because it identifies uromodulin as a potential therapeutic target, with the 
aim of delaying the progression of CKD. Thus disrupting the interaction of uromodulin 
with polyclonal FLCs may slow loss of renal function. However, the risks of such an 
approach might be significant, and must be evaluated carefully. One possible therapy 
that is already in use in this setting is the administration of oral sodium bicarbonate to 
patients with CKD who are acidaemic. A recent study showed that bicarbonate 
supplementation in patients with advanced CKD slowed the decline in renal 
function.(de Brito-Ashurst et al. 2009) Although other mechanistic explanations for this 
phenomenon may be important, it is also possible to hypothesise that the resultant 
alkalinisation of urine resulted in fewer casts forming within tubules.  
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The treatment of progressive CKD, in the absence of identifiable underlying diseases 
(e.g. ANCA associated vasculitis, SLE, etc) is usually limited to control of blood 
pressure and diabetes, if either are present, and blockade of the renin-angiotensin 
system. CKD affects a significant proportion of the adult population and constitutes a 
major health economic problem. Identification of additional therapeutic targets are 
therefore crucial. Further studies are now required to elucidate relationships between 
uromodulin, macrophages and fibrosis in CKD.  
 
 
 
 
 
  
 244 
9. PUBLICATIONS & ABSTRACTS FROM THIS THESIS 
9.1 Papers 
9.1.1 Basnayake K, Hutchison C, Kamel D, Sheaff M, Ashman N, Cook M, Oakervee 
H, Bradwell A, Cockwell P: Resolution of cast nephropathy following free light 
chain removal by haemodialysis in a patient with multiple myeloma: a case 
report. J Med Case Reports 2: 380, 2008. 
9.1.2 Basnayake K, Cheung CK, Sheaff M, Fuggle W, Kamel D, Nakoinz N, 
Hutchison CA, Cook M, Stoves J, Bradwell AR, Cockwell P: Differential 
progression of renal scarring and determinants of late renal recovery in sustained 
dialysis dependent acute kidney injury secondary to myeloma kidney. J Clin 
Pathol 63: 884-887, 2010. 
9.1.3 Basnayake K, Ying WZ, Wang PX, Sanders PW: Immunoglobulin light chains 
activate tubular epithelial cells through redox signaling. J Am Soc Nephrol 21: 
1165-1173, 2010. 
9.1.4 Ying WZ, Wang PX, Aaron KJ, Basnayake K, Sanders PW: Immunoglobulin 
light chains activate NF-B in renal epithelial cells through a Src-dependent 
mechanism. Blood: In press.  
 
9.2 Abstracts 
9.2.1 Basnayake K, Cheung CK, Hutchison CA, Stringer SJ, Cook M, Rylance P, et 
al. Differential progression of renal scarring and determinants of late renal 
recovery in sustained dialysis dependent acute kidney injury secondary to 
myeloma kidney. .  British Renal Society/Renal Association Conference; 2010; 
Manchester 2010. 
 
 
  
 245 
9.2.2 Basnayake K, Ying WZ, Wang PX, Cockwell P, Bradwell AR, Hutchison CA, 
et al. Myeloma Light Chains Activate Tubular Epithelial Cells by a c-Src 
Mediated Redox Signaling Mechanism. .  British Renal Society/Renal 
Association Conference; 2010; Manchester 2010. 
9.2.3 Basnayake K, Ghonemy T, Sanders PW, Hutchison CA, Stringer SJ, Bradwell 
AR, et al. An assessment of the pathogenicity of polyclonal immunoglobulin 
free light chains in chronic kidney disease. .  British Renal Society/Renal 
Association Conference; 2010; Manchester2010. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 246 
10. APPENDIX 
A.1 Antibodies Used for IHC    
Target Antigen Label Dilution  Species Vendor/Product No 
Albumin (Hu) - 1:2500 Sh(PC) /PC032 
Calbindin D28K 
(Hu) 
- 1:3000 Mo(MC) Sigma-
Aldrich/C9848 
CD34 (Hu) - 1:25 Mo(MC) Dako/M7165 
CD68 (Hu) - 1:200 Mo(MC) Dako/M0814 
Cubilin (Y20); (Hu) - 1:250 Gt(PC) Santa Cruz 
GAPDH (Hu) - 1:10000 Mo(MC) Abcam 
Gt Ig’s HrP 1:20000 Dk(PC) Santa Cruz 
IgA  chain (Hu) FITC 1:100 Sh(PC) /AF010 
IgA  chain (Hu) - 1:2500 Sh(PC) /AU010 
IgG (Mo) DyLight 549 1:100 Sh(PC) The Binding 
Site/AU271 
IgG  chain (Hu) FITC 1:100 Sh(PC) /AF004 
IgG  chain (Hu) - 1:2500  Sh(PC) /AU004 
IgM µ chain (Hu) FITC 1:100 Sh(PC) /AF012 
IgM µ chain (Hu) - 1:2500 Sh(PC) /AU012 
Megalin (C19); (Hu) - 1:250 Gt(PC) Santa Cruz 
Mo Ig’s  biotinylated 1:100 Rb(PC) Dako/E0354 
Mo IgG1 isotype - 1:100 Mo(MC) Dako/X0931 
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Target Antigen Label Dilution  Species Vendor/Product No 
Phospho-cSrc 
(Y416); (Hu) 
- 1:1000 Rb(PC) Cell Signalling 
Rb Ig’s HrP 1:5000 Sh(PC) /AP311  
Sh Ig’s  HrP 1:5000 Dk(PC) /AP360 
Sh IgG isotype FITC 1:100 Sh(PC)  
Total c-Src (Hu) - 1:1000 Rb(PC) Cell Signalling 
Transferrin (Hu) - 1:2500 Sh(PC) /PC070 
Uromodulin (Hu) DyLight 549 1:100 Sh(PC) /PC071 
 FLC (Hu) FITC 1:100 Sh(PC) /PX016 
 LC (Hu) - 1:2500 Rb(PC) Dako/A0191 
 LC (Hu) HrP 1:2500 Sh(PC) /AP015 
 LC (Hu) - - Sh(PC) /AU015 
 FLC (Hu) DyLight 649 1:50 Sh(PC) /PX018 
 LC (Hu) -  Rb(PC) Dako/A0193 
 LC (Hu) HrP 1:2500 Sh(PC) /AP017 
 LC (Hu) - - Sh(PC) /AU017 
Sh, sheep; Hu, human Mo, mouse; MC, monoclonal; PC, polyclonal; Rb, rabbit; Gt, 
goat; Dk, donkey;  
 
A.2 Buffers and Solutions    
Solution or Buffer Recipe 
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Solution or Buffer Recipe 
4',6-diamidino-2-phenylindole, 
dilactate (DAPI) 
Stock (10.95 mM): 10 mg lyophilised powder 
dissolved in 2 ml in ddH2O  
Working solution (300 nM): Stock diluted 
1:36500 in PBS  
Acetate buffer for coupling Sodium acetate 0.1 M 
Sodium chloride 0.5 M 
Water 
pH corrected to 4.0 with acetic acid 
Acetic acid 0.02 Normal 1 ml glacial acetic acid (Fisher Scientific)  
869 ml cell culture grade water (Invitrogen)  
AEC staining solution  AEC stock 0.5 ml 
Acetate buffer 9.5 ml () 
Filter 
Hydrogen peroxide 6 µl.  
Avidin and biotin block 0.1% avidin in Tris-HCl, ready-to-use 
0.01% biotin in Tris-HCl, ready-to-use  
(Dako) 
Citrate buffer for HIER Tri-sodium citrate 0.01 M (Sigma-Aldrich)  
pH corrected to 6.0 
Coomassie – destain solution Ethanol 15% v/v  
Acetic acid 7.5% v/v 
Coomassie – Fixative solution Ethanol 40 % v/v 
Acetic acid  10% v/v 
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Solution or Buffer Recipe 
Coupling buffer for Sepharose Sodium hydrogen carbonate 0.1 M 
Sodium chloride 0.5 M 
Water 
pH corrected to 8.3  
Glycine elution buffer Glycine 0.1 M (Sigma-Aldrich)  
pH corrected to 3.0 
Goat serum block Wash buffer 
Goat serum 10% v/v (Dako) 
HCl for coupling 1000 ml water; remove 83.3 µl 
83.3 µl concentrated (11 M) HCl  
HK-2 cell freezing medium DMSO 7.5% v/v (Sigma-Aldrich) 
K-SFM (Invitrogen)  
Hydrogen peroxide block Methanol (Fisher Scientific)  
Hydrogen peroxide (Sigma-Aldrich) 0.3% v/v  
Mouse serum block Wash buffer 
Mouse serum 10% v/v (Dako) 
Neutralisation buffer for elutants Tris 2 M  
Sodium chloride 1.5 M 
pH corrected to 8.0  
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Solution or Buffer Recipe 
Phosphate buffered saline  
(PBS) 
 
 
Variation: PBS-T, Tween-20 added 
Sodium dihydrogen orthophosphate 25 mM 
(Sigma-Aldrich)  
Sodium chloride 150 mM (Sigma-Aldrich) 
pH corrected to 7.2 
Tween-20 (Sigma-Aldrich) 0.05% added to 
some solutions 
Phosphate buffered saline for cell 
culture (PBS) 
Ready-to-use (Invitrogen)  
Rabbit serum (normal) Wash buffer 
Rabbit serum 10% v/v (Dako) 
Rabbit serum block Wash buffer 
Rabbit serum 10% v/v (Dako) 
Rat tail collagen - coating, 5 µg/ml  1 ml Rat tail collagen type 1 (Invitrogen)  
Dilute 1:1000 in 0.02 Normal acetic acid  
 
Sheep serum block Wash buffer  
Sheep serum 10% v/v () 
Silver stain – developer solution Sodium carbonate 2.5 g 
Formaldehyde 8 µl  
Make to 100 ml in ultrapure water  
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Solution or Buffer Recipe 
Silver stain – sensitisation reagent  Sodium acetate 3.4 g 
Sodium thiosulphate 0.1 g 
Industrial methylated spirit 15 ml 
Glutaraldehyde 0.26 ml 
Make to 50 ml with ultrapure water  
Silver stain – silver solution  Silver nitrate 0.05 – 0.06 g 
Formaldehyde 7 µl 
Make to 50 ml in ultrapure water 
Silver stain – stop solution  Tris 25 g 
Acetic acid 11 ml 
Make to 500 ml in ultrapure water  
Size-exclusion chromatography 
(SEC) buffer 
Sodium chloride 200 mM 
Sodium dihydrogen orthophosphate 25 mM 
pH corrected to 7.2 
Sodium borate buffer (antibody 
labelling) 
Sodium borate 0.67 M, pH 8.5, ready-to-use 
(Thermo Scientific Pierce)  
Sudan black B (0.1% w/v) 5 ml 70% ethanol (Fisher Scientific) v/v in 
ddH2O 
5 mg Sudan black B (Sigma-Aldrich) 
Tris-buffered saline  
(TBS) 
 
Variation: TBS-T, Tween-20 added 
Tris 50 mM (Sigma-Aldrich) 
Sodium chloride 150 mM  
pH corrected to 7.6 
Tween-20 0.05% added to some solutions 
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Solution or Buffer Recipe 
Tris-HCl for coupling Sodium chloride 0.5 M 
Tris 0.2 M 
Water 
pH corrected to 8.0 
Filtered to 0.45 µm 
Trypsin for cell detachment Trypsin 0.05%, EDTA 0.2 g/L, ready-to-use 
(Invitrogen)  
Western blotting blocking solution Skim milk (Marvel or Bio-Rad) 5% w/v 
TBS-T  
ddH2O, deionised distilled water;  
 
A.3 SDS-PAGE - Gel Recipes and Calculation of Measures  
 Stacking Gel Resolving Gel 
 4% 7.5% 12% X% 
40% Acrylamide/Bis 2.5ml 18.8ml 30ml 2.5(X%) = A 
0.5M Tris-HCl, pH6.8 6.3ml - - - 
1.5M Tris-HCl pH8.8 - 25ml 25ml 25ml 
10% SDS 250µl 1ml 1ml 1ml 
dH2O 15.9ml 54.7ml 43.5ml 73.5ml – A 
TEMED 25µl 50µl 50µl 50µl 
10% APS 125µl 500µl 500µl 500µl 
Total Volume 25ml 100ml 100ml 100ml 
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A.4 Useful Common Protein Extinction Coefficients for A280 Measurements  
Protein Extinction Coefficient 
Human albumin 4.5 
Human Ig free light chain 11.8 
Human IgG 13.8 
Sheep IgG 14.5 
 
A.5 BCA Assay Standards, Working Range 20 – 2000 µg/ml 
Vial Diluent Volume 
(µl) 
BSA Volume  
(µl) 
Final BSA Conc 
(µg/ml) 
A 0 300 of stock 2000 
B 125 375 of stock 1500 
C 325 325 of stock 1000 
D 175 175 of vial B 750 
E 325 325 of vial C 500 
F 325 325 of vial E 250 
G 325 325 of vial F 125 
H 400 100 of vial G 25 
I 400 0 0 
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A.6 Useful Numbers for Cell Culture  
Dish/Plate Area (mm
2
) Seeding 
Density 
Cells at 
Confluency 
Trypsin 
Vol (ml) 
Medium 
Vol (ml) 
35 mm 962 0.3 x 10
6
 1.2 x 10
6
 1 2 
60 mm 2827 0.8 x 10
6
 3.2 x 10
6
 2 3 
100 mm 7854 2.2 x 10
6
 8.8 x 10
6
 3 10 
150 mm 17671 5.0 x 10
6
 20.0 x 10
6
 8 20 
6-well 962 0.3 x 10
6
 1.2 x 10
6
 2 3-5 
12-well 401 0.1 x 10
6
 0.4 x 10
6
 1 1-2 
24-well 200 0.05 x 10
6
 0.2x 10
6
 0.5 0.5-1.0 
T-25 2500 0.7 x 10
6
 2.8 x 10
6
 3 3-5 
T-75 7500 2.1 x 10
6
 8.4 x 10
6
 5 8-15 
T-160 16000 4.6 x 10
6
 18.4 x 10
6
 10 15-30 
Number of cells varies with cell type, these numbers are a rough guide.  
 
A.7 Amino Acids   
Amino Acid Abbreviation 1-Letter Hydropathy Score 
Alanine Ala A 1.8 
Arginine Arg R -4.5 
Asparagine Asn N -3.5 
Aspartic Acid Asp D -3.5 
Cysteine Cys C 2.5 
Glutamic Acid Glu E -3.5 
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Amino Acid Abbreviation 1-Letter Hydropathy Score 
Glutamine Gln Q -3.5 
Glycine Gly G -0.4 
Histidine His H -3.2 
Isoleucine Ile I 4.5 
Leucine Leu L 3.8 
Lysine Lys K -3.9 
Methionine Met M 1.9 
Phenylalanine Phe F 2.8 
Proline Pro P -1.6 
Serine Ser S -0.8 
Threonine Thr T -0.7 
Tryptophan Trp W -0.9 
Tyrosine Tyr Y -1.3 
Valine  Val V 4.2 
 
 
A.8 E-TOXATE Endotoxin Assay Interpretation of Results 
Tube Interpretation 
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Tube Interpretation 
A 
Sample 
B 
Sample 
(LAL 
Inhibitor 
Control) 
C 
Negative 
Control 
D – I 
Endotoxin 
Standards 
 
Result  
- + - + Endotoxin at a level below the detection 
limits of assay. 
+ + - + Sample contains endotoxin equal to, or 
greater than, the amount present in the 
most dilute Endotoxin Standard giving a 
positive result. 
+ + + + Since negative control shows a hard gel, 
endotoxin contamination of water, 
glassware or LAL reagent is present.  
- - - + Absence of hard gel in Tube B and 
presence of hard gel in Tube D show that 
sample contains an inhibitor of LAL 
reagent. Test is not valid. 
-/+ -/+ - - LAL reagent or endotoxin standard has 
deteriorated. Sample results are not valid 
unless Tubes B and D show hard gels. 
Tubes D – I contain endotoxin standards at 0.5 – 0.015 EU/ml 
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A.9 Normal HK-2 Cells 
 
A.10 A Neubauer Haemocytometer  
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A.11 siRNA Mode of Action 
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A.12 Chromatography Apparatus  
 
  
  
 260 
11.  REFERENCES 
 
Abbate, M., Zoja, C., Corna, D., et al. 1998. In progressive nephropathies, overload of 
tubular cells with filtered proteins translates glomerular permeability 
dysfunction into cellular signals of interstitial inflammation. J Am Soc Nephrol, 
9, 1213-24. 
Abraham, G. N. & Waterhouse, C. 1974. Evidence for defective immunoglobulin 
metabolism in severe renal insufficiency. Am J Med Sci, 268, 227-33. 
Abraham, R. S., Geyer, S. M., Price-Troska, T. L., et al. 2003. Immunoglobulin light 
chain variable (V) region genes influence clinical presentation and outcome in 
light chain-associated amyloidosis (AL). Blood, 101, 3801-8. 
Abuelo, J. G. 2007. Normotensive ischemic acute renal failure. N Engl J Med, 357, 797-
805. 
Alpers, C. E., Magil, A. B. & Gown, A. M. 1989. Macrophage origin of the 
multinucleated cells of myeloma cast nephropathy. Am J Clin Pathol, 92, 662-5. 
Alpers, C. E., Tu, W. H., Hopper, J., Jr., et al. 1985. Single light chain subclass (kappa 
chain) immunoglobulin deposition in glomerulonephritis. Hum Pathol, 16, 294-
304. 
Ancsin, J. B. & Kisilevsky, R. 2001. Serum amyloid A peptide interactions with 
glycosaminoglycans. Evaluation by affinity chromatography. Methods Mol Biol, 
171, 449-456. 
Anders, H. J., Banas, B. & Schlondorff, D. 2004. Signaling danger: toll-like receptors 
and their potential roles in kidney disease. J Am Soc Nephrol, 15, 854-67. 
Arakawa, T. & Timasheff, S. N. 1985. Theory of protein solubility. Methods Enzymol, 
114, 49-77. 
Arimura, A., Li, M. & Batuman, V. 2006. Potential protective action of pituitary 
adenylate cyclase-activating polypeptide (PACAP38) on in vitro and in vivo 
models of myeloma kidney injury. Blood, 107, 661-8. 
Bang, F. B. 1956. A bacterial disease of Limulus polyphemus. Bull Johns Hopkins 
Hosp, 98, 325-51. 
Baschong, W., Suetterlin, R. & Laeng, R. H. 2001. Control of autofluorescence of 
archival formaldehyde-fixed, paraffin-embedded tissue in confocal laser 
scanning microscopy (CLSM). J Histochem Cytochem, 49, 1565-72. 
Basnayake, K., Ying, W. Z., Wang, P. X., et al. 2010. Immunoglobulin light chains 
activate tubular epithelial cells through redox signaling. J Am Soc Nephrol, 21, 
1165-73. 
Bate, K. L., Clouston, D., Packham, D., et al. 1998. Lambda light chain induced 
nephropathy: a rare cause of the Fanconi syndrome and severe osteomalacia. Am 
J Kidney Dis, 32, E3. 
Bates, J. M., Raffi, H. M., Prasadan, K., et al. 2004. Tamm-Horsfall protein knockout 
mice are more prone to urinary tract infection: rapid communication. Kidney Int, 
65, 791-7. 
Batuman, V., Dreisbach, A. W. & Cyran, J. 1990. Light-chain binding sites on renal 
brush-border membranes. Am J Physiol, 258, F1259-65. 
Batuman, V. & Guan, S. 1997. Receptor-mediated endocytosis of immunoglobulin light 
chains by renal proximal tubule cells. Am J Physiol, 272, F521-30. 
  
 261 
Batuman, V., Guan, S., O'Donovan, R., et al. 1994. Effect of myeloma light chains on 
phosphate and glucose transport in renal proximal tubule cells. Ren Physiol 
Biochem, 17, 294-300. 
Batuman, V., Sastrasinh, M. & Sastrasinh, S. 1986. Light chain effects on alanine and 
glucose uptake by renal brush border membranes. Kidney Int, 30, 662-5. 
Batuman, V., Verroust, P. J., Navar, G. L., et al. 1998. Myeloma light chains are ligands 
for cubilin (gp280). Am J Physiol, 275, F246-54. 
Bellotti, V., Mangione, P. & Merlini, G. 2000. Review: immunoglobulin light chain 
amyloidosis--the archetype of structural and pathogenic variability. J Struct Biol, 
130, 280-9. 
Berggard, I. & Peterson, P. A. 1969. Polymeric forms of free normal kappa and lambda 
chains of human immunoglobulin. J Biol Chem, 244, 4299-307. 
Bienert, G. P., Moller, A. L., Kristiansen, K. A., et al. 2007. Specific aquaporins 
facilitate the diffusion of hydrogen peroxide across membranes. J Biol Chem, 
282, 1183-92. 
Birn, H. & Christensen, E. I. 2006. Renal albumin absorption in physiology and 
pathology. Kidney Int, 69, 440-9. 
Birn, H., Spiegelstein, O., Christensen, E. I., et al. 2005. Renal tubular reabsorption of 
folate mediated by folate binding protein 1. J Am Soc Nephrol, 16, 608-15. 
Birn, H., Vorum, H., Verroust, P. J., et al. 2000. Receptor-associated protein is 
important for normal processing of megalin in kidney proximal tubules. J Am 
Soc Nephrol, 11, 191-202. 
Blade, J., Fernandez-Llama, P., Bosch, F., et al. 1998. Renal failure in multiple 
myeloma: presenting features and predictors of outcome in 94 patients from a 
single institution. Arch Intern Med, 158, 1889-93. 
Bland, J. M. & Altman, D. G. 1986. Statistical methods for assessing agreement 
between two methods of clinical measurement. Lancet, 1, 307-10. 
Bock, H. A. 1997. Pathogenesis of acute renal failure: new aspects. Nephron, 76, 130-
42. 
Bohne, S., Sletten, K., Menard, R., et al. 2004. Cleavage of AL amyloid proteins and 
AL amyloid deposits by cathepsins B, K, and L. J Pathol, 203, 528-37. 
Bonvini, P., Zorzi, E., Basso, G., et al. 2007. Bortezomib-mediated 26S proteasome 
inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic 
large cell lymphoma. Leukemia, 21, 838-42. 
Bradwell, A. R. 2006. Serum Free Light Chain Analysis, Birmingham, The Binding Site 
Ltd. 
Bradwell, A. R. 2010. Serum Free Light Chain Analysis, Birmingham, The Binding Site 
Ltd. 
Bradwell, A. R., Carr-Smith, H. D., Mead, G. P., et al. 2001. Highly sensitive, 
automated immunoassay for immunoglobulin free light chains in serum and 
urine. Clin Chem, 47, 673-80. 
Brown, M. T. & Cooper, J. A. 1996. Regulation, substrates and functions of src. 
Biochim Biophys Acta, 1287, 121-49. 
Bruccoleri, R. E., Haber, E. & Novotny, J. 1988. Structure of antibody hypervariable 
loops reproduced by a conformational search algorithm. Nature, 335, 564-8. 
Bruneval, P., Foidart, J. M., Nochy, D., et al. 1985. Glomerular matrix proteins in 
nodular glomerulosclerosis in association with light chain deposition disease and 
diabetes mellitus. Hum Pathol, 16, 477-84. 
  
 262 
Burton, C. J., Combe, C., Walls, J., et al. 1999. Secretion of chemokines and cytokines 
by human tubular epithelial cells in response to proteins. Nephrol Dial 
Transplant, 14, 2628-33. 
Camargo, M. J., Sumpio, B. E. & Maack, T. 1984. Kinetics of renal catabolism of 
absorbed proteins: influence of lysosomal pH. Contrib Nephrol, 42, 19-29. 
Catalan, M. P., Subira, D., Reyero, A., et al. 2003. Regulation of apoptosis by lethal 
cytokines in human mesothelial cells. Kidney Int, 64, 321-30. 
Chothia, C. & Lesk, A. M. 1987. Canonical structures for the hypervariable regions of 
immunoglobulins. J Mol Biol, 196, 901-17. 
Chothia, C., Lesk, A. M., Tramontano, A., et al. 1989. Conformations of 
immunoglobulin hypervariable regions. Nature, 342, 877-83. 
Christensen, E. I. & Birn, H. 2001. Megalin and cubilin: synergistic endocytic receptors 
in renal proximal tubule. Am J Physiol Renal Physiol, 280, F562-73. 
Christensen, E. I. & Nielsen, R. 2006. Role of megalin and cubilin in renal physiology 
and  
pathophysiology. Reviews of Physiology, Biochemistry and Pharmacology. Heidelberg: 
Springer Berlin Heidelberg. 
Cicchetti, D. V. & Feinstein, A. R. 1990. High agreement but low kappa: II. Resolving 
the paradoxes. J Clin Epidemiol, 43, 551-558. 
Clark, W. F., Stewart, A. K., Rock, G. A., et al. 2005. Plasma exchange when myeloma 
presents as acute renal failure: a randomized, controlled trial.[see 
comment][summary for patients in Ann Intern Med. 2005 Dec 6;143(11):I20; 
PMID: 16330784]. Annals of Internal Medicine, 143, 777-84. 
Clyne, D. H., Pesce, A. J. & Thompson, R. E. 1979. Nephrotoxicity of Bence Jones 
proteins in the rat: importance of protein isoelectric point. Kidney Int, 16, 345-
52. 
Clyne, D. H. & Pollak, V. E. 1981. Renal handling and pathophysiology of Bence Jones 
proteins. Contrib Nephrol, 24, 78-87. 
Cohen, G., Haag-Weber, M., Mai, B., et al. 1995. Effect of immunoglobulin light 
chains from hemodialysis and continuous ambulatory peritoneal dialysis patients 
on polymorphonuclear leukocyte functions. J Am Soc Nephrol, 6, 1592-9. 
Cohen, G., Rudnicki, M., Deicher, R., et al. 2003. Immunoglobulin light chains 
modulate polymorphonuclear leucocyte apoptosis. Eur J Clin Invest, 33, 669-76. 
Cohen, J. 1960. A coefficient of agreement for nominal scales. Educ Psychol Meas, 20, 
37-46. 
Comenzo, R. L., Zhang, Y., Martinez, C., et al. 2001. The tropism of organ involvement 
in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use 
and clonal plasma cell burden. Blood, 98, 714-20. 
Cooper, J. A. & Howell, B. 1993. The when and how of Src regulation. Cell, 73, 1051-
4. 
Cowen, T., Haven, A. J. & Burnstock, G. 1985. Pontamine sky blue: a counterstain for 
background autofluorescence in fluorescence and immunofluorescence 
histochemistry. Histochemistry, 82, 205-8. 
D'Amico, G. & Bazzi, C. 2003. Pathophysiology of proteinuria. Kidney Int, 63, 809-25. 
Darby, I., Skalli, O. & Gabbiani, G. 1990. Alpha-smooth muscle actin is transiently 
expressed by myofibroblasts during experimental wound healing. Lab Invest, 63, 
21-9. 
  
 263 
Day, E. D. 1990. The Light Chains of Immunoglobulins. In: Day, E. D. (ed.) Advanced 
Immunochemistry. New York: Wiley. 
de Brito-Ashurst, I., Varagunam, M., Raftery, M. J., et al. 2009. Bicarbonate 
supplementation slows progression of CKD and improves nutritional status. J 
Am Soc Nephrol, 20, 2075-84. 
Decourt, C., Bridoux, F., Touchard, G., et al. 2003. A monoclonal V kappa l light chain 
responsible for incomplete proximal tubulopathy. Am J Kidney Dis, 41, 497-504. 
DeFronzo, R. A., Cooke, C. R., Wright, J. R., et al. 1978. Renal function in patients 
with multiple myeloma. Medicine (Baltimore), 57, 151-66. 
Dember, L. M. 2006. Amyloidosis-associated kidney disease. J Am Soc Nephrol, 17, 
3458-71. 
Dember, L. M., Sanchorawala, V., Seldin, D. C., et al. 2001. Effect of dose-intensive 
intravenous melphalan and autologous blood stem-cell transplantation on al 
amyloidosis-associated renal disease. Ann Intern Med, 134, 746-53. 
Denoroy, L., Deret, S. & Aucouturier, P. 1994. Overrepresentation of the V kappa IV 
subgroup in light chain deposition disease. Immunol Lett, 42, 63-6. 
Deret, S., Chomilier, J., Huang, D. B., et al. 1997. Molecular modeling of 
immunoglobulin light chains implicates hydrophobic residues in non-amyloid 
light chain deposition disease. Protein Eng, 10, 1191-7. 
Deret, S., Denoroy, L., Lamarine, M., et al. 1999. Kappa light chain-associated 
Fanconi's syndrome: molecular analysis of monoclonal immunoglobulin light 
chains from patients with and without intracellular crystals. Protein Eng, 12, 
363-9. 
DeYulia, G. J., Jr., Carcamo, J. M., Borquez-Ojeda, O., et al. 2005. Hydrogen peroxide 
generated extracellularly by receptor-ligand interaction facilitates cell signaling. 
Proc Natl Acad Sci U S A, 102, 5044-9. 
Divry, P. & Florkin, M. 1927. Sur les proprietes optiques de l'amyloide. C R Soc Biol, 
97, 1808-1810. 
Dominici, S., Valentini, M., Maellaro, E., et al. 1999. Redox modulation of cell surface 
protein thiols in U937 lymphoma cells: the role of gamma-glutamyl 
transpeptidase-dependent H2O2 production and S-thiolation. Free Radic Biol 
Med, 27, 623-35. 
Duque, N., Gomez-Guerrero, C. & Egido, J. 1997. Interaction of IgA with Fc alpha 
receptors of human mesangial cells activates transcription factor nuclear factor-
kappa B and induces expression and synthesis of monocyte chemoattractant 
protein-1, IL-8, and IFN-inducible protein 10. J Immunol, 159, 3474-82. 
Dwulet, F. E., O'Connor, T. P. & Benson, M. D. 1986. Polymorphism in a kappa I 
primary (AL) amyloid protein (BAN). Mol Immunol, 23, 73-8. 
Eardley, K. S., Kubal, C., Zehnder, D., et al. 2008. The role of capillary density, 
macrophage infiltration and interstitial scarring in the pathogenesis of human 
chronic kidney disease. Kidney Int. 
Eardley, K. S., Zehnder, D., Quinkler, M., et al. 2006. The relationship between 
albuminuria, MCP-1/CCL2, and interstitial macrophages in chronic kidney 
disease. Kidney Int, 69, 1189-97. 
Edelman, G. M., Gall, W. E., Waxdal, M. J., et al. 1968. The covalent structure of a 
human gamma G-immunoglobulin. I. Isolation and characterization of the whole 
molecule, the polypeptide chains, and the tryptic fragments. Biochemistry, 7, 
1950-8. 
  
 264 
Elbashir, S. M., Harborth, J., Lendeckel, W., et al. 2001. Duplexes of 21-nucleotide 
RNAs mediate RNA interference in cultured mammalian cells. Nature, 411, 
494-8. 
Enqvist, S., Sletten, K., Stevens, F. J., et al. 2007. Germ line origin and somatic 
mutations determine the target tissues in systemic AL-amyloidosis. PLoS ONE, 
2, e981. 
Feinstein, A. R. & Cicchetti, D. V. 1990. High agreement but low kappa: I. The 
problems of two paradoxes. J Clin Epidemiol, 43, 543-549. 
Fish, R., Pinney, J., Jain, P., et al. 2010. The Incidence of Major Hemorrhagic 
Complications After Renal Biopsies in Patients with Monoclonal 
Gammopathies. Clin J Am Soc Nephrol. 
Fletcher, A. P., Neuberger, A. & Ratcliffe, W. A. 1970a. Tamm-Horsfall urinary 
glycoprotein. The chemical composition. Biochem J, 120, 417-24. 
Fletcher, A. P., Neuberger, A. & Ratcliffe, W. A. 1970b. Tamm-Horsfall urinary 
glycoprotein. The subunit structure. Biochem J, 120, 425-32. 
Furness, P. N., Rogers-Wheatley, L. & Harris, K. P. 1997. Semiautomatic quantitation 
of macrophages in human renal biopsy specimens in proteinuric states. J Clin 
Pathol, 50, 118-22. 
Gallo, G., Picken, M., Frangione, B., et al. 1988. Nonamyloidotic monoclonal 
immunoglobulin deposits lack amyloid P component. Mod Pathol, 1, 453-6. 
Ganeval, D., Noel, L. H., Preud'homme, J. L., et al. 1984. Light-chain deposition 
disease: its relation with AL-type amyloidosis. Kidney Int, 26, 1-9. 
Gertz, M. A. 2005. Managing myeloma kidney.[comment]. Annals of Internal 
Medicine, 143, 835-7. 
Giannoni, E., Buricchi, F., Raugei, G., et al. 2005. Intracellular reactive oxygen species 
activate Src tyrosine kinase during cell adhesion and anchorage-dependent cell 
growth. Mol Cell Biol, 25, 6391-403. 
Gilmore, T. D. & Herscovitch, M. 2006. Inhibitors of NF-kappaB signaling: 785 and 
counting. Oncogene, 25, 6887-99. 
Glockshuber, R., Steipe, B., Huber, R., et al. 1990. Crystallization and preliminary X-
ray studies of the VL domain of the antibody McPC603 produced in Escherichia 
coli. J Mol Biol, 213, 613-5. 
Goldfarb, S. & Golper, T. A. 1994. Proinflammatory cytokines and hemofiltration 
membranes. J Am Soc Nephrol, 5, 228-32. 
Goni, F. & Gallo, G. 2005. Extraction and chemical characterization of tissue-deposited 
proteins from minute diagnostic biopsy specimens. Methods Mol Biol, 299, 261-
6. 
Goranov, S. 1996. Acute renal failure in patients with multiple myeloma. Folia Med 
(Plovdiv), 38, 57-63. 
Gottenberg, J. E., Aucouturier, F., Goetz, J., et al. 2007. Serum immunoglobulin free 
light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome. 
Ann Rheum Dis, 66, 23-7. 
Grandaliano, G., Gesualdo, L., Ranieri, E., et al. 1996. Monocyte chemotactic peptide-1 
expression in acute and chronic human nephritides: a pathogenetic role in 
interstitial monocytes recruitment. J Am Soc Nephrol, 7, 906-13. 
Guan, S., el-Dahr, S., Dipp, S., et al. 1999. Inhibition of Na-K-ATPase activity and 
gene expression by a myeloma light chain in proximal tubule cells. J Investig 
Med, 47, 496-501. 
  
 265 
Hanke, J. H., Gardner, J. P., Dow, R. L., et al. 1996. Discovery of a novel, potent, and 
Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-
dependent T cell activation. J Biol Chem, 271, 695-701. 
Harmar, A. J., Arimura, A., Gozes, I., et al. 1998. International Union of Pharmacology. 
XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary 
adenylate cyclase-activating polypeptide. Pharmacol Rev, 50, 265-70. 
Hayat, M. A. 2002. Microscopy, Immunohistochemistry and Antigen Retrieval Methods: 
For Light and Electron Microscopy, New York, Kluwer Academic / Plenum 
Publishers. 
Hayden, M. S. & Ghosh, S. 2004. Signaling to NF-kappaB. Genes Dev, 18, 2195-224. 
Heinzelmann, M., Mercer-Jones, M. A. & Passmore, J. C. 1999. Neutrophils and renal 
failure. Am J Kidney Dis, 34, 384-99. 
Herrera, G. A. 2000. Renal manifestations of plasma cell dyscrasias: an appraisal from 
the patients' bedside to the research laboratory. Ann Diagn Pathol, 4, 174-200. 
Herrera, G. A., Joseph, L., Gu, X., et al. 2004. Renal pathologic spectrum in an autopsy 
series of patients with plasma cell dyscrasia. Arch Pathol Lab Med, 128, 875-9. 
Herrera, G. A., Russell, W. J. & Cardelli, J. 2001. Phenotypic transformation of 
mesangial cells precedes and is required for AL-amyloidogenesis in amyloid and 
amyloidosis. In: AA, B. M. (ed.) The Proceedings of the IXth International 
Symposium on Amyloidosis. Budapest: David Apathy. 
Herrera, G. A., Russell, W. J., Isaac, J., et al. 1999. Glomerulopathic light chain-
mesangial cell interactions modulate in vitro extracellular matrix remodeling and 
reproduce mesangiopathic findings documented in vivo. Ultrastruct Pathol, 23, 
107-26. 
Herrera, G. A., Shultz, J. J., Soong, S. J., et al. 1994. Growth factors in monoclonal 
light-chain--related renal diseases. Hum Pathol, 25, 883-92. 
Hoffman, U., Opperman, M., Kuchler, S., et al. 2003. Free immunoglobulin light chains 
in patients with rheumatic diseases. . Z Rheumatol, 62, 1051. 
Holland, M. D., Galla, J. H., Sanders, P. W., et al. 1985. Effect of urinary pH and 
diatrizoate on Bence Jones protein nephrotoxicity in the rat. Kidney Int, 27, 46-
50. 
Howie, A. J., Ferreira, M. A. & Adu, D. 2001. Prognostic value of simple measurement 
of chronic damage in renal biopsy specimens. Nephrol Dial Transplant, 16, 
1163-9. 
Hoyer, J. R. & Seiler, M. W. 1979. Pathophysiology of Tamm-Horsfall protein. Kidney 
Int, 16, 279-89. 
Huang, Z. Q., Kirk, K. A., Connelly, K. G., et al. 1993. Bence Jones proteins bind to a 
common peptide segment of Tamm-Horsfall glycoprotein to promote 
heterotypic aggregation. J Clin Invest, 92, 2975-83. 
Huang, Z. Q. & Sanders, P. W. 1995. Biochemical interaction between Tamm-Horsfall 
glycoprotein and Ig light chains in the pathogenesis of cast nephropathy. Lab 
Invest, 73, 810-7. 
Huang, Z. Q. & Sanders, P. W. 1997. Localization of a single binding site for 
immunoglobulin light chains on human Tamm-Horsfall glycoprotein. J Clin 
Invest, 99, 732-6. 
Hutchison, C. A., Bradwell, A. R., Cook, M., et al. 2009. Treatment of acute renal 
failure secondary to multiple myeloma with chemotherapy and extended high 
cut-off hemodialysis. Clin J Am Soc Nephrol, 4, 745-54. 
  
 266 
Hutchison, C. A., Cockwell, P., Harding, S., et al. 2008a. Quantitative assessment of 
serum and urinary polyclonal free light chains in patients with type II diabetes: 
an early marker of diabetic kidney disease? Expert Opin Ther Targets, 12, 667-
76. 
Hutchison, C. A., Cockwell, P., Reid, S., et al. 2007. Efficient removal of 
immunoglobulin free light chains by hemodialysis for multiple myeloma: in 
vitro and in vivo studies. J Am Soc Nephrol, 18, 886-95. 
Hutchison, C. A., Cook, M., Heyne, N., et al. 2008b. European trial of free light chain 
removal by extended haemodialysis in cast nephropathy (EuLITE): A 
randomised control trial. Trials, 9, 55. 
Hutchison, C. A., Harding, S., Hewins, P., et al. 2008c. Quantitative assessment of 
serum and urinary polyclonal free light chains in patients with chronic kidney 
disease. Clin J Am Soc Nephrol, 3, 1684-90. 
Imai, K., Kusakabe, M., Sakakura, T., et al. 1994. Susceptibility of tenascin to 
degradation by matrix metalloproteinases and serine proteinases. FEBS Lett, 
352, 216-8. 
Imbert, V., Rupec, R. A., Livolsi, A., et al. 1996. Tyrosine phosphorylation of I kappa 
B-alpha activates NF-kappa B without proteolytic degradation of I kappa B-
alpha. Cell, 86, 787-98. 
Issekutz, A. C. 1983. Removal of gram-negative endotoxin from solutions by affinity 
chromatography. J Immunol Methods, 61, 275-81. 
Ivanyi, B. 1989. Renal complications in multiple myeloma. Acta Morphol Hung, 37, 
235-43. 
Jackson, J. H., Berger, E. M. & Repine, J. E. 1988. Thiourea and dimethylthiourea 
decrease human neutrophil bactericidal function in vitro. Inflammation, 12, 515-
24. 
Jackson, P. 2007. Quality assurance in immunochemistry. In: Renshaw, S. (ed.) 
Immunohistochemistry. 1 ed. Bloxham: Scion Publishing Limited. 
Johns, E. A., Turner, R., Cooper, E. H., et al. 1986. Isoelectric points of urinary light 
chains in myelomatosis: analysis in relation to nephrotoxicity. J Clin Pathol, 39, 
833-7. 
Johnson, R. J. 1994. The glomerular response to injury: progression or resolution? 
Kidney Int, 45, 1769-82. 
Kapadia, S. B. 1980. Multiple myeloma: a clinicopathologic study of 62 consecutively 
autopsied cases. Medicine (Baltimore), 59, 380-92. 
Karimi, M., Sletten, K. & Westermark, P. 2003. Biclonal systemic AL-amyloidosis with 
one glycosylated and one nonglycosylated AL-protein. Scand J Immunol, 57, 
319-23. 
Katzmann, J. A., Clark, R. J., Abraham, R. S., et al. 2002. Serum reference intervals and 
diagnostic ranges for free kappa and free lambda immunoglobulin light chains: 
relative sensitivity for detection of monoclonal light chains. Clin Chem, 48, 
1437-44. 
Kawasaki, K., Minoshima, S., Schooler, K., et al. 1995. The organization of the human 
immunoglobulin lambda gene locus. Genome Res, 5, 125-35. 
Keeling, J. & Herrera, G. A. 2005a. matrix composition alters matrix metalloproteinase 
expression in mesangial cells incubated with glomerulopathic light chains. . Lab 
Invest, 85, 267A. 
  
 267 
Keeling, J. & Herrera, G. A. 2005b. Matrix metalloproteinases and mesangial 
remodeling in light chain-related glomerular damage. Kidney Int, 68, 1590-603. 
Keeling, J. & Herrera, G. A. 2005c. MMP-7 expression and the accumulation of 
tenascin in light chain deposition disease mesangial nodules. J Am Soc Nephrol, 
16, 663A  
Keeling, J. & Herrera, G. A. 2009. An in vitro model of light chain deposition disease. 
Kidney Int, 75, 634-45. 
Keeling, J., Teng, J., Herrera, G. A., et al. 2004. AL-amyloidosis and light-chain 
deposition disease light chains induce divergent phenotypic transformations of 
human mesangial cells. Laboratory Investigation, 84, 1322-38. 
Kim, J. R., Yoon, H. W., Kwon, K. S., et al. 2000. Identification of proteins containing 
cysteine residues that are sensitive to oxidation by hydrogen peroxide at neutral 
pH. Anal Biochem, 283, 214-21. 
Kim, L. C., Song, L. & Haura, E. B. 2009. Src kinases as therapeutic targets for cancer. 
Nat Rev Clin Oncol, 6, 587-95. 
Kjellsson, B., Soderstrom, T. & Hanson, L. A. 1987. An ELISA method for 
quantification of Tamm-Horsfall protein using monoclonal antibodies. J 
Immunol Methods, 98, 105-11. 
Klassen, R. B., Allen, P. L., Batuman, V., et al. 2005. Light chains are a ligand for 
megalin. J Appl Physiol, 98, 257-63. 
Knudsen, L. M., Hjorth, M. & Hippe, E. 2000. Renal failure in multiple myeloma: 
reversibility and impact on the prognosis. Nordic Myeloma Study Group. 
European Journal of Haematology, 65, 175-81. 
Kobayashi, K. & Fukuoka, S. 2001. Conditions for solubilization of Tamm-Horsfall 
protein/uromodulin in human urine and establishment of a sensitive and accurate 
enzyme-linked immunosorbent assay (ELISA) method. Arch Biochem Biophys, 
388, 113-20. 
Koss, M. N., Pirani, C. L. & Osserman, E. F. 1976. Experimental Bence Jones cast 
nephropathy. Lab Invest, 34, 579-91. 
Kottgen, A., Glazer, N. L., Dehghan, A., et al. 2009. Multiple loci associated with 
indices of renal function and chronic kidney disease. Nat Genet. 
Kottgen, A., Hwang, S. J., Larson, M. G., et al. 2010. Uromodulin levels associate with 
a common UMOD variant and risk for incident CKD. J Am Soc Nephrol, 21, 
337-44. 
Kozyraki, R., Fyfe, J., Verroust, P. J., et al. 2001. Megalin-dependent cubilin-mediated 
endocytosis is a major pathway for the apical uptake of transferrin in polarized 
epithelia. Proc Natl Acad Sci U S A, 98, 12491-6. 
Kreft, B., Jabs, W. J., Laskay, T., et al. 2002. Polarized expression of Tamm-Horsfall 
protein by renal tubular epithelial cells activates human granulocytes. Infect 
Immun, 70, 2650-6. 
Kriz, W. & LeHir, M. 2005. Pathways to nephron loss starting from glomerular 
diseases-insights from animal models. Kidney Int, 67, 404-19. 
Kumar, G. L. & Rudbeck, L. 2009. Immunohistochemical Staining Methods, 
Carpinteria, Dako. 
Kumar, R., Schaefer, J., Grande, J. P., et al. 1994. Immunolocalization of calcitriol 
receptor, 24-hydroxylase cytochrome P-450, and calbindin D28k in human 
kidney. Am J Physiol, 266, F477-85. 
  
 268 
Kumar, S. & Muchmore, A. 1990. Tamm-Horsfall protein--uromodulin (1950-1990). 
Kidney Int, 37, 1395-401. 
Kyle, R. A. 1975. Multiple myeloma: review of 869 cases. Mayo Clin Proc, 50, 29-40. 
Kyle, R. A., Gertz, M. A., Witzig, T. E., et al. 2003. Review of 1027 patients with 
newly diagnosed multiple myeloma. Mayo Clin Proc, 78, 21-33. 
Kyle, R. A. & Rajkumar, S. V. 2004. Multiple myeloma. N Engl J Med, 351, 1860-73. 
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., et al. 2006. Prevalence of monoclonal 
gammopathy of undetermined significance. N Engl J Med, 354, 1362-9. 
Kyle, R. A., Wagoner, R. D. & Holley, K. E. 1982. Primary systemic amyloidosis: 
resolution of the nephrotic syndrome with melphalan and prednisone. Arch 
Intern Med, 142, 1445-7. 
Lacy, M. Q. & Gertz, M. A. 1999. Acquired Fanconi's syndrome associated with 
monoclonal gammopathies. Hematol Oncol Clin North Am, 13, 1273-80. 
Lathe, G. H. & Ruthven, C. R. 1956. The separation of substances and estimation of 
their relative molecular sizes by the use of colums of starch in water. Biochem J, 
62, 665-74. 
Leung, N., Dispenzieri, A., Fervenza, F. C., et al. 2005. Renal response after high-dose 
melphalan and stem cell transplantation is a favorable marker in patients with 
primary systemic amyloidosis. Am J Kidney Dis, 46, 270-7. 
Li, M., Balamuthusamy, S., Simon, E. E., et al. 2008a. Silencing megalin and cubilin 
genes inhibits myeloma light chain endocytosis and ameliorates toxicity in 
human renal proximal tubule epithelial cells. Am J Physiol Renal Physiol, 295, 
F82-90. 
Li, M., Cortez, S., Nakamachi, T., et al. 2006. Pituitary adenylate cyclase-activating 
polypeptide is a potent inhibitor of the growth of light chain-secreting human 
multiple myeloma cells. Cancer Res, 66, 8796-803. 
Li, M., Hering-Smith, K. S., Simon, E. E., et al. 2008b. Myeloma light chains induce 
epithelial-mesenchymal transition in human renal proximal tubule epithelial 
cells. Nephrol Dial Transplant, 23, 860-70. 
Li, M., Maderdrut, J. L., Lertora, J. J., et al. 2008c. Renoprotection by pituitary 
adenylate cyclase-activating polypeptide in multiple myeloma and other kidney 
diseases. Regul Pept, 145, 24-32. 
Li, M., Maderdrut, J. L., Lertora, J. J., et al. 2007. Intravenous infusion of pituitary 
adenylate cyclase-activating polypeptide (PACAP) in a patient with multiple 
myeloma and myeloma kidney: a case study. Peptides, 28, 1891-5. 
Li, S. D., Chono, S. & Huang, L. 2008d. Efficient oncogene silencing and metastasis 
inhibition via systemic delivery of siRNA. Mol Ther, 16, 942-6. 
Liu, Y. 2004. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic 
significance, molecular mechanism, and therapeutic intervention. J Am Soc 
Nephrol, 15, 1-12. 
Loffing, J., Vallon, V., Loffing-Cueni, D., et al. 2004. Altered renal distal tubule 
structure and renal Na(+) and Ca(2+) handling in a mouse model for Gitelman's 
syndrome. J Am Soc Nephrol, 15, 2276-88. 
Ludwig, H., Adam, Z., Hajek, R., et al. 2010. Light Chain-Induced Acute Renal Failure 
Can Be Reversed by Bortezomib-Doxorubicin-Dexamethasone in Multiple 
Myeloma: Results of a Phase II Study. J Clin Oncol. 
  
 269 
Lundmark, K., Westermark, G. T., Olsen, A., et al. 2005. Protein fibrils in nature can 
enhance amyloid protein A amyloidosis in mice: Cross-seeding as a disease 
mechanism. Proc Natl Acad Sci U S A, 102, 6098-102. 
Maack, T., Johnson, V., Kau, S. T., et al. 1979. Renal filtration, transport, and 
metabolism of low-molecular-weight proteins: a review. Kidney Int, 16, 251-70. 
Magee, C. C. 2006. Kidney biopsy in myeloma. Nephrol Dial Transplant, 21, 3601-2; 
author reply 3602. 
Malcolm, S., Barton, P., Murphy, C., et al. 1982. Localization of human 
immunoglobulin kappa light chain variable region genes to the short arm of 
chromosome 2 by in situ hybridization. Proc Natl Acad Sci U S A, 79, 4957-61. 
Maldonado, J. E., Velosa, J. A., Kyle, R. A., et al. 1975. Fanconi syndrome in adults. A 
manifestation of a latent form of myeloma. Am J Med, 58, 354-64. 
Mallozzi, C., Di Stasi, A. M. & Minetti, M. 1999. Activation of src tyrosine kinases by 
peroxynitrite. FEBS Lett, 456, 201-6. 
Mardle, S. 2007. The selection of reporter labels. In: Renshaw, S. (ed.) 
Immunohistochemistry. 1 ed. Bloxham: Scion Publishing Limited. 
Martin, J., Eynstone, L., Davies, M., et al. 2001. Induction of metalloproteinases by 
glomerular mesangial cells stimulated by proteins of the extracellular matrix. J 
Am Soc Nephrol, 12, 88-96. 
Mason, D. Y., Micklem, K. & Jones, M. 2000. Double immunofluorescence labelling of 
routinely processed paraffin sections. J Pathol, 191, 452-61. 
Massova, I., Kotra, L. P., Fridman, R., et al. 1998. Matrix metalloproteinases: 
structures, evolution, and diversification. FASEB J, 12, 1075-95. 
McBride, O. W., Hieter, P. A., Hollis, G. F., et al. 1982. Chromosomal location of 
human kappa and lambda immunoglobulin light chain constant region genes. J 
Exp Med, 155, 1480-90. 
McGiven, A. R., Hunt, J. S., Day, W. A., et al. 1978. Tamm-Horsfall protein in the 
glomerular capsular space. J Clin Pathol, 31, 620-5. 
Medici, D. & Nawshad, A. 2010. Type I collagen promotes epithelial-mesenchymal 
transition through ILK-dependent activation of NF-kappaB and LEF-1. Matrix 
Biol, 29, 161-5. 
Merlini, G. & Bellotti, V. 2003. Molecular mechanisms of amyloidosis. N Engl J Med, 
349, 583-96. 
Merlini, G. & Westermark, P. 2004. The systemic amyloidoses: clearer understanding 
of the molecular mechanisms offers hope for more effective therapies. J Intern 
Med, 255, 159-78. 
Messiaen, T., Deret, S., Mougenot, B., et al. 2000. Adult Fanconi syndrome secondary 
to light chain gammopathy. Clinicopathologic heterogeneity and unusual 
features in 11 patients. Medicine (Baltimore), 79, 135-54. 
Mian, I. S., Bradwell, A. R. & Olson, A. J. 1991. Structure, function and properties of 
antibody binding sites. J Mol Biol, 217, 133-51. 
Miettinen, T. A. & Kekki, M. 1967. Effect of impaired hepatic and renal function on 
Bence Jones protein catabolism in human subjects. Clin Chim Acta, 18, 395-
407. 
Misko, T. P., Highkin, M. K., Veenhuizen, A. W., et al. 1998. Characterization of the 
cytoprotective action of peroxynitrite decomposition catalysts. J Biol Chem, 
273, 15646-53. 
  
 270 
Mohanty, J. G., Jaffe, J. S., Schulman, E. S., et al. 1997. A highly sensitive fluorescent 
micro-assay of H2O2 release from activated human leukocytes using a 
dihydroxyphenoxazine derivative. J Immunol Methods, 202, 133-41. 
Morel-Maroger, L., Basch, A., Danon, F., et al. 1970. Pathology of the kidney in 
Waldenstrom's macroglobulinemia. Study of sixteen cases. N Engl J Med, 283, 
123-9. 
Morigi, M., Macconi, D., Zoja, C., et al. 2002. Protein overload-induced NF-kappaB 
activation in proximal tubular cells requires H2O2 through a PKC-dependent 
pathway. J Am Soc Nephrol, 13, 1179-89. 
Morii, T., Fujita, H., Narita, T., et al. 2003. Increased urinary excretion of monocyte 
chemoattractant protein-1 in proteinuric renal diseases. Ren Fail, 25, 439-44. 
Mott, J. D. & Werb, Z. 2004. Regulation of matrix biology by matrix 
metalloproteinases. Curr Opin Cell Biol, 16, 558-64. 
Murphy, C. L., Eulitz, M., Hrncic, R., et al. 2001. Chemical typing of amyloid protein 
contained in formalin-fixed paraffin-embedded biopsy specimens. Am J Clin 
Pathol, 116, 135-42. 
Myatt, E. A., Westholm, F. A., Weiss, D. T., et al. 1994. Pathogenic potential of human 
monoclonal immunoglobulin light chains: relationship of in vitro aggregation to 
in vivo organ deposition. Proc Natl Acad Sci U S A, 91, 3034-8. 
Nasr, S. H., Galgano, S. J., Markowitz, G. S., et al. 2006. Immunofluorescence on 
pronase-digested paraffin sections: a valuable salvage technique for renal 
biopsies. Kidney Int, 70, 2148-51. 
Nathan, C. 2003. Specificity of a third kind: reactive oxygen and nitrogen intermediates 
in cell signaling. J Clin Invest, 111, 769-78. 
Negulescu, O., Bognar, I., Lei, J., et al. 2002. Estradiol reverses TGF-beta1-induced 
mesangial cell apoptosis by a casein kinase 2-dependent mechanism. Kidney Int, 
62, 1989-98. 
Norden, A. G., Flynn, F. V., Fulcher, L. M., et al. 1989. Renal impairment in myeloma: 
negative association with isoelectric point of excreted Bence-Jones protein. J 
Clin Pathol, 42, 59-62. 
Nyquist, J., Ramstad, H. M., Sletten, K., et al. 1993. Structural Studies of two 
carbohydrate-containing immunoglobulin-kappa-light chain amyloid fibril-
proteins of the variable group 1. In: Kisilevsky, R., Benson, M. D., Frangione, 
B., Gsuldie, J., Muckle, T. J. & Young, I. D. (eds.) Amyloid and Amyloidosis. 
New York: Partenton Pub. . 
O'Callaghan, C. A. 2004. Renal manifestations of systemic autoimmune disease: 
diagnosis and therapy. Best Pract Res Clin Rheumatol, 18, 411-427. 
Omtvedt, L. A., Bailey, D., Renouf, D. V., et al. 2000. Glycosylation of 
immunoglobulin light chains associated with amyloidosis. Amyloid, 7, 227-44. 
Onley, C. 2007. Antibodies for immunochemistry. In: Renshaw, S. (ed.) 
Immunohistochemistry. 1 ed. Bloxham: Scion Publishing Limited. 
Pak, J., Pu, Y., Zhang, Z. T., et al. 2001. Tamm-Horsfall protein binds to type 1 
fimbriated Escherichia coli and prevents E. coli from binding to uroplakin Ia and 
Ib receptors. J Biol Chem, 276, 9924-30. 
Parker, N. B., Berger, E. M., Curtis, W. E., et al. 1985. Hydrogen peroxide causes 
dimethylthiourea consumption while hydroxyl radical causes dimethyl sulfoxide 
consumption in vitro. J Free Radic Biol Med, 1, 415-9. 
  
 271 
Parks, W. C. 1999. Matrix metalloproteinases in repair. Wound Repair Regen, 7, 423-
32. 
Parrish, A. E. 1992. Complications of percutaneous renal biopsy: a review of 37 years' 
experience. Clin Nephrol, 38, 135-41. 
Parsons, S. J. & Parsons, J. T. 2004. Src family kinases, key regulators of signal 
transduction. Oncogene, 23, 7906-9. 
Pasquali, S., Zucchelli, P., Casanova, S., et al. 1987. Renal histological lesions and 
clinical syndromes in multiple myeloma. Renal Immunopathology Group. Clin 
Nephrol, 27, 222-8. 
Patel, R., McKenzie, J. K. & McQueen, E. G. 1964. Tamm-Horsfall Urinary 
Mucoprotein and Tubular Obstruction by Casts in Acute Renal Failure. Lancet, 
1, 457-61. 
Perkins, N. D. 2007. Integrating cell-signalling pathways with NF-kappaB and IKK 
function. Nat Rev Mol Cell Biol, 8, 49-62. 
Pesce, A. J., Clyne, D. H., Pollak, V. E., et al. 1980. Renal tubular interactions of 
proteins. Clin Biochem, 13, 209-15. 
Picken, M. M., Gallo, G., Buxbaum, J., et al. 1986. Characterization of renal amyloid 
derived from the variable region of the lambda light chain subgroup II. Am J 
Pathol, 124, 82-7. 
Pirani, C. L., Silva, F., D'Agati, V., et al. 1987. Renal lesions in plasma cell dyscrasias: 
ultrastructural observations. Am J Kidney Dis, 10, 208-21. 
Porter, K. R. & Tamm, I. 1955. Direct visualization of a mucoprotein component of 
urine. J Biol Chem, 212, 135-40. 
Porter, R. R. 1973. Structural studies of immunoglobulins. Science, 180, 713-6. 
Pote, A., Zwizinski, C., Simon, E. E., et al. 2000. Cytotoxicity of myeloma light chains 
in cultured human kidney proximal tubule cells. Am J Kidney Dis, 36, 735-44. 
Pozzi, C., D'Amico, M., Fogazzi, G. B., et al. 2003. Light chain deposition disease with 
renal involvement: clinical characteristics and prognostic factors. American 
Journal of Kidney Diseases, 42, 1154-63. 
Pozzi, C., Pasquali, S., Donini, U., et al. 1987. Prognostic factors and effectiveness of 
treatment in acute renal failure due to multiple myeloma: a review of 50 cases. 
Report of the Italien Renal Immunopathology Group. Clin Nephrol, 28, 1-9. 
Prajczer, S., Heidenreich, U., Pfaller, W., et al. 2010. Evidence for a role of uromodulin 
in chronic kidney disease progression. Nephrol Dial Transplant, 25, 1896-1903. 
Preud'homme, J. L., Aucouturier, P., Touchard, G., et al. 1994. Monoclonal 
immunoglobulin deposition disease (Randall type). Relationship with structural 
abnormalities of immunoglobulin chains. Kidney Int, 46, 965-72. 
Prodjosudjadi, W., Gerritsma, J. S., van Es, L. A., et al. 1995. Monocyte 
chemoattractant protein-1 in normal and diseased human kidneys: an 
immunohistochemical analysis. Clin Nephrol, 44, 148-55. 
Raffen, R., Dieckman, L. J., Szpunar, M., et al. 1999. Physicochemical consequences of 
amino acid variations that contribute to fibril formation by immunoglobulin light 
chains. Protein Sci, 8, 509-17. 
Rastaldi, M. P., Ferrario, F., Giardino, L., et al. 2002. Epithelial-mesenchymal 
transition of tubular epithelial cells in human renal biopsies. Kidney Int, 62, 137-
46. 
  
 272 
Reinhart, H. H., Obedeanu, N., Walz, D., et al. 1989. A new ELISA method for the 
rapid quantification of Tamm-Horsfall protein in urine. Am J Clin Pathol, 92, 
199-205. 
Remuzzi, G. 1999. Nephropathic nature of proteinuria. Curr Opin Nephrol Hypertens, 
8, 655-63. 
Remuzzi, G. & Bertani, T. 1998. Pathophysiology of progressive nephropathies. N Engl 
J Med, 339, 1448-56. 
Renshaw, S. 2007. Immunochemical staining techniques. In: Renshaw, S. (ed.) 
Immunohistochemistry. 1 ed. Bloxham: Scion Publishing Limited. 
Rhee, S. G. 2006. Cell signaling. H2O2, a necessary evil for cell signaling. Science, 
312, 1882-3. 
Richardson, P. G., Hideshima, T. & Anderson, K. C. 2003. Bortezomib (PS-341): a 
novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma 
and other cancers. Cancer Control, 10, 361-9. 
Rindler, M. J., Naik, S. S., Li, N., et al. 1990. Uromodulin (Tamm-Horsfall 
glycoprotein/uromucoid) is a phosphatidylinositol-linked membrane protein. J 
Biol Chem, 265, 20784-9. 
Rocca, A., Khamlichi, A. A., Aucouturier, P., et al. 1993. Primary structure of a 
variable region of the V kappa I subgroup (ISE) in light chain deposition 
disease. Clin Exp Immunol, 91, 506-9. 
Rocca, A., Khamlichi, A. A., Touchard, G., et al. 1995. Sequences of V kappa I 
subgroup light chains in Fanconi's syndrome. Light chain V region gene usage 
restriction and peculiarities in myeloma-associated Fanconi's syndrome. J 
Immunol, 155, 3245-52. 
Ronco, P. M., Alyanakian, M. A., Mougenot, B., et al. 2001. Light chain deposition 
disease: a model of glomerulosclerosis defined at the molecular level. J Am Soc 
Nephrol, 12, 1558-65. 
Rose, P. E., McGonigle, R., Michael, J., et al. 1987. Renal failure and the 
histopathological features of myeloma kidney reversed by intensive 
chemotherapy and peritoneal dialysis. Br Med J (Clin Res Ed), 294, 411-2. 
Rovin, B. H., Dickerson, J. A., Tan, L. C., et al. 1995. Activation of nuclear factor-
kappa B correlates with MCP-1 expression by human mesangial cells. Kidney 
Int, 48, 1263-71. 
Russell, W. J., Cardelli, J., Harris, E., et al. 2001. Monoclonal light chain--mesangial 
cell interactions: early signaling events and subsequent pathologic effects. Lab 
Invest, 81, 689-703. 
Ryan, M. J., Johnson, G., Kirk, J., et al. 1994. HK-2: an immortalized proximal tubule 
epithelial cell line from normal adult human kidney. Kidney Int, 45, 48-57. 
Saemann, M. D., Weichhart, T., Zeyda, M., et al. 2005. Tamm-Horsfall glycoprotein 
links innate immune cell activation with adaptive immunity via a Toll-like 
receptor-4-dependent mechanism. J Clin Invest, 115, 468-75. 
Saito, K., Shimizu, F., Sato, T., et al. 1993. Modulation of human mesangial cell 
behaviour by extracellular matrix components--the possible role of interstitial 
type III collagen. Clin Exp Immunol, 91, 510-5. 
Sanders, P. W. 2005. Management of paraproteinemic renal disease. Curr Opin Nephrol 
Hypertens, 14, 97-103. 
Sanders, P. W. & Booker, B. B. 1992. Pathobiology of cast nephropathy from human 
Bence Jones proteins. J Clin Invest, 89, 630-9. 
  
 273 
Sanders, P. W., Booker, B. B., Bishop, J. B., et al. 1990. Mechanisms of intranephronal 
proteinaceous cast formation by low molecular weight proteins. J Clin Invest, 
85, 570-6. 
Sanders, P. W., Herrera, G. A., Chen, A., et al. 1988a. Differential nephrotoxicity of 
low molecular weight proteins including Bence Jones proteins in the perfused rat 
nephron in vivo. J Clin Invest, 82, 2086-96. 
Sanders, P. W., Herrera, G. A. & Galla, J. H. 1987. Human Bence Jones protein toxicity 
in rat proximal tubule epithelium in vivo. Kidney Int, 32, 851-61. 
Sanders, P. W., Herrera, G. A., Kirk, K. A., et al. 1991. Spectrum of glomerular and 
tubulointerstitial renal lesions associated with monotypical immunoglobulin 
light chain deposition. Lab Invest, 64, 527-37. 
Sanders, P. W., Herrera, G. A., Lott, R. L., et al. 1988b. Morphologic alterations of the 
proximal tubules in light chain-related renal disease. Kidney Int, 33, 881-9. 
Sanz, A. B., Sanchez-Nino, M. D., Ramos, A. M., et al. 2010. NF-{kappa}B in Renal 
Inflammation. J Am Soc Nephrol, 21, 1254-62. 
Savill, J., Wyllie, A. H., Henson, J. E., et al. 1989. Macrophage phagocytosis of ageing 
neutrophils in inflammation. Programmed cell death in the neutrophil leads to its 
recognition by macrophages. J Clin Invest, 83, 865-875. 
Schlondorff, D. 1996. Roles of the mesangium in glomerular function. Kidney Int, 49, 
1583-5. 
Schmid, M., Prajczer, S., Gruber, L. N., et al. 2010. Uromodulin Facilitates Neutrophil 
Migration Across Renal Epithelial Monolayers. Cell Physiol Biochem, 26, 311-
318. 
Schnaper, H. W., Kopp, J. B., Poncelet, A. C., et al. 1996. Increased expression of 
extracellular matrix proteins and decreased expression of matrix proteases after 
serial passage of glomerular mesangial cells. J Cell Sci, 109 ( Pt 10), 2521-8. 
Scholefield, Z., Yates, E. A., Wayne, G., et al. 2003. Heparan sulfate regulates amyloid 
precursor protein processing by BACE1, the Alzheimer's beta-secretase. J Cell 
Biol, 163, 97-107. 
Scopes, R. K. 1994. Protein Purification: Principles and Practice, New York, Springer. 
Segerer, S., Heller, F., Lindenmeyer, M. T., et al. 2008. Compartment specific 
expression of dendritic cell markers in human glomerulonephritis. Kidney Int, 
74, 37-46. 
Sengul, S., Li, M. & Batuman, V. 2009. Myeloma kidney: toward its prevention--with 
new insights from in vitro and in vivo models of renal injury. J Nephrol, 22, 17-
28. 
Sengul, S., Zwizinski, C. & Batuman, V. 2003. Role of MAPK pathways in light chain-
induced cytokine production in human proximal tubule cells. Am J Physiol 
Renal Physiol, 284, F1245-54. 
Sengul, S., Zwizinski, C., Simon, E. E., et al. 2002. Endocytosis of light chains induces 
cytokines through activation of NF-kappaB in human proximal tubule cells. 
Kidney Int, 62, 1977-88. 
Serafini-Cessi, F., Malagolini, N. & Cavallone, D. 2003. Tamm-Horsfall glycoprotein: 
biology and clinical relevance. Am J Kidney Dis, 42, 658-76. 
Shirahama, T. & Cohen, A. S. 1973. An analysis of the close relationship of lysosomes 
to early deposits of amyloid. Ultrastructural evidence in experimental mouse 
amyloidosis. Am J Pathol, 73, 97-114. 
  
 274 
Shirahama, T. & Cohen, A. S. 1975. Intralysosomal formation of amyloid fibrils. Am J 
Pathol, 81, 101-16. 
Simerville, J. A., Maxted, W. C. & Pahira, J. J. 2005. Urinalysis: a comprehensive 
review. Am Fam Physician, 71, 1153-62. 
Simmonds, P. D., Cottrell, B. J., Mead, G. M., et al. 1997. Lymphadenopathy due to 
amyloid deposition in non-Hodgkin's lymphoma. Ann Oncol, 8, 267-70. 
Smith, P. K., Krohn, R. I., Hermanson, G. T., et al. 1985. Measurement of protein using 
bicinchoninic acid. Anal Biochem, 150, 76-85. 
Smithline, N., Kassirer, J. P. & Cohen, J. J. 1976. Light-chain nephropathy. Renal 
tubular dysfunction associated with light-chain proteinuria. N Engl J Med, 294, 
71-4. 
Smolens, P. & Miller, V. 1987. Renal tubular uptake of light chains (LC) of different 
isoelectric points (pI). Clin Res, 35, 33A. 
Smolens, P., Venkatachalam, M. & Stein, J. H. 1983. Myeloma kidney cast 
nephropathy in a rat model of multiple myeloma. Kidney Int, 24, 192-204. 
Solling, K., Solling, J. & Romer, F. K. 1981. Free light chains of immunoglobulins in 
serum from patients with rheumatoid arthritis, sarcoidosis, chronic infections 
and pulmonary cancer. Acta Med Scand, 209, 473-7. 
Solomon, A. 1985. Light Chains of Human Immunoglobulins. Meth Enzymol, 116, 101-
121. 
Solomon, A. 1986. Light chains of immunoglobulins: structural-genetic correlates. 
Blood, 68, 603-10. 
Solomon, A., Frangione, B. & Franklin, E. C. 1982. Bence Jones proteins and light 
chains of immunoglobulins. Preferential association of the V lambda VI 
subgroup of human light chains with amyloidosis AL (lambda). J Clin Invest, 
70, 453-60. 
Solomon, A., Waldmann, T. A., Fahey, J. L., et al. 1964. Metabolism of Bence Jones 
Proteins. J Clin Invest, 43, 103-17. 
Solomon, A., Weiss, D. T. & Kattine, A. A. 1991. Nephrotoxic potential of Bence Jones 
proteins. N Engl J Med, 324, 1845-51. 
Solomon, A., Weiss, D. T. & Pepys, M. B. 1992. Induction in mice of human light-
chain-associated amyloidosis. Am J Pathol, 140, 629-37. 
Stanford, B. L. & Zondor, S. D. 2003. Bortezomib treatment for multiple myeloma. Ann 
Pharmacother, 37, 1825-30. 
Start, D. A., Silva, F. G., Davis, L. D., et al. 1988. Myeloma cast nephropathy: 
immunohistochemical and lectin studies. Mod Pathol, 1, 336-47. 
Steffensen, B., Hakkinen, L. & Larjava, H. 2001. Proteolytic events of wound-healing--
coordinated interactions among matrix metalloproteinases (MMPs), integrins, 
and extracellular matrix molecules. Crit Rev Oral Biol Med, 12, 373-98. 
Stevens, F. J. 2000. Four structural risk factors identify most fibril-forming kappa light 
chains. Amyloid, 7, 200-11. 
Stevens, F. J. & Kisilevsky, R. 2000. Immunoglobulin light chains, 
glycosaminoglycans, and amyloid. Cell Mol Life Sci, 57, 441-9. 
Stevens, F. J., Myatt, E. A., Chang, C. H., et al. 1995. A molecular model for self-
assembly of amyloid fibrils: immunoglobulin light chains. Biochemistry, 34, 
10697-702. 
  
 275 
Stevenson, F. K., Cleave, A. J. & Kent, P. W. 1971. The effect of ions on the 
viscometric and ultracentrifugal behaviour of Tamm-Horsfall glycoprotein. 
Biochim Biophys Acta, 236, 59-66. 
Striker, L. J., Doi, T., Elliot, S., et al. 1989. The contribution of glomerular mesangial 
cells to progressive glomerulosclerosis. Semin Nephrol, 9, 318-28. 
Su, S. J., Chang, K. L., Lin, T. M., et al. 1997. Uromodulin and Tamm-Horsfall protein 
induce human monocytes to secrete TNF and express tissue factor. J Immunol, 
158, 3449-56. 
Sugiyama, H., Kashihara, N., Makino, H., et al. 1996. Apoptosis in glomerular 
sclerosis. Kidney Int, 49, 103-11. 
Tagouri, Y. M., Sanders, P. W., Picken, M. M., et al. 1996. In vitro AL-amyloid 
formation by rat and human mesangial cells. Lab Invest, 74, 290-302. 
Tagouri, Y. M., Sanders, P. W., Zhu, L., et al. 1995. Glomerulopathic monoclonal light 
chains potentiate mesangial cell apoptosis in vitro (abstract). Lab Invest, Mod 
Pathol, 8, 161A. 
Tamm, I. & Horsfall, F. L., Jr. 1952. A mucoprotein derived from human urine which 
reacts with influenza, mumps, and Newcastle disease viruses. J Exp Med, 95, 
71-97. 
Tanner, G. A. & Evan, A. P. 1989. Glomerular and proximal tubular morphology after 
single nephron obstruction. Kidney Int, 36, 1050-60. 
Tanner, G. A. & Knopp, L. C. 1986. Glomerular blood flow after single nephron 
obstruction in the rat kidney. Am J Physiol, 250, F77-85. 
Teng, J., Russell, W. J., Gu, X., et al. 2004. Different types of glomerulopathic light 
chains interact with mesangial cells using a common receptor but exhibit 
different intracellular trafficking patterns.[erratum appears in Lab Invest. 2004 
Sep;84(9):1219]. Lab Invest, 84, 440-51. 
Teng, J., Zhang, P. L., Russell, W. J., et al. 2003. Insights into mechanisms responsible 
for mesangial alterations associated with fibrogenic glomerulopathic light 
chains. Nephron Physiol, 94, p28-38. 
Tennent, G. A., Lovat, L. B. & Pepys, M. B. 1995. Serum amyloid P component 
prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic 
amyloidosis. Proc Natl Acad Sci U S A, 92, 4299-303. 
Tesch, G. H., Schwarting, A., Kinoshita, K., et al. 1999. Monocyte chemoattractant 
protein-1 promotes macrophage-mediated tubular injury, but not glomerular 
injury, in nephrotoxic serum nephritis. J Clin Invest, 103, 73-80. 
Thomas, M. E., Harris, K. P., Walls, J., et al. 2002. Fatty acids exacerbate 
tubulointerstitial injury in protein-overload proteinuria. Am J Physiol Renal 
Physiol, 283, F640-7. 
Thorner, P. S., Bedard, Y. C. & Fernandes, B. J. 1983. Lambda-light-chain nephropathy 
with Fanconi's syndrome. Arch Pathol Lab Med, 107, 654-7. 
Toor, A. A., Ramdane, B. A., Joseph, J., et al. 2006. Cardiac nonamyloidotic 
immunoglobulin deposition disease. Mod Pathol, 19, 233-7. 
Toyoda, M., Kita, S., Furiya, K., et al. 1991. Characterization of AL amyloid protein 
identified by immunoelectron microscopy: a simple method using the protein A-
gold technique. J Histochem Cytochem, 39, 239-42. 
Truong, L. D., Pindur, J., Barrios, R., et al. 1994. Tenascin is an important component 
of the glomerular extracellular matrix in normal and pathologic conditions. 
Kidney Int, 45, 201-10. 
  
 276 
Turbat-Herrera, E. A., Isaac, J., Sanders, P. W., et al. 1997. Integrated expression of 
glomerular extracellular matrix proteins and beta 1 integrins in monoclonal light 
chain-related renal diseases. Mod Pathol, 10, 485-95. 
Van Wart, H. E. & Birkedal-Hansen, H. 1990. The cysteine switch: a principle of 
regulation of metalloproteinase activity with potential applicability to the entire 
matrix metalloproteinase gene family. Proc Natl Acad Sci U S A, 87, 5578-82. 
Veeramachaneni, R., Gu, X. & Herrera, G. A. 2004. Atypical amyloidosis: diagnostic 
challenges and the role of immunoelectron microscopy in diagnosis. Ultrastruct 
Pathol, 28, 75-82. 
Verroust, P. J., Birn, H., Nielsen, R., et al. 2002. The tandem endocytic receptors 
megalin and cubilin are important proteins in renal pathology. Kidney Int, 62, 
745-56. 
Viedt, C., Dechend, R., Fei, J., et al. 2002. MCP-1 induces inflammatory activation of 
human tubular 
Light Chains Stimulate Cellular Redox Signaling 1245 epithelial cells: Involvement 
of the transcription factors, 
nuclear factor-kappaB and activating protein-1. J Am Soc Nephrol, 13, 1543-1547. 
Viegas, M. S., Martins, T. C., Seco, F., et al. 2007. An improved and cost-effective 
methodology for the reduction of autofluorescence in direct 
immunofluorescence studies on formalin-fixed paraffin-embedded tissues. Eur J 
Histochem, 51, 59-66. 
Visse, R. & Nagase, H. 2003. Matrix metalloproteinases and tissue inhibitors of 
metalloproteinases: structure, function, and biochemistry. Circ Res, 92, 827-39. 
von Gise, H., Christ, H. & Bohle, A. 1981. Early glomerular lesions in amyloidosis. 
Electronmicroscopic findings. Virchows Arch A Pathol Anat Histol, 390, 259-
72. 
Vu, T. H. & Werb, Z. 2000. Matrix metalloproteinases: effectors of development and 
normal physiology. Genes Dev, 14, 2123-33. 
Wada, T., Furuichi, K., Sakai, N., et al. 2000. Up-regulation of monocyte 
chemoattractant protein-1 in tubulointerstitial lesions of human diabetic 
nephropathy. Kidney Int, 58, 1492-1499. 
Waldmann, T. A., Strober, W. S. & Mogielnicki, R. P. 1972. The Renal Handling of 
Low Molecular Weight Proteins II. Disorders of Serum Protein Catabolism in 
Patients with Tubular Proteinuria, the Nephrotic Syndrome or Uraemia. . J Clin 
Invest, 51, 2162-2174. 
Walker, R. G. 2003. Chronic Interstitial Nephritis. In: Johnson, R. J. & Feehally, J. 
(eds.) Comprehensive Clinical Nephrology. 2 ed. London: Mosby. 
Wang, P. X. & Sanders, P. W. 2007. Immunoglobulin light chains generate hydrogen 
peroxide. J Am Soc Nephrol, 18, 1239-45. 
Wang, Y., Chen, J., Chen, L., et al. 1997. Induction of monocyte chemoattractant 
protein-1 in proximal tubule cells by urinary protein. J Am Soc Nephrol, 8, 
1537-45. 
Wang, Y., Rangan, G. K., Tay, Y. C., et al. 1999. Induction of monocyte 
chemoattractant protein-1 by albumin is mediated by nuclear factor kappaB in 
proximal tubule cells. J Am Soc Nephrol, 10, 1204-13. 
Wangsiripaisan, A., Gengaro, P. E., Edelstein, C. L., et al. 2001. Role of polymeric 
Tamm-Horsfall protein in cast formation: oligosaccharide and tubular fluid ions. 
Kidney Int, 59, 932-40. 
  
 277 
Watanabe, S., Yoshimura, A., Inui, K., et al. 2001. Acquisition of the 
monocyte/macrophage phenotype in human mesangial cells. J Lab Clin Med, 
138, 193-9. 
Weichhart, T., Zlabinger, G. J. & Saemann, M. D. 2005. The multiple functions of 
Tamm-Horsfall protein in human health and disease: a mystery clears up. Wien 
Klin Wochenschr, 117, 316-22. 
Weiss, J. H., Williams, R. H., Galla, J. H., et al. 1981. Pathophysiology of acute Bence-
Jones protein nephrotoxicity in the rat. Kidney Int, 20, 198-210. 
Wentworth, A. D., Jones, L. H., Wentworth, P., Jr., et al. 2000. Antibodies have the 
intrinsic capacity to destroy antigens. Proc Natl Acad Sci U S A, 97, 10930-5. 
Wentworth, P., Jr., Jones, L. H., Wentworth, A. D., et al. 2001. Antibody catalysis of 
the oxidation of water. Science, 293, 1806-11. 
Westermark, P. 2005. Aspects on human amyloid forms and their fibril polypeptides. 
FEBS J, 272, 5942-9. 
Wetzel, R. 1997. Domain stability in immunoglobulin light chain deposition disorders. 
Adv Protein Chem, 50, 183-242. 
Whiteman, M. & Halliwell, B. 1997. Thiourea and dimethylthiourea inhibit 
peroxynitrite-dependent damage: nonspecificity as hydroxyl radical scavengers. 
Free Radic Biol Med, 22, 1309-12. 
Wochner, R. D., Strober, W. & Waldmann, T. A. 1967. The role of the kidney in the 
catabolism of Bence Jones proteins and immunoglobulin fragments. J Exp Med, 
126, 207-21. 
Wong, T. Y., Phillips, A. O., Witowski, J., et al. 2003. Glucose-mediated induction of 
TGF-beta 1 and MCP-1 in mesothelial cells in vitro is osmolality and polyol 
pathway dependent. Kidney Int, 63, 1404-16. 
Xu, W., Harrison, S. C. & Eck, M. J. 1997. Three-dimensional structure of the tyrosine 
kinase c-Src. Nature, 385, 595-602. 
Yamaguchi, I., Suda, H., Tsuzuike, N., et al. 2003. Glycosaminoglycan and 
proteoglycan inhibit the depolymerization of beta2-microglobulin amyloid 
fibrils in vitro. Kidney Int, 64, 1080-8. 
Ying, W. Z. & Sanders, P. W. 2001. Mapping the binding domain of immunoglobulin 
light chains for Tamm-Horsfall protein. Am J Pathol, 158, 1859-66. 
Zeier, M., Perz, J., Linke, R. P., et al. 2003. No regression of renal AL amyloid in 
monoclonal gammopathy after successful autologous blood stem cell 
transplantation and significant clinical improvement. Nephrol Dial Transplant, 
18, 2644-7. 
Zhou, M., Diwu, Z., Panchuk-Voloshina, N., et al. 1997. A stable nonfluorescent 
derivative of resorufin for the fluorometric determination of trace hydrogen 
peroxide: applications in detecting the activity of phagocyte NADPH oxidase 
and other oxidases. Anal Biochem, 253, 162-8. 
Zhu, H., Yu, J. & Kindy, M. S. 2001. Inhibition of amyloidosis using low-molecular-
weight heparins. Mol Med, 7, 517-22. 
Zhu, L., Herrera, G. A., Murphy-Ullrich, J. E., et al. 1995. Pathogenesis of 
glomerulosclerosis in light chain deposition disease. Role for transforming 
growth factor-beta. Am J Pathol, 147, 375-85. 
Zhu, L., Herrera, G. A., White, C. R., et al. 1997. Immunoglobulin light chain alters 
mesangial cell calcium homeostasis. Am J Physiol, 272, F319-24. 
  
 278 
Zoja, C., Benigni, A. & Remuzzi, G. 1999. Protein overload activates proximal tubular 
cells to release vasoactive and inflammatory mediators. Exp Nephrol, 7, 420-8. 
 
 
